US20040106904A1 - Microneedle array patch - Google Patents

Microneedle array patch Download PDF

Info

Publication number
US20040106904A1
US20040106904A1 US10/681,777 US68177703A US2004106904A1 US 20040106904 A1 US20040106904 A1 US 20040106904A1 US 68177703 A US68177703 A US 68177703A US 2004106904 A1 US2004106904 A1 US 2004106904A1
Authority
US
United States
Prior art keywords
microneedle
microneedles
delivery device
tissue
distal end
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/681,777
Inventor
Robert Gonnelli
Devin McAllister
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Valeritas Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US10/681,777 priority Critical patent/US20040106904A1/en
Publication of US20040106904A1 publication Critical patent/US20040106904A1/en
Assigned to BIOVALVE TECHNOLOGIES, INC. reassignment BIOVALVE TECHNOLOGIES, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MCALLISTER, DEVIN V., GONNELLI, ROBERT R.
Assigned to VALERITAS LLC reassignment VALERITAS LLC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BIOVALVE TECHNOLOGIES, INC.
Priority to US11/975,717 priority patent/US8162901B2/en
Assigned to VALERITAS, INC. reassignment VALERITAS, INC. CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: VALERITAS LLC
Assigned to CAPITAL ROYALTY PARTNERS II - PARALLEL FUND "A" L.P., CAPITAL ROYALTY PARTNERS II L.P., PARALLEL INVESTMENT OPPORTUNITIES PARTNERS II L.P. reassignment CAPITAL ROYALTY PARTNERS II - PARALLEL FUND "A" L.P. SHORT-FORM PATENT SECURITY AGREEMENT Assignors: VALERITAS, INC.
Abandoned legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M37/0015Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/20Surgical instruments, devices or methods, e.g. tourniquets for vaccinating or cleaning the skin previous to the vaccination
    • A61B17/205Vaccinating by means of needles or other puncturing devices
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M37/0015Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
    • A61M2037/0038Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles having a channel at the side surface
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M37/0015Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
    • A61M2037/0046Solid microneedles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M37/0015Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
    • A61M2037/0053Methods for producing microneedles
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B33ADDITIVE MANUFACTURING TECHNOLOGY
    • B33YADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3-D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3-D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
    • B33Y80/00Products made by additive manufacturing

Definitions

  • This invention relates to injection devices, such as microneedle devices having an array of microneedles for placing on the skin.
  • microneedles refers to a plurality of elongated structures that are sufficiently long to penetrate through the stratum corneum skin layer and into the epidermal layer, yet are also sufficiently short to not penetrate to the dermal layer. However, if the dead cells have been completely or mostly removed from a portion of skin, then a very minute length of microneedle could be used to reach the viable epidermal tissue.
  • Microneedle devices for transport of molecules, including drugs and biological molecules, across tissue, are provided.
  • the microneedle devices permit drug delivery or removal of body fluids at clinically relevant rates across skin or other tissue barriers, with minimal or no damage, pain, or irritation to the tissue.
  • Microneedles can be formed of a variety of materials, including biodegradable or non-biodegradable polymeric materials or metals.
  • the microneedle devices described herein include a hollow microneedle capable of penetrating the stratum corneum.
  • the microneedle has a movable barrier located at a distal end of the microneedle. The moveable barrier prevents or reduces tissue from blocking an interior channel that extends though the microneedle.
  • the microneedle device include a platform or substrate having a plurality of microneedles each with plugs disposed at their distal ends for preventing skin or other tissue barriers from entering the hollow microneedles.
  • a microneedle device includes a plurality of bioerodible elements for temporarily plugging the hollow microneedles, thereby preventing skin or other tissue barriers from entering the hollow microneedles.
  • the bio erodible elements may be plugs that are fitted within the distal end of a channel extending through the microneedle.
  • the plugs may be frangible and optionally may have a seam that allows the plug to separate from the microneedle. Once separated the plug may dissolve over time.
  • the devices described herein may include moveable barriers that comprise pins or pistons that fit within the interior channels of the mcironeedle and may be moved through the channel so that a distal portion of the pin or piston sits within the distal end of the channel and prevents tissue from blocking the microneedle.
  • the pin or piston may be capable of pushing tissue from the channel to dislodge any tissue blocking the channel.
  • FIG. 1 depicts a microneedle surface of one embodiment of the invention.
  • FIG. 2A depicts a cross-sectional view of the microneedle device of FIG. 1 in its resting state.
  • FIG. 2B depicts a cross-sectional view of the microneedle device of FIG. 1 when pressure is applied to back of the patch.
  • FIG. 3 depicts a microneedle surface of a different embodiment of the invention.
  • FIG. 4A depicts a cross-sectional view of the microneedle device of FIG. 3 prior to its application to skin.
  • FIG. 4B depicts a cross-sectional view of the microneedle device of FIG. 3 during its application to skin.
  • FIG. 4C depicts a cross-sectional view of the microneedle device of FIG. 3 after its application to skin.
  • FIG. 4D depicts a cross-sectional view of a microneedle and plug.
  • FIGS. 5A and 5B depict a process for clearing tissue from the channel of a microneedle and pumping fluid through the channel.
  • the systems and methods described herein are, in one aspect, directed to transdermal devices, including an intraepidermal delivery devices for administering a substance to a patient. More particularly, the invention is directed to devices and to methods for establishing fluid communication for administering agents and monitoring a patent's condition.
  • the systems and methods provide delivery devices for administering a substance into or below the stratum corneum of the skin of a patient.
  • the term penetrate refers to entering a layer of the skin without necessarily passing completely through. Piercing refers to passing completely through a layer of the skin.
  • transdermal refers to the exchange of a substance, such as blood, a pharmaceutical, a biological agent or a vaccine, through one or more layers of skin.
  • Intradermal refers to one or more layers within the skin and not limited to the dermis layer of the skin.
  • the devices and methods are particularly suitable for use in administering various substances, including pharmaceutical agents, to a patient, and notably to a human patient.
  • a pharmaceutical agent includes a substance having biological activity that can be delivered through the body membranes and surfaces, and particularly the skin. Examples include antibiotics, antiviral agents, analgesics, anesthetics, anorexics, antiarthritics, antidepressants, antihistamines, anti-inflammatory agents, antineoplastic agents, vaccines, including DNA vaccines, adjuvants, biologics, and the like.
  • Other substances which can be delivered intradermally to a patient include proteins, peptides and fragments thereof. The proteins and peptides can be naturally occurring, synthesized or recombinantly produced.
  • a vaccine is administered using the device and method.
  • the multipuncture devices of described herein are believed in addition to have a unique immunological advantage in the delivery of vaccines with the potential of increasing the vaccine's clinical value.
  • the insertion of the multiple needle points into the tissue is suggested as having an adjuvant-like stimulatory effect.
  • the needle stick response from multiple microneedle points is believed more than a simple acute inflammatory response. Needle sticks can cause damage to a variety of cells and cellular architecture, causing the appearance of polymorphonuclear neutrophil (PMN) and microphages as well as the release of cytokines, including IL1, tumor necrosis factor (TNF) and other agents, which can lead to a number of other immunological responses.
  • the soluble stimulatory factors influence the proliferation of lymphocytes and are central to the immune response to vaccines.
  • the immune stimulation is proportional to the direct needle-cell interaction.
  • the microneedle device is valuable in promoting significant immune response to a vaccine by delivering a vaccine below the stratum corneum and into the cells of the tissue.
  • Some of the microneedles can have a length selected to penetrate and pass through the stratum corneum without penetrating the dermis to minimize absorption of the vaccine into the bloodstream.
  • the small intracellular depots created by the microneedle array are believed to increase the availability of the vaccine antigen for interaction with antigen presenting cells more than would a vaccine deposited by standard needles in a larger depot quantity.
  • some or all of the microneedles can have a length to penetrate, but not pierce, the stratum corneum.
  • microneedle array is believed to magnify several-fold the trivial or inconsequential immune stimulatory impact of a single needlestick independent of the route of delivery and vaccine.
  • the microneedle delivery device facilitates and enhances vaccine immunogenicity by an adjuvant-like immune stimulation.
  • the primary barrier properties of the skin including the resistance to drug penetration reside in the outermost layer of the skin, referred to as the stratum corneum.
  • the inner layers of the epidermis generally include three layers, commonly identified as the stratum granulosum, the stratum malpighii, and the stratum germinativum.
  • the devices and methods described herein will, among other things, for deliver a substance, and particularly a pharmaceutical agent, into or below the stratum corneum for administering the substance or pharmaceutical agent to the patient.
  • the device and method pierce the stratum corneum substantially without penetrating the dermis to target the tissue layers below the stratum corneum. It is of potential benefit for vaccines to target presentation of antigen to various antigen presenting cells and other immunostimulatory sites, such as Langerhans cells and intraepithelial cells, as well as proximal delivery of adjuvants.
  • FIG. 1 depicts one embodiment of a microneedle device.
  • Microneedle device 1 shows microneedle surface 10 , including microneedles 20 with microneedles openings 30 .
  • the microneedle device may comprise an array of microneedles, each of which is hollow and each of which can penetrate the stratum corneum.
  • the microneedle array may be used as part of a transdermal patch that transdermally delivers a substance to the patient or transdermally collects a sample from the patient.
  • the device 1 may include a reservoir that can store a fluid substance or substances to deliver to the patient or that was collected from the patient.
  • the microneedle device 1 includes a distal barrier over or within one or more of the microneedles 20 , and typically, the barrier is disposed over or within the distal end of the channel 30 to prevent tissue from blocking the channel openings 30 when the patient or doctor applies pressure to device 1 to force the mcironeedles 20 through the tissue.
  • FIG. 2A depicts a cross-sectional view of microneedle device 1 in its resting state.
  • Drug reservoir 70 is loaded with a predetermined amount of a therapeutic in liquid form.
  • Platform 60 includes microneedle plugs 61 which are arrayed to fit into microneedles 20 in order to prevent punctured skin from entering and plugging microneedles 20 , and preventing the release of therapeutic. Platform 60 rests on springs 50 which hold platform 60 and microneedle plugs 61 above microneedles 20 .
  • FIG. 2B depicts a cross-sectional view of microneedle device 1 when pressure (represented by three arrows) is applied to device surface 40 while microneedle device 1 is being applied to skin.
  • Microneedle device 1 is applied to skin with microneedle surface 10 in contact with the skin.
  • the pressure pushes down platform 60 depresses springs 50 , and forces microneedle plugs 61 into microneedles 20 , preventing skin from entering and plugging microneedles 20 .
  • device 1 After pressure is released from device surface 40 , device 1 returns to the formation shown in FIG. 2A.
  • Springs 50 re-extend to lift platform 60 and microneedle plugs 61 from microneedles 20 .
  • microneedles 20 are embedded into skin and the therapeutic in a liquid composition or form escapes from drug reservoir 70 through microneedles openings 30 .
  • the plugs 61 act as moveable barriers that prevent tissue from blocking the openings 30 of microneedles 20 .
  • Platform 60 is depicted in FIGS. 2 A- 2 B as solid, however, other embodiments are contemplated.
  • platform 60 may include a plurality of openings, in the areas surrounding platform plugs 61 , through which a therapeutic may flow from drug reservoir 70 through microneedles 20 .
  • FIGS. 2 A- 2 B depict the interior microneedles 61 (as being sized to fit within the interior of microneedles 20 .
  • the microneedles 20 may have narrow interior channels and in this embodiment microneedles 61 may be narrow pin shaped elements that may slide into, and optionally extend from, the distal opening of the microneedles 20 .
  • the microneedles 61 do not need to have interior channels for passing fluid as microneedles may be slid out of, at least partially, the interior channel of the microneedle 20 .
  • the conical shape of the microneedle interior channel will provide space between the microneedle 61 and the interior wall of the conical channel, thereby providing a space through which the therapeutic fluid may flow.
  • the microneedle 61 may have an exterior surface that is grooved or scored to provide a path through which liquid may flow.
  • the wall of the interior channel may be similarly grooved or scored.
  • FIG. 3 depicts an alternative embodiment of a microneedle device.
  • Microneedle device 101 shows microneedle surface 110 , including microneedles 120 with microneedle plugs 130 .
  • An optional adhesive patch 112 secures the device 101 to the tissue of the patient.
  • FIG. 4A depicts a cross-sectional view of microneedle device 101 prior to its application to skin.
  • drug reservoir 170 is loaded with a predetermined amount of a therapeutic in liquid form.
  • the microneedle openings 121 of microneedles 120 are blocked by microneedle plugs 130 .
  • Microneedle plugs 130 have an accurate shape with shoulders 132 that extend beyond the diameter of microneedles 120 .
  • the plugs 130 have a shape adapted to act as a barb and catch biological tissue.
  • the plugs 130 may have a frangible seam that fractures when the microneedle device 101 is applied to the patient's tissue. This allows the plug 130 to separate from the needle 120 , and thereby facilitates the flow of agent through the needle 120 .
  • FIG. 4B depicts a cross-sectional view of the microneedle device 101 during its application to skin.
  • Microneedle device 101 is applied to skin with microneedle surface 110 in contact with the skin.
  • Microneedle plugs 130 block microneedles openings 121 , preventing skin from entering and plugging microneedles 120 , thereby preventing the release of therapeutic.
  • Microneedle device 101 is pressed into skin to a deeper level than when the pressure applied to microneedle device 101 is released. When the pressure is released, microneedle device 101 rises from the level it has been pushed to and rests on the surface of the skin.
  • microneedle plugs 130 anchor microneedle plugs 130 at the level to which microneedle plugs 130 have been pushed. Thus, as microneedle device 101 rises to rest on the surface of the skin, microneedle plugs 130 are pulled out of microneedle openings 121 and microneedles 120 .
  • FIG. 4C depicts a cross-sectional view of microneedle device 101 after its application to skin and microneedle plugs 130 are anchored in skin.
  • the therapeutic in a liquid composition or form escapes from drug reservoir 170 through microneedles openings 121 .
  • the anchored plugs 130 may be comprised of a biologically erodible material that over time will dissolve.
  • the plugs 130 may comprise a therapeutic material that caries a medicant into the patient's tissue to provide a time release dose that may work in cooperation with the fluidic medicant delivered through the microneedles 120 .
  • FIG. 4D depicts a cross-sectional view of the microneedle 120 having a plug 130 disposed therein.
  • the microneedle 120 may have an interior channel 122 that is conically shaped.
  • the plug 130 may have a lower accurate section 132 and an upper conical section 134 .
  • the upper conical section 134 mates up with the interior wall of the channel 122 to form a mechanical stop that prevents the plug 130 from sliding out of the distal end of the interior channel 122 .
  • the plug 130 may include a proximal end that secures to the exterior surface of the microneedle 120 .
  • the plug 130 does not enter into the microneedle channel, or does not enter a substantial amount.
  • the plug 130 includes a frangible collar that wraps around and secures to the exterior distal surface of the microneedle 120 .
  • FIG. 4A shows one of the microneedles 130 having a proximal collar 132 .
  • the proximal collar 132 may be formed of the same material as the plug 130 , or optionally of a different material.
  • a frangible seam 134 which may be a perforated seam, may be disposed between the collar 132 and the distal end of the plug 130 . The frangible seam 134 may facilitate the separation of the distal end of the plug 130 from the device 101 .
  • the plug 130 may be formed of a bioerodible material. Such materials include polymers of hydroxy acid and are enumerated in more detail below.
  • the plug 130 may be made of other materials, including materials that carry a medicant for delivering medicant to the patient. Still, in other embodiments, the plug 130 may include a combination of materials. In any case, the material or materials selected will depend upon the application at hand and all are understood to fall within the scope of the invention.
  • Microneedle device 1 or 101 can be used as a Continuous non-invasive medical device that continuously delivers a fluidic drug through the skin and into the body.
  • Microneedle device 1 or 101 is applied to the skin such that microneedles 20 or 120 penetrate through the stratum corneum and enter the viable epidermis so that the tip of microneedles 20 or 120 at least penetrates into the viable epidermis.
  • insulin could be delivered to the blood stream via microneedles 20 or 120 through the stratum corneum and epidermis, and also into the dermis where the insulin would be absorbed into the capillaries (not shown).
  • FIG. 5A depicts a microneedle system 200 that may be employed for delivering a fluid medicant to a patient. More particularly, FIG. 5A depicts a microneedle system 200 that includes a silicon substrate 210 , an adhesive patch 212 , a microneedle 214 , and a pin 218 having an arcuate distal end 220 .
  • the microneedle 200 may be employed by applying the adhesive patch 212 to the skin of a patient.
  • the needle 214 can penetrate through the outer layer of the patient's skin to provide a drug delivery channel.
  • the distal end 222 of the microneedle 214 may become obstructed, either in part or in whole, by tissue, fluid, or some other material that travels up into an interior channel (not shown) that extends through the microneedle 214 .
  • the microneedle system 200 includes a pin 218 that provides a moveable barrier that is dimensionally adapted for sliding through the interior channel of the microneedle 214 and applying a force to tissue located at the distal end 222 such that the tissue is dislodged from the distal end 222 of the microneedle 214 .
  • the pin 218 includes an arcuate tip 220 .
  • the arcuate tip 220 is optional and is there to provide the ability to penetrate more deeply into the patient's tissue and thereby move any blocking or obstructing tissue from the distal end 222 of the microneedle into a position that is further away from the microneedle 214 .
  • the pin 218 may be extendable past the opening of the microneedle to dislodge tissue from the mcironeedle. However, as discussed above, the pin 218 may also be placed at the distal end of the microneedle 214 as the microneedle is applied to the patient's tissue to block tissue from entering into the interior of the microneedle.
  • the microneedle 214 is formed as a tube and the pointed distal end 220 of the pin 218 provides the cutting edge that penetrates through the patient's tissue.
  • the microneedle 214 may independently have a pointed distal end for penetrating the patient's tissue.
  • FIG. 5B there is depicted another step in the process for delivering the fluid to the patient through the microneedle system 200 .
  • the pin 218 is removed from the microneedle 214 .
  • the interior channel is available and may be attached to a pump 224 .
  • the pump 224 could be a fluidic piston or pump of a kind commonly employed for delivering a low dosage of medicine to a patient.
  • the pump 224 can connect to a proximal end of the microneedle 214 to allow for the delivery of fluid through the interior channel and into the patient.
  • Dosage is delivered through the microneedle 214 as shown in Table 1.
  • Silicone substrate 210 60 mil thick; Die cut 3 ⁇ 8′′ diam.; Class VI Medical Grade; 60 Shore A; Part No. 87315k65; McMaster-Carr Supply Co.
  • Adhesive tape 212 Medical Tape 1513; 3M Transparent Polyester 3.4 Mil Double Coated Medical Tape
  • Liquid adhesive RP 30; Advanced Performance Instant Adhesive; USP Class 6; exp. Aug. 27, 2003; Adhesive Systems Inc., Franklin, Ill.
  • Syringe pump 224 BD 1 ml disposable plastic syringe with hypodermic needle; Becton, Dickinson and Co., Franklin Lakes, N.J.
  • Syringe pump 224 Model KDS100; Ser. No. 4736; kdScientific Inc., New Hope, Pa.
  • the systems and methods described herein may be employed to increase the amount of medicant or fluid delivered to the patient.
  • the pump 224 includes a valve and a controller for regulating the flow of fluid through the interior channel and into the patient. Any suitable pump, valve and controller may be employed and the devices selected will depend at least in part on the application.
  • the pump may be a manually operated pump, such as a syringe. In other embodiments the pump may include a motorized pumping mechanism.
  • the devices disclosed herein are useful in transport of material into or across biological barriers including the skin (or parts thereof); the blood-brain barrier; mucosal tissue (e.g., oral, nasal, ocular, vaginal, urethral, gastrointestinal, respiratory); blood vessels; lymphatic vessels; or cell membranes (e.g., for the introduction of material into the interior of a cell or cells).
  • the biological barriers can be in humans or other types of animals, as well as in plants, insects, or other organisms, including bacteria, yeast, fungi, and embryos.
  • microneedle devices can be applied to tissue internally with the aid of a catheter or laparoscope.
  • the devices can be surgically implanted.
  • the microneedle device disclosed herein is typically applied to skin.
  • the skin consists of multiple layers.
  • the stratum corneum is the outer layer (comprising dead cells), generally between 10 and 50 cells for humans, or between 10 and 20 ⁇ m thick.
  • Below the stratum corneum is the viable epidermis, which is between 50 and 100 ⁇ m thick.
  • the viable epidermis contains no blood vessels, and it exchanges metabolites by diffusion to and from the dermis.
  • Beneath the viable epidermis is the dermis, which is between 1 and 3 mm thick and contains blood vessels, lymphatics, and nerves.
  • the dermis contains a rich capillary network close to the dermal/epidermal junction, and once a drug reaches the dermal depth it diffuses rapidly to deep tissue layers (such as hair follicles, muscles, and internal organs), or systemically via blood circulation.
  • deep tissue layers such as hair follicles, muscles, and internal organs
  • microneedle devices disclosed herein include a substrate; one or more microneedles; a reservoir for delivery of drugs; an element for plugging each of the one or more microneedles; and optionally, pump(s), sensor(s), and/or microprocessor(s) to control the interaction of the foregoing.
  • the substrate of the device can be constructed from a variety of materials, including metals, ceramics, semiconductors, organics, polymers, and composites.
  • the substrate includes the base to which the microneedles are attached or integrally formed.
  • the substrate includes a reservoir for drugs and/or biological molecules.
  • the microneedles of the device can be constructed from a variety of materials, including metals, ceramics, semiconductors, organics, polymers, and composites.
  • Preferred materials of construction include pharmaceutical grade stainless steel, gold, titanium, nickel, iron, gold, tin, chromium, copper, alloys of these or other metals, silicon, silicon dioxide, and polymers.
  • biodegradable polymers include polymers of hydroxy acids such as lactic acid and glycolic acid polylactide, polyglycolide, polylactide-co-glycolide, and copolymers with PEG, polyanhydrides, poly(ortho)esters, polyurethanes; poly(butyric acid), poly(valeric acid), and poly(lactide-co-caprolactone).
  • Representative non-biodegradable polymers include polycarbonate, polymethacrylic acid, ethylenevinyl acetate, polytetrafluorethylene (TEFLONTM), and polyesters.
  • the microneedles should have the mechanical strength to remain intact for delivery of drugs, or serve as a conduit for the collection of biological fluid, while being inserted into the skin, while remaining in place for up to a number of days, and while being removed.
  • this mechanical requirement is less stringent, since the microneedles or tips thereof can break off, for example in the skin, and will biodegrade. Nonetheless, even a biodegradable microneedle still needs to remain intact at least long enough for the microneedle to serve its intended purpose (e.g, its conduit function). Therefore, biodegradable microneedles can provide an increased level of safety, as compared to nonbiodegradable ones.
  • the microneedles should be sterilizable using standard methods.
  • the microneedles of the device may be constructed as described in U.S. Pat. No. 6,312,612 and U.S. Pat. No. 6,334,856.
  • U.S. Pat. No. 6,312,612 describes a microneedle array constructed of silicon and silicon dioxide compounds using MEMS (i.e., Micro-Electro-Mechanical-Systems) technology and standard microfabrication techniques.
  • the microneedle array may be fabricated from a silicon die which can be etched in a microfabrication process to create hollow cylindrical individual microneedles.
  • One process for manufacturing microneedles described by U.S. Pat. No. 6,312,612 comprises providing a mold comprising a plurality of micropillars that are mounted to a base and differentially melting a thin lay of plastic onto the micropillars, such that the plastic coats the micropillars to form hollow microneedles.
  • U.S. Pat. No. 6,334,856 describes microfabrication processes for manufacturing microneedles such as lithography; etching techniques, such as wet chemical, dry, and photoresist removal; thermal oxidation of silicon; electroplating and electroless plating; diffusion processes, such as boron, phosphorus, arsenic, and antimony diffusion; ion implantation; film deposition, such as evaporation (filament, electron beam, flash, and shadowing and step coverage), sputtering, chemical vapor deposition (CVD), epitaxy (vapor phase, liquid phase, and molecular beam), electroplating, screen printing, lamination, stereolithography, laser machining, and laser ablation (including projection ablation).
  • etching techniques such as wet chemical, dry, and photoresist removal
  • thermal oxidation of silicon such as boron, phosphorus, arsenic, and antimony diffusion
  • ion implantation film deposition, such as evaporation (filament, electron beam,
  • the microneedles of the invention may be hollow.
  • the tern “hollow” means having one or more substantially annular bores or channels through the interior of the microneedle structure, having a diameter sufficiently large to permit passage of fluid and/or solid materials through the microneedle.
  • the annular bores may extend throughout all or a portion of the needle in the direction of the tip to the base, extending parallel to the direction of the needle or branching or exiting at a side of the needle, as appropriate.
  • One of skill in the art can select the appropriate bore features required for specific applications. For example, one can adjust the bore diameter to permit passage of the particular material to be transported through the microneedle device.
  • the microneedles can have straight or tapered shafts.
  • the tern “microneedle” includes both microtubes and tapered needles unless otherwise indicated.
  • the diameter of the microneedle is greatest at the base end of the microneedle and tapers to a point at the distal end of the microneedle.
  • the microneedle can also be fabricated to have a shaft that includes both a straight (untapered) portion and a tapered portion.
  • the microneedles can be formed with shafts that have a circular cross-section in the perpendicular, or the cross-section can be non-circular.
  • the cross-section of the microneedle can be polygonal (e.g. star-shaped, square, triangular), oblong, or another shape.
  • the shaft can have one or more bores.
  • the cross-sectional dimensions typically are between about 10 ⁇ m and 1 mm, preferably between 1 micron and 200 microns, and more preferably between 10 and 100 ⁇ m.
  • the outer diameter is typically between about 10 ⁇ m and about 100 ⁇ m
  • the inner diameter is typically between about 3 ⁇ m and about 80 ⁇ m.
  • the length of the microneedles typically is between about 1 ⁇ m and 1 mm, preferably between 10 microns and 500 microns, and more preferably between 30 and 200 ⁇ m. The length is selected for the particular application, accounting for both an inserted and uninserted portion.
  • An array of microneedles can include a mixture of microneedles having, for example, various lengths, outer diameters, inner diameters, cross-sectional shapes, and spacings between the microneedles.
  • the microneedles can be oriented perpendicular or at an angle to the substrate.
  • the microneedles are oriented perpendicular to the substrate so that a larger density of microneedles per unit area of substrate can be provided.
  • An array of microneedles can include a mixture of microneedle orientations, heights, or other parameters.
  • the substrate and/or microneedles, as well as other components are formed from flexible materials to allow the device to fit the contours of the biological barrier, such as the skin, vessel walls, or the eye, to which the device is applied.
  • a flexible device will facilitate more consistent penetration during use, since penetration can be limited by deviations in the attachment surface. For example, the surface of human skin is not flat due to dermatoglyphics (i.e. tiny wrinkles) and hair.
  • the microneedle devices of the invention also include a reservoir in fluid communication with the microneedles.
  • the reservoir is formed in the substrate in a space below the base (to which the microneedles are attached).
  • the reservoir will accommodate about 0.2-10.0 ml of a solution or a suspension containing a therapeutic agent (e.g., the reservoir can contain about 0.4, 0.5, 1.0, 2.5, 5.0 or 7.5 ml of such a solution).
  • the reservoir and therapeutic agent may be chosen such that the device contains not more than 1, 2, 3, 5, or 10 days supply of the agent.
  • the reservoir contains drug, for delivery through the microneedles.
  • the reservoir may be a hollow vessel, a porous matrix, or a solid form including drug which is transported therefrom.
  • the reservoir can be formed from a variety of materials that are compatible with the drug or biological fluid contained therein. Preferred materials include natural and synthetic polymers, metals, ceramics, semiconductors, organics, and composites.
  • the microneedle device can include one or a plurality of chambers for storing materials to be delivered.
  • each can be in fluid connection with all or a portion of the microneedles of the device array.
  • at least two chambers are used to separately contain drug (e.g., a lyophilized drug, such as a vaccine) and an administration vehicle (e.g., saline) in order to prevent or minimize degradation during storage.
  • drug e.g., a lyophilized drug, such as a vaccine
  • an administration vehicle e.g., saline
  • the contents of the chambers are mixed. Mixing can be triggered by any means, including, for example, mechanical disruption (i.e. puncturing or breaking), changing the porosity, or electrochemical degradation of the walls or membranes separating the chambers.
  • a single device is used to deliver different drugs, which are stored separately in different chambers. In this embodiment, the rate of delivery of each drug can be independently controlled.
  • the reservoir should be in fluid communication with the microneedles so that the therapeutic in a fluid composition or form could exit the reservoir and flow into the hollow microneedles.
  • the microneedle devices of the invention also include one or more elements for plugging each of the one or more microneedles (the plugging element).
  • the plugging element of the device can be constructed from a variety of materials, including metals, ceramics, semiconductors, organics, polymers, and composites. Generally, the plugging element should have the mechanical strength to prevent skin or other tissue from enter the hollow microneedles when the microneedle device is applied to the skin.
  • the plugging element may comprise a platform, held up by springs, including a plurality of protuberances (microneedle plugs) sized to fit into the hollow microneedles to prevent slain or other tissue barriers from entering the hollow microneedles.
  • the outer diameter of the microneedle plugs will typically be between about 3 ⁇ m and about 80 ⁇ m, depending oil the diameter of the microneedles.
  • the length of the microneedles typically is between about 1 ⁇ m and about 1 mm.
  • the length of the microneedle plugs will also be between about 1 ⁇ m and about 1 mm.
  • the microneedle plug may, however, extend past the length of the microneedles.
  • the microneedle plugs also may mimic the perpendicular, cross-sectional shape of microneedles, for example, the perpendicular cross-section of the microneedle plug can be polygonal (e.g. star-shaped, square, triangular), oblong, or another shape best able to fit the microneedle.
  • a microneedle device in another preferred embodiment, includes a plurality of bioerodible elements (microneedle plugs) for temporarily plugging the hollow microneedles, thereby preventing skin or other tissue barriers from entering the hollow microneedles.
  • the microneedle plug is comprised of a continuous piece of bioerodible polymer having a portion inside and a portion outside the distal end of the microneedle. The portion inside the distal end of the microneedle is held in place by friction or by a small amount of biocompatible adhesive.
  • the microneedle plug also may mimic the perpendicular, cross-sectional shape of microneedle, for example, the perpendicular cross-section of the microneedle plug can be polygonal (e.g.
  • the portion inside the distal end of the microneedle may be from about 1 ⁇ m to about 500 ⁇ m in length, preferably from about 1 m to about 250 ⁇ m, more preferably from about 5 ⁇ m to about 100 ⁇ m.
  • the cross-sectional dimensions of the portion inside the distal end of the microneedle may be from about 10 nm to about 1 mm, preferably from about 1 ⁇ m to about 200 ⁇ m, more preferably from about 3 ⁇ m to about 80 ⁇ m.
  • the portion outside the distal end of the microneedle may have a cone shape with the base (widest portion) of the cone attached to the polymer portion inside the microneedle.
  • the outside portion may be from about 1 ⁇ m up to about 500 ⁇ m in length and have a diameter at the base from about 1 ⁇ m up to about 1.2 mm in diameter.
  • the diameter of the base of the cone will be greater than the diameter of the microneedle to which it is fitted.
  • the outside portion may have an arrowhead shape, the barbed ends of the arrowhead shape extending past the sides of the microneedle. The width of the arrowshead across the barbed ends should be wider than the diameter of the microneedle.
  • microneedle devices of the invention also must be capable of transporting material across the barrier at a useful rate.
  • a microneedle device must be capable of delivering drug across the skin at a rate sufficient to be therapeutically useful.
  • a device may include a housing with microelectronics and other micromachined structures to control the rate of delivery either according to a preprogrammed schedule or through active interface with the patient, a healthcare professional, or a biosensor.
  • the rate can be controlled by manipulating a variety of factors, including the characteristics of the drug formulation to be delivered (e.g., its viscosity, electric charge, and chemical composition); the dimensions of each microneedle (e.g., its outer diameter and the area of porous or hollow openings); the number of microneedles in the device; the application of a driving force (e.g., a concentration gradient, a voltage gradient, a pressure gradient); and the use of a valve.
  • a driving force e.g., a concentration gradient, a voltage gradient, a pressure gradient
  • the rate also can be controlled by interposing between the drug in the reservoir and the opening(s) at the base end of the microneedle polymer or other materials selected for their diffusion characteristics.
  • the material composition and layer thickness can be manipulated using methods known in the art to vary the rate of diffusion of the drug of interest through the material, thereby controlling the rate at which the drug flows from the reservoir through a microneedle and into the tissue.
  • Transportation of molecules through the microneedles can be controlled or monitored using, for example, various combinations of valves, pumps, sensors, actuators, and microprocessors. These components can be produced using standard manufacturing or microfabrication techniques. Actuators that may be useful with the microneedle devices disclosed herein include micropumps, microvalves, and positioners. In a preferred embodiment, a microprocessor is programmed to control a pump or valve, thereby controlling the rate of delivery.
  • Flow of molecules through the microneedles can occur based on diffusion, capillary action, or can be induced using conventional mechanical pumps or nonmechanical driving forces, such as electroosmosis or electrophoresis, or convection.
  • electroosmosis electrodes are positioned on the biological barrier surface, one or more microneedles, and/or the substrate adjacent the needles, to create a convective flow which carries oppositely charged ionic species and/or neutral molecules toward or into the biological barrier.
  • the microneedle device is used in combination with another mechanism that enhances the permeability of the biological barrier, for example by increasing cell uptake or membrane disruption, using electric fields, ultrasound, chemical enhancers, viruses, pH, heat and/or light.
  • Passage of the microneedles, or drug to be transported via the microneedles can be manipulated by shaping the microneedle surface, or by selection of the material forming the microneedle surface (which could be a coating rather than the microneedle per se).
  • the physical surface properties of the microneedle could be manipulated to either promote or inhibit transport of material along the microneedle surface, such as by controlling hydrophillicity or hydrophobicity.
  • valves or gates can be the type that are selectively and repeatedly opened and closed, or they can be single-use types.
  • a fracturable barrier or one-way gate may be installed in the device between the reservoir and the opening of the microneedles. When ready to use, the barrier can be broken or gate opened to permit flow through the microneedles.
  • Other valves or gates used in the microneedle devices can be activated thermally, electrochemically, mechanically, or magnetically to selectively initiate, modulate, or stop the flow of molecules through the needles. In a preferred embodiment, flow is controlled by using a rate-limiting membrane as a “valve.”
  • the microneedle devices can further include a flowmeter or other means to monitor flow through the microneedles and to coordinate use of the pumps and valves.
  • the microneedle devices of the invention can further include sensors.
  • Useful sensors may include sensors of pressure, temperature, chemicals, and/or electromagnetic fields.
  • Biosensors can be located on the microneedle surface, inside a hollow or porous microneedle, or inside a device in communication with the body tissue via the microneedle (solid, hollow, or porous).
  • These microneedle biosensors can include four classes of principal transducers: potentiometric, amperometric, optical, and physiochemical.
  • An amperoimetric sensor monitors currents generated when electrons are exchanged between a biological system and an electrode. Blood glucose sensors frequently are of this type.
  • the microneedle may function as a conduit for fluids, solutes, electric charge, light, or other materials.
  • hollow microneedles can be filled with a substance, such as a gel, that has a sensing functionality associated with it.
  • the substrate or enzyme can be immobilized in the needle interior.
  • Wave guides can be incorporated into the microneedle device to direct light to a specific location, or for detection, for example, using means such as a pH dye for color evaluation.
  • heat, electricity, light or other energy forms may be precisely transmitted to directly stimulate, damage, or heal a specific tissue or intermediary (e.g., tattoo remove for dark skinned persons), or diagnostic purposes, such as measurement of blood glucose based on IR spectra or by chromatographic means, measuring a color change in the presence of immobilized glucose oxidase in combination with an appropriate substrate.
  • the microneedle devices can further include a collar or flange, for example, around the periphery of the substrate or the base. It preferably is attached to the device, but alternatively can be formed as integral part of the substrate, for example by forming microneedles only near the center of an “oversized” substrate.
  • the collar can also emanate from other parts of the device. The collar can provide an interface to attach the microneedle array to the rest of the device, and can facilitate handling of the smaller devices.
  • the device may be attached to the patient by a belt, strap, or adhesive (e.g., it can be attached to the patient's skin by an adhesive patch).
  • an adhesive and a second security device e.g., a belt or strap can be used.
  • a microneedle device includes an adhesive to temporarily secure the device to the surface of the biological barrier.
  • the adhesive can be essentially anywhere on the device to facilitate contact with the biological barrier.
  • the adhesive can be on the surface of the collar (same side as microneedles), on the surface of the substrate between the microneedles (near the base of the microneedles), or a combination thereof.
  • microneedle devices of the present invention may be used for single or multiple uses for rapid transport across a biological barrier or may be left in place for longer times (e.g., hours or days) for long-term transport of molecules.
  • the device may be used to introduce or remove molecules at specific locations.
  • the device should be “user-friendly.” For example, in some transdermal applications, affixing the device to the skin should be relatively simple, and not require special skills.
  • the embodiment of a microneedle may include an array of microneedles attached to a housing containing drug in an internal reservoir, wherein the housing has a bioadhesive coating around the microneedles and the microneedles are plugged with bioerodible elements. The patient can remove a peel-away backing to expose an adhesive coating, and then press the device onto a clean part of the skin, leaving it to administer drug over the course of, for example, several days.
  • any drug or other bioactive agents can be delivered using these devices.
  • Drugs can be proteins, enzymes, polysaccharides, polynucleotide molecules, and synthetic organic and inorganic compounds.
  • a preferred drug is insulin.
  • Representative agents include anti-infectives, hormones, growth regulators, drugs regulating cardiac action or blood flow, vaccines, chemotherapy agents, pain relief agents, dialysis-related agents, blood thinning agents, and drugs for pain control.
  • the drug can be for local treatment or for regional or systemic therapy.
  • calcitonin osteoporosis
  • enoxaprin anticoagulant
  • etanercept rheumatoid arthritis
  • erythropoietin anemia
  • fentanyl postoperative and chronic pain
  • filgrastin low white blood cells from chemotherapy
  • heparin anticoagulant
  • insulin human, diabetes
  • interferon beta 1 a multiple sclerosis
  • lidocaine local anesthesia
  • somatropin growth hormone
  • sumatriptan migraine headaches
  • vaccines towards tumors and vaccines towards infectious diseases.
  • the microneedle device of the present invention can be used in many applications, including as a painless and convenient transdermal drug-delivery system for continuous and controlled outpatient therapies.
  • Another use of the microneedle device of the present invention is to form a portable drug delivery system for outpatient delivery of the following drugs and therapeutic agents, for example: central nervous system therapy agents, psychic energizing drugs, tranquilizers, anticonvulsants, muscle relaxants and anti-parkinson agents, smoking cessation agents, analgesics, antipyretics and anti-inflammatory agents, antispasmodics and antiulcer agents, antimicrobials, antimalarias, sympathomimetric patches, antiparasitic agents, neoplastic agents, nutritional agents, and vitamins.
  • drugs and therapeutic agents for example: central nervous system therapy agents, psychic energizing drugs, tranquilizers, anticonvulsants, muscle relaxants and anti-parkinson agents, smoking cessation agents, analgesics, antipyretics and anti-inflammatory agents, antis
  • the devices may contain a predetermined dosage of therapeutic which may be dependent on the disease or disorder being treated, the size of the individual to be treated, the effective dose of the therapeutic, etc.
  • the rate can be controlled by varying a number of design factors, including the outer diameter of the microneedle, the number and size of channels in each microneedle, the number of microneedles in an array, the magnitude and frequency of application of the force driving the drug through the microneedle and/or the holes created by the microneedles.
  • design factors including the outer diameter of the microneedle, the number and size of channels in each microneedle, the number of microneedles in an array, the magnitude and frequency of application of the force driving the drug through the microneedle and/or the holes created by the microneedles.
  • devices designed to deliver drug at different rates might have more microneedles for more rapid delivery and fewer microneedles for less rapid delivery.
  • a device designed to deliver drug at a variable rate could vary the driving force (e.g., pressure gradient controlled by a pump) for transport according to a schedule which was pre-programmed or controlled by, for example, the user or his doctor.
  • the devices can be affixed to the skin or other tissue to deliver drugs continuously or intermittently, for durations ranging from a few seconds to several hours or days.
  • One of skill in the art can measure the rate of drug delivery for particular microneedle devices using in vitro and in vivo methods known in the art.
  • human cadaver skin mounted on standard diffusion chambers can be used to predict actual rates. See Hadgraft & Guy, eds., Transdermal Drug Delivery: Developmental Issues and Research Initiatives (Marcel Dekker, New York 1989); Bronaugh & Maibach, Percutaneous Absorption, Mechanisms—Methodology—Drug Delivery (Marcel Dekker, New York 1989).
  • a microneedle array is inserted into the stratum corneum; a drug solution is placed in the reservoir of the microneedle device; and samples of the saline solution are taken over time and assayed to determine the rates of drug transport.
  • One embodiment of the devices described herein may be used to remove material from the body across a biological barrier, i.e. for minimally invasive diagnostic sensing.
  • fluids can be transported from interstitial fluid in a tissue into a reservoir in the upper portion of the device. The fluid can then be assayed while in the reservoir or the fluid can be removed from the reservoir to be assayed, for diagnostic or other purposes.
  • interstitial fluids can be removed from the epidermis across the stratum corneum to assay for glucose concentration, which should be useful in aiding diabetics in determining their required insulin dose.
  • Other substances or properties that would be desirable to detect include lactate (important for athletes), oxygen, pH, alcohol, tobacco metabolites, and illegal drugs (important for both medical diagnosis and law enforcement).
  • the sensing device can be in or attached to one or more microneedles, or in a housing adapted to the substrate.
  • Sensing information or signals can be transferred optically (e.g., refractive index) or electrically (e.g., measuring changes in electrical impedance, resistance, current, voltage, or combination thereof).
  • optically e.g., refractive index
  • electrically e.g., measuring changes in electrical impedance, resistance, current, voltage, or combination thereof.
  • one or more microneedle devices can be used for (1) withdrawal of interstitial fluid, (2) assay of the fluid, and/or (3) delivery of the appropriate amount of a therapeutic agent based on the results of the assay, either automatically or with human intervention.
  • a sensor delivery system may be combined to form, for example, a system which withdraws bodily fluid, measures its glucose content, and delivers an appropriate amount of insulin.
  • the sensing or delivery step also can be performed using conventional techniques, which would be integrated into use of the microneedle device.
  • the microneedle device could be used to withdraw and assay glucose, and a conventional syringe and needle used to administer the insulin, or vice versa.
  • the microneedles may be used to transmit or transfer other materials and energy forms, such as light, electricity, heat, or pressure.
  • the microneedles could be used to direct light to specific locations within the body, in order that the light can directly act on a tissue or on an intermediary, such as light-sensitive molecules in photodynamic therapy.
  • the microneedles can also be used for aerosolization or delivery for example directly to a mucosal surface in the nasal or buccal regions or to the pulmonary system.
  • microneedle devices disclosed herein also should be useful for controlling transport across tissues other than skin.
  • microneedles could be inserted into the eye across, for example, conjunctiva, sclera, and/or cornea, to facilitate delivery of drugs into the eye.
  • microneedles inserted into the eye could facilitate transport of fluid out of the eye, which may be of benefit for treatment of glaucoma.
  • Microneedles may also be inserted into the buccal (oral), nasal, vaginal, or other accessible mucosa to facilitate transport into, out of, or across those tissues.
  • a drug may be delivered across the buccal mucosa for local treatment in the mouth or for systemic uptake and delivery.
  • microneedle devices may be used internally within the body on, for example, the lining of the gastrointestinal tract to facilitate uptake of orally-ingested drugs or the lining of blood vessels to facilitate penetration of drugs into the vessel wall.
  • cardiovascular applications include using microneedle devices to facilitate vessel distension or immobilization, similarly to a stent, wherein the microneedles/substrate can function as a “staple-like” device to penetrate into different tissue segments and hold their relative positions for a period of time to permit tissue regeneration. This application would be particularly useful with biodegradable devices. These uses may involve invasive procedures to introduce the microneedle devices into the body or could involve swallowing, inhaling, injecting or otherwise introducing the devices in a non-invasive or minimally-invasive manner.
  • the length of the individual microneedles is by far the most important dimension with regard to providing a painless and bloodless drug-dispensing system, or a painless and bloodless body-fluids sampling system using the opposite direction of fluid flow. While the dimensions discussed hereinabove are preferred, and the ranges discussed are normal for human skin, it will further be understood that the microneedle arrays of the present invention can be used on skin of any other form of living (or even dead) creatures or organisms, and the preferred dimensions may be quite different as compared to those same dimensions for use with human skin, all without departing from the principles of the present invention.

Abstract

Microneedle devices for transport of molecules, including drugs and biological molecules, across tissue, are provided. The microneedle devices permit drug delivery or removal of body fluids at clinically relevant rates across skin or other tissue barriers, with minimal or no damage, pain, or irritation to the tissue. Microneedles can be formed of biodegradable or non-biodegradable polymeric materials or metals. In a preferred embodiment, a microneedle device includes a plugging element comprising a platform including a plurality of microneedle plugs for preventing skin or other tissue barriers from entering the hollow microneedles. In another preferred embodiment, a microneedle device includes a plurality of bioerodible elements for temporarily plugging the hollow microneedles, thereby preventing skin or other tissue barriers from entering the hollow microneedles.

Description

    RELATED APPLICATIONS
  • This application claims priority to U.S. [0001] Provisional Application 60/416,740 entitled Microneedle Array Patch, the contents of which are herein incorporated by reference.
  • BACKGROUND
  • This invention relates to injection devices, such as microneedle devices having an array of microneedles for placing on the skin. [0002]
  • Conventional methods of biological fluid sampling and non-oral drug delivery are normally invasive. That is, the skin is lanced to extract blood and measure various components when performing fluid sampling, or a drug delivery procedure is normally performed by injection, which causes pain and requires special medical training. Alternatives to drug delivery by injection have been disclosed, for example, by Henry, McAllister, Allen, and Prausnitz, of Georgia Institute of Technology (in a paper titled “Micromachined Needles for the Transdermal Delivery of Drugs”), U.S. Pat. No. 3,964,482, WO 98/00193, WO 97/48440, WO 97/48441, and WO 97/48442. [0003]
  • The use of microneedles has great advantages in that intracutaneous drug delivery can be accomplished without pain, leading to increased patient compliance, and without bleeding. Further, patients may apply the drug delivery devices themselves without extensive training. As used herein, the term “microneedles” refers to a plurality of elongated structures that are sufficiently long to penetrate through the stratum corneum skin layer and into the epidermal layer, yet are also sufficiently short to not penetrate to the dermal layer. However, if the dead cells have been completely or mostly removed from a portion of skin, then a very minute length of microneedle could be used to reach the viable epidermal tissue. [0004]
  • However, technical problems exist in the use of such microneedles. Among them is the plugging of hollow microneedles with skin or other tissues, thus, preventing the flow of therapeutic through the microneedle. This may have an impact on the amount of therapeutic actually delivered to the patient, which can be important for proper dosing. [0005]
  • SUMMARY OF THE INVENTION
  • Microneedle devices for transport of molecules, including drugs and biological molecules, across tissue, are provided. The microneedle devices permit drug delivery or removal of body fluids at clinically relevant rates across skin or other tissue barriers, with minimal or no damage, pain, or irritation to the tissue. Microneedles can be formed of a variety of materials, including biodegradable or non-biodegradable polymeric materials or metals. The microneedle devices described herein include a hollow microneedle capable of penetrating the stratum corneum. The microneedle has a movable barrier located at a distal end of the microneedle. The moveable barrier prevents or reduces tissue from blocking an interior channel that extends though the microneedle. In one particular embodiment, the microneedle device include a platform or substrate having a plurality of microneedles each with plugs disposed at their distal ends for preventing skin or other tissue barriers from entering the hollow microneedles. In another embodiment, a microneedle device includes a plurality of bioerodible elements for temporarily plugging the hollow microneedles, thereby preventing skin or other tissue barriers from entering the hollow microneedles. The bio erodible elements may be plugs that are fitted within the distal end of a channel extending through the microneedle. The plugs may be frangible and optionally may have a seam that allows the plug to separate from the microneedle. Once separated the plug may dissolve over time. [0006]
  • In a further optional embodiment, the devices described herein may include moveable barriers that comprise pins or pistons that fit within the interior channels of the mcironeedle and may be moved through the channel so that a distal portion of the pin or piston sits within the distal end of the channel and prevents tissue from blocking the microneedle. In a further optional embodiment, the pin or piston may be capable of pushing tissue from the channel to dislodge any tissue blocking the channel. [0007]
  • Additional advantages and other novel features of the invention will be set forth in part in the description that follows and in part will become apparent to those skilled in the art upon examination of the following or may be learned with the practice of the invention. As will be realized, the invention is capable of other different embodiments, and its several details are capable of modification in various, aspects all without departing from the invention. Accordingly, the drawings and descriptions will be regarded as illustrative in nature and not as restrictive.[0008]
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 depicts a microneedle surface of one embodiment of the invention. [0009]
  • FIG. 2A depicts a cross-sectional view of the microneedle device of FIG. 1 in its resting state. [0010]
  • FIG. 2B depicts a cross-sectional view of the microneedle device of FIG. 1 when pressure is applied to back of the patch. [0011]
  • FIG. 3 depicts a microneedle surface of a different embodiment of the invention. [0012]
  • FIG. 4A depicts a cross-sectional view of the microneedle device of FIG. 3 prior to its application to skin. [0013]
  • FIG. 4B depicts a cross-sectional view of the microneedle device of FIG. 3 during its application to skin. [0014]
  • FIG. 4C depicts a cross-sectional view of the microneedle device of FIG. 3 after its application to skin. [0015]
  • FIG. 4D depicts a cross-sectional view of a microneedle and plug. [0016]
  • FIGS. 5A and 5B depict a process for clearing tissue from the channel of a microneedle and pumping fluid through the channel.[0017]
  • DETAILED DESCRIPTION OF EXEMPLARY EMBODIMENTS
  • The systems and methods described herein are, in one aspect, directed to transdermal devices, including an intraepidermal delivery devices for administering a substance to a patient. More particularly, the invention is directed to devices and to methods for establishing fluid communication for administering agents and monitoring a patent's condition. In one exemplary embodiment the systems and methods provide delivery devices for administering a substance into or below the stratum corneum of the skin of a patient. As used herein, the term penetrate refers to entering a layer of the skin without necessarily passing completely through. Piercing refers to passing completely through a layer of the skin. As used herein, transdermal refers to the exchange of a substance, such as blood, a pharmaceutical, a biological agent or a vaccine, through one or more layers of skin. Intradermal refers to one or more layers within the skin and not limited to the dermis layer of the skin. [0018]
  • The devices and methods are particularly suitable for use in administering various substances, including pharmaceutical agents, to a patient, and notably to a human patient. A pharmaceutical agent includes a substance having biological activity that can be delivered through the body membranes and surfaces, and particularly the skin. Examples include antibiotics, antiviral agents, analgesics, anesthetics, anorexics, antiarthritics, antidepressants, antihistamines, anti-inflammatory agents, antineoplastic agents, vaccines, including DNA vaccines, adjuvants, biologics, and the like. Other substances which can be delivered intradermally to a patient include proteins, peptides and fragments thereof. The proteins and peptides can be naturally occurring, synthesized or recombinantly produced. [0019]
  • In some embodiments, a vaccine is administered using the device and method. The multipuncture devices of described herein are believed in addition to have a unique immunological advantage in the delivery of vaccines with the potential of increasing the vaccine's clinical value. The insertion of the multiple needle points into the tissue is suggested as having an adjuvant-like stimulatory effect. The needle stick response from multiple microneedle points is believed more than a simple acute inflammatory response. Needle sticks can cause damage to a variety of cells and cellular architecture, causing the appearance of polymorphonuclear neutrophil (PMN) and microphages as well as the release of cytokines, including IL1, tumor necrosis factor (TNF) and other agents, which can lead to a number of other immunological responses. The soluble stimulatory factors influence the proliferation of lymphocytes and are central to the immune response to vaccines. The immune stimulation is proportional to the direct needle-cell interaction. [0020]
  • The microneedle device is valuable in promoting significant immune response to a vaccine by delivering a vaccine below the stratum corneum and into the cells of the tissue. Some of the microneedles can have a length selected to penetrate and pass through the stratum corneum without penetrating the dermis to minimize absorption of the vaccine into the bloodstream. The small intracellular depots created by the microneedle array are believed to increase the availability of the vaccine antigen for interaction with antigen presenting cells more than would a vaccine deposited by standard needles in a larger depot quantity. In further embodiments, some or all of the microneedles can have a length to penetrate, but not pierce, the stratum corneum. [0021]
  • The microneedle array is believed to magnify several-fold the trivial or inconsequential immune stimulatory impact of a single needlestick independent of the route of delivery and vaccine. The microneedle delivery device facilitates and enhances vaccine immunogenicity by an adjuvant-like immune stimulation. [0022]
  • The primary barrier properties of the skin including the resistance to drug penetration reside in the outermost layer of the skin, referred to as the stratum corneum. The inner layers of the epidermis generally include three layers, commonly identified as the stratum granulosum, the stratum malpighii, and the stratum germinativum. Once a drug or other substance penetrates below the stratum corneum, there is substantially less resistance to permeation into the subsequent layers of the skin and eventual absorption by the body. Thus, delivery of a substance below the stratum corneum can be an effective system for administering some substances, and particularly some vaccines, to the body. The devices and methods described herein will, among other things, for deliver a substance, and particularly a pharmaceutical agent, into or below the stratum corneum for administering the substance or pharmaceutical agent to the patient. Preferably, the device and method pierce the stratum corneum substantially without penetrating the dermis to target the tissue layers below the stratum corneum. It is of potential benefit for vaccines to target presentation of antigen to various antigen presenting cells and other immunostimulatory sites, such as Langerhans cells and intraepithelial cells, as well as proximal delivery of adjuvants. [0023]
  • FIG. 1 depicts one embodiment of a microneedle device. Microneedle device [0024] 1 shows microneedle surface 10, including microneedles 20 with microneedles openings 30. As shown, the microneedle device may comprise an array of microneedles, each of which is hollow and each of which can penetrate the stratum corneum. In this embodiment, the microneedle array may be used as part of a transdermal patch that transdermally delivers a substance to the patient or transdermally collects a sample from the patient. To this end the device 1 may include a reservoir that can store a fluid substance or substances to deliver to the patient or that was collected from the patient. In either case, and as will be described in more detail herein, the microneedle device 1 includes a distal barrier over or within one or more of the microneedles 20, and typically, the barrier is disposed over or within the distal end of the channel 30 to prevent tissue from blocking the channel openings 30 when the patient or doctor applies pressure to device 1 to force the mcironeedles 20 through the tissue.
  • FIG. 2A depicts a cross-sectional view of microneedle device [0025] 1 in its resting state. Drug reservoir 70 is loaded with a predetermined amount of a therapeutic in liquid form. Platform 60 includes microneedle plugs 61 which are arrayed to fit into microneedles 20 in order to prevent punctured skin from entering and plugging microneedles 20, and preventing the release of therapeutic. Platform 60 rests on springs 50 which hold platform 60 and microneedle plugs 61 above microneedles 20.
  • FIG. 2B depicts a cross-sectional view of microneedle device [0026] 1 when pressure (represented by three arrows) is applied to device surface 40 while microneedle device 1 is being applied to skin. Microneedle device 1 is applied to skin with microneedle surface 10 in contact with the skin. The pressure pushes down platform 60 depresses springs 50, and forces microneedle plugs 61 into microneedles 20, preventing skin from entering and plugging microneedles 20. After pressure is released from device surface 40, device 1 returns to the formation shown in FIG. 2A. Springs 50 re-extend to lift platform 60 and microneedle plugs 61 from microneedles 20. At this point, microneedles 20 are embedded into skin and the therapeutic in a liquid composition or form escapes from drug reservoir 70 through microneedles openings 30. Thus the plugs 61 act as moveable barriers that prevent tissue from blocking the openings 30 of microneedles 20.
  • [0027] Platform 60 is depicted in FIGS. 2A-2B as solid, however, other embodiments are contemplated. For example, platform 60 may include a plurality of openings, in the areas surrounding platform plugs 61, through which a therapeutic may flow from drug reservoir 70 through microneedles 20. Further, FIGS. 2A-2B depict the interior microneedles 61 (as being sized to fit within the interior of microneedles 20. However, in other embodiments, the microneedles 20 may have narrow interior channels and in this embodiment microneedles 61 may be narrow pin shaped elements that may slide into, and optionally extend from, the distal opening of the microneedles 20. In either case the microneedles 61 do not need to have interior channels for passing fluid as microneedles may be slid out of, at least partially, the interior channel of the microneedle 20. In such embodiments, the conical shape of the microneedle interior channel will provide space between the microneedle 61 and the interior wall of the conical channel, thereby providing a space through which the therapeutic fluid may flow. In further optional embodiments, the microneedle 61 may have an exterior surface that is grooved or scored to provide a path through which liquid may flow. Optionally, the wall of the interior channel may be similarly grooved or scored. Other techniques for increasing fluid flow may be practiced with the systems described herein without departing from the scope of the invention.
  • FIG. 3 depicts an alternative embodiment of a microneedle device. [0028] Microneedle device 101 shows microneedle surface 110, including microneedles 120 with microneedle plugs 130. An optional adhesive patch 112 secures the device 101 to the tissue of the patient.
  • FIG. 4A depicts a cross-sectional view of [0029] microneedle device 101 prior to its application to skin. In this embodiment, drug reservoir 170 is loaded with a predetermined amount of a therapeutic in liquid form. The microneedle openings 121 of microneedles 120 are blocked by microneedle plugs 130. Microneedle plugs 130 have an accurate shape with shoulders 132 that extend beyond the diameter of microneedles 120. In this embodiment, the plugs 130 have a shape adapted to act as a barb and catch biological tissue. The plugs 130 may have a frangible seam that fractures when the microneedle device 101 is applied to the patient's tissue. This allows the plug 130 to separate from the needle 120, and thereby facilitates the flow of agent through the needle 120.
  • FIG. 4B depicts a cross-sectional view of the [0030] microneedle device 101 during its application to skin. Microneedle device 101 is applied to skin with microneedle surface 110 in contact with the skin. Microneedle plugs 130 block microneedles openings 121, preventing skin from entering and plugging microneedles 120, thereby preventing the release of therapeutic. Microneedle device 101 is pressed into skin to a deeper level than when the pressure applied to microneedle device 101 is released. When the pressure is released, microneedle device 101 rises from the level it has been pushed to and rests on the surface of the skin. However, shoulders 132 of microneedle plugs 130 anchor microneedle plugs 130 at the level to which microneedle plugs 130 have been pushed. Thus, as microneedle device 101 rises to rest on the surface of the skin, microneedle plugs 130 are pulled out of microneedle openings 121 and microneedles 120.
  • FIG. 4C depicts a cross-sectional view of [0031] microneedle device 101 after its application to skin and microneedle plugs 130 are anchored in skin. The therapeutic in a liquid composition or form escapes from drug reservoir 170 through microneedles openings 121. The anchored plugs 130 may be comprised of a biologically erodible material that over time will dissolve. Optionally and alternatively, the plugs 130 may comprise a therapeutic material that caries a medicant into the patient's tissue to provide a time release dose that may work in cooperation with the fluidic medicant delivered through the microneedles 120.
  • FIG. 4D depicts a cross-sectional view of the [0032] microneedle 120 having a plug 130 disposed therein. Specifically, FIG. 4D depicts that the microneedle 120 may have an interior channel 122 that is conically shaped. The plug 130 may have a lower accurate section 132 and an upper conical section 134. The upper conical section 134 mates up with the interior wall of the channel 122 to form a mechanical stop that prevents the plug 130 from sliding out of the distal end of the interior channel 122. In a further optional embodiment, the plug 130 may include a proximal end that secures to the exterior surface of the microneedle 120. In such an embodiment, the plug 130 does not enter into the microneedle channel, or does not enter a substantial amount. Instead the plug 130 includes a frangible collar that wraps around and secures to the exterior distal surface of the microneedle 120. Such an embodiment is depicted in FIG. 4A which shows one of the microneedles 130 having a proximal collar 132. The proximal collar 132 may be formed of the same material as the plug 130, or optionally of a different material. A frangible seam 134, which may be a perforated seam, may be disposed between the collar 132 and the distal end of the plug 130. The frangible seam 134 may facilitate the separation of the distal end of the plug 130 from the device 101. In these embodiments, the plug 130 may be formed of a bioerodible material. Such materials include polymers of hydroxy acid and are enumerated in more detail below. In other embodiment, the plug 130 may be made of other materials, including materials that carry a medicant for delivering medicant to the patient. Still, in other embodiments, the plug 130 may include a combination of materials. In any case, the material or materials selected will depend upon the application at hand and all are understood to fall within the scope of the invention.
  • [0033] Microneedle device 1 or 101 can be used as a Continuous non-invasive medical device that continuously delivers a fluidic drug through the skin and into the body. Microneedle device 1 or 101 is applied to the skin such that microneedles 20 or 120 penetrate through the stratum corneum and enter the viable epidermis so that the tip of microneedles 20 or 120 at least penetrates into the viable epidermis. For one example, insulin could be delivered to the blood stream via microneedles 20 or 120 through the stratum corneum and epidermis, and also into the dermis where the insulin would be absorbed into the capillaries (not shown).
  • FIG. 5A depicts a [0034] microneedle system 200 that may be employed for delivering a fluid medicant to a patient. More particularly, FIG. 5A depicts a microneedle system 200 that includes a silicon substrate 210, an adhesive patch 212, a microneedle 214, and a pin 218 having an arcuate distal end 220.
  • As discussed above, the [0035] microneedle 200 may be employed by applying the adhesive patch 212 to the skin of a patient. The needle 214 can penetrate through the outer layer of the patient's skin to provide a drug delivery channel. As also discussed above, the distal end 222 of the microneedle 214 may become obstructed, either in part or in whole, by tissue, fluid, or some other material that travels up into an interior channel (not shown) that extends through the microneedle 214. To this end, the microneedle system 200 includes a pin 218 that provides a moveable barrier that is dimensionally adapted for sliding through the interior channel of the microneedle 214 and applying a force to tissue located at the distal end 222 such that the tissue is dislodged from the distal end 222 of the microneedle 214. In the embodiment depicted in FIG. 5A, the pin 218 includes an arcuate tip 220. The arcuate tip 220 is optional and is there to provide the ability to penetrate more deeply into the patient's tissue and thereby move any blocking or obstructing tissue from the distal end 222 of the microneedle into a position that is further away from the microneedle 214. As discussed above the pin 218 may be extendable past the opening of the microneedle to dislodge tissue from the mcironeedle. However, as discussed above, the pin 218 may also be placed at the distal end of the microneedle 214 as the microneedle is applied to the patient's tissue to block tissue from entering into the interior of the microneedle. In this embodiment, the microneedle 214 is formed as a tube and the pointed distal end 220 of the pin 218 provides the cutting edge that penetrates through the patient's tissue. Optionally however the microneedle 214 may independently have a pointed distal end for penetrating the patient's tissue.
  • Turning to FIG. 5B, there is depicted another step in the process for delivering the fluid to the patient through the [0036] microneedle system 200. Specifically, as shown therein, the pin 218 is removed from the microneedle 214. Once removed, the interior channel is available and may be attached to a pump 224. The pump 224 could be a fluidic piston or pump of a kind commonly employed for delivering a low dosage of medicine to a patient. As depicted in FIG. 5B, the pump 224 can connect to a proximal end of the microneedle 214 to allow for the delivery of fluid through the interior channel and into the patient. In experiments Dosage is delivered through the microneedle 214 as shown in Table 1.
    TABLE 1
    Flow Vol- Time
    rate ume (min:
    (ul/min) (ul) sec) Comments
     1 50 50:00 Some pain during insertion; slight stinging be-
    gins 6 minutes into the experiment and gradu-
    ally becomes more painful up until about the 20
    min mark, then decreases until it disappears at
    ˜32 min; piston moved ˜50 ul; minor leaking
    upon removal ˜1 ul; site does not appear raised
    immediately after removal, observed after two
    minutes - skin was slightly raised in 1-2 mm
    region as evidenced by touch
     2 50 25:00 No insertion pain; very little sensation during
    infusion; piston moved ˜50 ul; minor leaking
    upon removal <1 ul (probably spilled from
    tube); site does not appear raised immediately
    after removal, site after 2 min was slightly
    raised, ˜2 mm diam, reddened
     5 50 10:00 Some insertion pain; some stinging during in-
    fusion, big pain increase at 8 min, strong
    stinging/burning sensation; no leaking; site
    does not appear raise immediately after
    removal, after 2 min site was slightly raised,
    ˜2 mm diam region, reddened
    10 50  5:00 No insertion pain; slight infusion pain starts at
    2 min; no leaking; site does not appear raised
    immediately after removal, 2 min after removal
    site was slightly raised, 2 mm diam, reddened
    20 50  2:30 Relatively pain free insertion; very low infusion
    sensation, some pain a few seconds before end
    of the run; piston moved ˜50 ul; no leaking;
    site is reddened over a 2 mm diam area, but
    doesn't appear to be raised
    40 50  1:15 Low pain; no infusion sensation; piston moved
    ˜50 ul; no leaking; site is raised immediately
    after removal just less than a 1 cm diam region,
    reddened zone ˜1 mm diam.
    80 50  0:37. Painless insertion; stinging during infusion;
     5 piston moved ˜50 ul; no leaking; site is raised
    ˜1 cm diam
    160 50  0:18. Relatively pain free insertion; stinging and cold
    75 sensation, ˜2 ul leaked when removed tubing
    from tube; piston moved ˜50 ul; site raised to a
    height ˜500 um over an ˜1 cm diam region
  • Materials: [0037]
  • The above experiment was conducted with a system constructed as depicted in FIGS. 5A and 5B and applied to the underside of a forearm. The data collected and recorded is set out in Table 1 above. The experimental setup was constructed using the following materials, however other materials and components may be substituted by those skill in the art without substantially detracting from the results achieved. [0038]
  • Microneedle Pin insert 218-0.12 mm Diam Seirin Accupuncture Needle; J Type; No. 2; Sterilized with ETO; Lot 0121505; expiration 12/03; Seirin Corp., Shizuoka, JP [0039]
  • Microneedle 214 (30 G tube)-304 SS; ID=0.0055″/0.0065″; OD 0.0120″/0.0125″; L=0.155″/0.165″; [0040] Micro Tube 30 Ga; Eagle Stainless Tube & Manufacturing, Inc., Franklin, Mass.
  • [0041] Silicone substrate 210—60 mil thick; Die cut ⅜″ diam.; Class VI Medical Grade; 60 Shore A; Part No. 87315k65; McMaster-Carr Supply Co.
  • [0042] Adhesive tape 212— Medical Tape 1513; 3M Transparent Polyester 3.4 Mil Double Coated Medical Tape
  • Liquid adhesive—[0043] RP 30; Advanced Performance Instant Adhesive; USP Class 6; exp. Aug. 27, 2003; Adhesive Systems Inc., Franklin, Ill.
  • Tygon tubing—Tygong Flexible Plastic Tubing; ID=0.010″; OD=0.030″; Formulation S-54-HL for surgical and hospital use; Norton Performance Plastics, Akron, Ohio; Lot # 133341; Saint-Gobain PPL Corp. [0044]
  • [0045] Syringe pump 224— BD 1 ml disposable plastic syringe with hypodermic needle; Becton, Dickinson and Co., Franklin Lakes, N.J.
  • Saline —100 ml bag of 0.9% Sodium Chloride Injection USP; Lot PS 114900; Exp. Apr. 03; Baxter Healthcare Corp., Deerfield, Ill. [0046]
  • [0047] Syringe pump 224—Model KDS100; Ser. No. 4736; kdScientific Inc., New Hope, Pa.
  • Accordingly, as shown in FIGS. 5 and 5B the systems and methods described herein may be employed to increase the amount of medicant or fluid delivered to the patient. In one embodiment, the [0048] pump 224 includes a valve and a controller for regulating the flow of fluid through the interior channel and into the patient. Any suitable pump, valve and controller may be employed and the devices selected will depend at least in part on the application. In one embodiment, the pump may be a manually operated pump, such as a syringe. In other embodiments the pump may include a motorized pumping mechanism.
  • The devices disclosed herein are useful in transport of material into or across biological barriers including the skin (or parts thereof); the blood-brain barrier; mucosal tissue (e.g., oral, nasal, ocular, vaginal, urethral, gastrointestinal, respiratory); blood vessels; lymphatic vessels; or cell membranes (e.g., for the introduction of material into the interior of a cell or cells). The biological barriers can be in humans or other types of animals, as well as in plants, insects, or other organisms, including bacteria, yeast, fungi, and embryos. [0049]
  • The microneedle devices can be applied to tissue internally with the aid of a catheter or laparoscope. For certain applications, such as for drug delivery to an internal tissue, the devices can be surgically implanted. [0050]
  • The microneedle device disclosed herein is typically applied to skin. The skin consists of multiple layers. The stratum corneum is the outer layer (comprising dead cells), generally between 10 and 50 cells for humans, or between 10 and 20 μm thick. Below the stratum corneum is the viable epidermis, which is between 50 and 100 μm thick. The viable epidermis contains no blood vessels, and it exchanges metabolites by diffusion to and from the dermis. Beneath the viable epidermis is the dermis, which is between 1 and 3 mm thick and contains blood vessels, lymphatics, and nerves. The dermis contains a rich capillary network close to the dermal/epidermal junction, and once a drug reaches the dermal depth it diffuses rapidly to deep tissue layers (such as hair follicles, muscles, and internal organs), or systemically via blood circulation. [0051]
  • The microneedle devices disclosed herein include a substrate; one or more microneedles; a reservoir for delivery of drugs; an element for plugging each of the one or more microneedles; and optionally, pump(s), sensor(s), and/or microprocessor(s) to control the interaction of the foregoing. [0052]
  • The substrate of the device can be constructed from a variety of materials, including metals, ceramics, semiconductors, organics, polymers, and composites. The substrate includes the base to which the microneedles are attached or integrally formed. The substrate includes a reservoir for drugs and/or biological molecules. [0053]
  • The microneedles of the device can be constructed from a variety of materials, including metals, ceramics, semiconductors, organics, polymers, and composites. Preferred materials of construction include pharmaceutical grade stainless steel, gold, titanium, nickel, iron, gold, tin, chromium, copper, alloys of these or other metals, silicon, silicon dioxide, and polymers. Representative biodegradable polymers include polymers of hydroxy acids such as lactic acid and glycolic acid polylactide, polyglycolide, polylactide-co-glycolide, and copolymers with PEG, polyanhydrides, poly(ortho)esters, polyurethanes; poly(butyric acid), poly(valeric acid), and poly(lactide-co-caprolactone). Representative non-biodegradable polymers include polycarbonate, polymethacrylic acid, ethylenevinyl acetate, polytetrafluorethylene (TEFLON™), and polyesters. [0054]
  • Generally, the microneedles should have the mechanical strength to remain intact for delivery of drugs, or serve as a conduit for the collection of biological fluid, while being inserted into the skin, while remaining in place for up to a number of days, and while being removed. In embodiments where the microneedles are formed of biodegradable polymers, however, this mechanical requirement is less stringent, since the microneedles or tips thereof can break off, for example in the skin, and will biodegrade. Nonetheless, even a biodegradable microneedle still needs to remain intact at least long enough for the microneedle to serve its intended purpose (e.g, its conduit function). Therefore, biodegradable microneedles can provide an increased level of safety, as compared to nonbiodegradable ones. The microneedles should be sterilizable using standard methods. [0055]
  • The microneedles of the device may be constructed as described in U.S. Pat. No. 6,312,612 and U.S. Pat. No. 6,334,856. For example, U.S. Pat. No. 6,312,612 describes a microneedle array constructed of silicon and silicon dioxide compounds using MEMS (i.e., Micro-Electro-Mechanical-Systems) technology and standard microfabrication techniques. The microneedle array may be fabricated from a silicon die which can be etched in a microfabrication process to create hollow cylindrical individual microneedles. One process for manufacturing microneedles described by U.S. Pat. No. 6,312,612 comprises providing a mold comprising a plurality of micropillars that are mounted to a base and differentially melting a thin lay of plastic onto the micropillars, such that the plastic coats the micropillars to form hollow microneedles. [0056]
  • Another example, U.S. Pat. No. 6,334,856 describes microfabrication processes for manufacturing microneedles such as lithography; etching techniques, such as wet chemical, dry, and photoresist removal; thermal oxidation of silicon; electroplating and electroless plating; diffusion processes, such as boron, phosphorus, arsenic, and antimony diffusion; ion implantation; film deposition, such as evaporation (filament, electron beam, flash, and shadowing and step coverage), sputtering, chemical vapor deposition (CVD), epitaxy (vapor phase, liquid phase, and molecular beam), electroplating, screen printing, lamination, stereolithography, laser machining, and laser ablation (including projection ablation). See generally Jaeger, Introduction to Microelectronic Fabrication (Addison-Wesley Publishing Co., Reading Mass. 1988); Runyan, et al., Semiconductor Integrated Circuit Processing Technology (Addison-Wesley Publishing Co., Reading Mass. 1990); Proceedings of the IEEE Micro Electro Mechanical Systems Conference 1987-1998; Rai-Choudhury, ed., Handbook of Microlithography, Micromachining & Microfabrication (SPIE Optical Engineering Press, Bellingham, Wash. 1997). [0057]
  • The microneedles of the invention may be hollow. As used herein, the tern “hollow” means having one or more substantially annular bores or channels through the interior of the microneedle structure, having a diameter sufficiently large to permit passage of fluid and/or solid materials through the microneedle. The annular bores may extend throughout all or a portion of the needle in the direction of the tip to the base, extending parallel to the direction of the needle or branching or exiting at a side of the needle, as appropriate. One of skill in the art can select the appropriate bore features required for specific applications. For example, one can adjust the bore diameter to permit passage of the particular material to be transported through the microneedle device. [0058]
  • The microneedles can have straight or tapered shafts. A hollow microneedle that has a substantially uniform diameter, which needle does not taper to a point, is referred to herein as a “microtube.” As used herein, the tern “microneedle” includes both microtubes and tapered needles unless otherwise indicated. In a preferred embodiment, the diameter of the microneedle is greatest at the base end of the microneedle and tapers to a point at the distal end of the microneedle. The microneedle can also be fabricated to have a shaft that includes both a straight (untapered) portion and a tapered portion. [0059]
  • The microneedles can be formed with shafts that have a circular cross-section in the perpendicular, or the cross-section can be non-circular. For example, the cross-section of the microneedle can be polygonal (e.g. star-shaped, square, triangular), oblong, or another shape. The shaft can have one or more bores. The cross-sectional dimensions typically are between about 10 μm and 1 mm, preferably between [0060] 1 micron and 200 microns, and more preferably between 10 and 100 μm. The outer diameter is typically between about 10 μm and about 100 μm, and the inner diameter is typically between about 3 μm and about 80 μm.
  • The length of the microneedles typically is between about 1 μm and 1 mm, preferably between 10 microns and 500 microns, and more preferably between 30 and 200 μm. The length is selected for the particular application, accounting for both an inserted and uninserted portion. An array of microneedles can include a mixture of microneedles having, for example, various lengths, outer diameters, inner diameters, cross-sectional shapes, and spacings between the microneedles. [0061]
  • The microneedles can be oriented perpendicular or at an angle to the substrate. Preferably, the microneedles are oriented perpendicular to the substrate so that a larger density of microneedles per unit area of substrate can be provided. An array of microneedles can include a mixture of microneedle orientations, heights, or other parameters. [0062]
  • In a preferred embodiment of the device, the substrate and/or microneedles, as well as other components, are formed from flexible materials to allow the device to fit the contours of the biological barrier, such as the skin, vessel walls, or the eye, to which the device is applied. A flexible device will facilitate more consistent penetration during use, since penetration can be limited by deviations in the attachment surface. For example, the surface of human skin is not flat due to dermatoglyphics (i.e. tiny wrinkles) and hair. [0063]
  • The microneedle devices of the invention also include a reservoir in fluid communication with the microneedles. The reservoir is formed in the substrate in a space below the base (to which the microneedles are attached). Typically, the reservoir will accommodate about 0.2-10.0 ml of a solution or a suspension containing a therapeutic agent (e.g., the reservoir can contain about 0.4, 0.5, 1.0, 2.5, 5.0 or 7.5 ml of such a solution). The reservoir and therapeutic agent may be chosen such that the device contains not more than 1, 2, 3, 5, or 10 days supply of the agent. [0064]
  • In a preferred embodiment, the reservoir contains drug, for delivery through the microneedles. The reservoir may be a hollow vessel, a porous matrix, or a solid form including drug which is transported therefrom. The reservoir can be formed from a variety of materials that are compatible with the drug or biological fluid contained therein. Preferred materials include natural and synthetic polymers, metals, ceramics, semiconductors, organics, and composites. [0065]
  • The microneedle device can include one or a plurality of chambers for storing materials to be delivered. In the embodiment having multiple chambers, each can be in fluid connection with all or a portion of the microneedles of the device array. In one embodiment, at least two chambers are used to separately contain drug (e.g., a lyophilized drug, such as a vaccine) and an administration vehicle (e.g., saline) in order to prevent or minimize degradation during storage. Immediately before use, the contents of the chambers are mixed. Mixing can be triggered by any means, including, for example, mechanical disruption (i.e. puncturing or breaking), changing the porosity, or electrochemical degradation of the walls or membranes separating the chambers. In another embodiment, a single device is used to deliver different drugs, which are stored separately in different chambers. In this embodiment, the rate of delivery of each drug can be independently controlled. [0066]
  • In a preferred embodiment, the reservoir should be in fluid communication with the microneedles so that the therapeutic in a fluid composition or form could exit the reservoir and flow into the hollow microneedles. [0067]
  • The microneedle devices of the invention also include one or more elements for plugging each of the one or more microneedles (the plugging element). The plugging element of the device can be constructed from a variety of materials, including metals, ceramics, semiconductors, organics, polymers, and composites. Generally, the plugging element should have the mechanical strength to prevent skin or other tissue from enter the hollow microneedles when the microneedle device is applied to the skin. In a preferred embodiment, the plugging element may comprise a platform, held up by springs, including a plurality of protuberances (microneedle plugs) sized to fit into the hollow microneedles to prevent slain or other tissue barriers from entering the hollow microneedles. As the inner diameter of the microneedles is typically between about 3 μm and about 80 μm, the outer diameter of the microneedle plugs will typically be between about 3 μm and about 80 μm, depending oil the diameter of the microneedles. The length of the microneedles typically is between about 1 μm and about 1 mm. The length of the microneedle plugs will also be between about 1 μm and about 1 mm. The microneedle plug may, however, extend past the length of the microneedles. The microneedle plugs also may mimic the perpendicular, cross-sectional shape of microneedles, for example, the perpendicular cross-section of the microneedle plug can be polygonal (e.g. star-shaped, square, triangular), oblong, or another shape best able to fit the microneedle. [0068]
  • In another preferred embodiment, a microneedle device includes a plurality of bioerodible elements (microneedle plugs) for temporarily plugging the hollow microneedles, thereby preventing skin or other tissue barriers from entering the hollow microneedles. The microneedle plug is comprised of a continuous piece of bioerodible polymer having a portion inside and a portion outside the distal end of the microneedle. The portion inside the distal end of the microneedle is held in place by friction or by a small amount of biocompatible adhesive. The microneedle plug also may mimic the perpendicular, cross-sectional shape of microneedle, for example, the perpendicular cross-section of the microneedle plug can be polygonal (e.g. star-shaped, square, triangular), oblong, or another shape best able to fit the microneedle. The portion inside the distal end of the microneedle may be from about 1 μm to about 500 μm in length, preferably from about 1 m to about 250 μm, more preferably from about 5 μm to about 100 μm. The cross-sectional dimensions of the portion inside the distal end of the microneedle may be from about 10 nm to about 1 mm, preferably from about 1 μm to about 200 μm, more preferably from about 3 μm to about 80 μm. [0069]
  • The portion outside the distal end of the microneedle may have a cone shape with the base (widest portion) of the cone attached to the polymer portion inside the microneedle. The outside portion may be from about 1 μm up to about 500 μm in length and have a diameter at the base from about 1 μm up to about 1.2 mm in diameter. The diameter of the base of the cone will be greater than the diameter of the microneedle to which it is fitted. The outside portion may have an arrowhead shape, the barbed ends of the arrowhead shape extending past the sides of the microneedle. The width of the arrowshead across the barbed ends should be wider than the diameter of the microneedle. [0070]
  • The microneedle devices of the invention also must be capable of transporting material across the barrier at a useful rate. For example, a microneedle device must be capable of delivering drug across the skin at a rate sufficient to be therapeutically useful. A device may include a housing with microelectronics and other micromachined structures to control the rate of delivery either according to a preprogrammed schedule or through active interface with the patient, a healthcare professional, or a biosensor. The rate can be controlled by manipulating a variety of factors, including the characteristics of the drug formulation to be delivered (e.g., its viscosity, electric charge, and chemical composition); the dimensions of each microneedle (e.g., its outer diameter and the area of porous or hollow openings); the number of microneedles in the device; the application of a driving force (e.g., a concentration gradient, a voltage gradient, a pressure gradient); and the use of a valve. [0071]
  • The rate also can be controlled by interposing between the drug in the reservoir and the opening(s) at the base end of the microneedle polymer or other materials selected for their diffusion characteristics. For example, the material composition and layer thickness can be manipulated using methods known in the art to vary the rate of diffusion of the drug of interest through the material, thereby controlling the rate at which the drug flows from the reservoir through a microneedle and into the tissue. [0072]
  • Transportation of molecules through the microneedles can be controlled or monitored using, for example, various combinations of valves, pumps, sensors, actuators, and microprocessors. These components can be produced using standard manufacturing or microfabrication techniques. Actuators that may be useful with the microneedle devices disclosed herein include micropumps, microvalves, and positioners. In a preferred embodiment, a microprocessor is programmed to control a pump or valve, thereby controlling the rate of delivery. [0073]
  • Flow of molecules through the microneedles can occur based on diffusion, capillary action, or can be induced using conventional mechanical pumps or nonmechanical driving forces, such as electroosmosis or electrophoresis, or convection. For example, in electroosmosis, electrodes are positioned on the biological barrier surface, one or more microneedles, and/or the substrate adjacent the needles, to create a convective flow which carries oppositely charged ionic species and/or neutral molecules toward or into the biological barrier. In a preferred embodiment, the microneedle device is used in combination with another mechanism that enhances the permeability of the biological barrier, for example by increasing cell uptake or membrane disruption, using electric fields, ultrasound, chemical enhancers, viruses, pH, heat and/or light. [0074]
  • Passage of the microneedles, or drug to be transported via the microneedles, can be manipulated by shaping the microneedle surface, or by selection of the material forming the microneedle surface (which could be a coating rather than the microneedle per se). For example, the physical surface properties of the microneedle could be manipulated to either promote or inhibit transport of material along the microneedle surface, such as by controlling hydrophillicity or hydrophobicity. [0075]
  • The flow of molecules can be regulated using a wide range of valves or gates. These valves can be the type that are selectively and repeatedly opened and closed, or they can be single-use types. For example, in a disposable, single-use drug delivery device, a fracturable barrier or one-way gate may be installed in the device between the reservoir and the opening of the microneedles. When ready to use, the barrier can be broken or gate opened to permit flow through the microneedles. Other valves or gates used in the microneedle devices can be activated thermally, electrochemically, mechanically, or magnetically to selectively initiate, modulate, or stop the flow of molecules through the needles. In a preferred embodiment, flow is controlled by using a rate-limiting membrane as a “valve.”[0076]
  • The microneedle devices can further include a flowmeter or other means to monitor flow through the microneedles and to coordinate use of the pumps and valves. [0077]
  • The microneedle devices of the invention can further include sensors. Useful sensors may include sensors of pressure, temperature, chemicals, and/or electromagnetic fields. Biosensors can be located on the microneedle surface, inside a hollow or porous microneedle, or inside a device in communication with the body tissue via the microneedle (solid, hollow, or porous). These microneedle biosensors can include four classes of principal transducers: potentiometric, amperometric, optical, and physiochemical. An amperoimetric sensor monitors currents generated when electrons are exchanged between a biological system and an electrode. Blood glucose sensors frequently are of this type. [0078]
  • The microneedle may function as a conduit for fluids, solutes, electric charge, light, or other materials. In one embodiment, hollow microneedles can be filled with a substance, such as a gel, that has a sensing functionality associated with it. In an application for sensing based on binding to a substrate or reaction mediated by an enzyme, the substrate or enzyme can be immobilized in the needle interior. [0079]
  • Wave guides can be incorporated into the microneedle device to direct light to a specific location, or for detection, for example, using means such as a pH dye for color evaluation. Similarly, heat, electricity, light or other energy forms may be precisely transmitted to directly stimulate, damage, or heal a specific tissue or intermediary (e.g., tattoo remove for dark skinned persons), or diagnostic purposes, such as measurement of blood glucose based on IR spectra or by chromatographic means, measuring a color change in the presence of immobilized glucose oxidase in combination with an appropriate substrate. [0080]
  • The microneedle devices can further include a collar or flange, for example, around the periphery of the substrate or the base. It preferably is attached to the device, but alternatively can be formed as integral part of the substrate, for example by forming microneedles only near the center of an “oversized” substrate. The collar can also emanate from other parts of the device. The collar can provide an interface to attach the microneedle array to the rest of the device, and can facilitate handling of the smaller devices. [0081]
  • The device may be attached to the patient by a belt, strap, or adhesive (e.g., it can be attached to the patient's skin by an adhesive patch). In some instances, an adhesive and a second security device (e.g., a belt or strap) can be used. [0082]
  • In a preferred embodiment, a microneedle device includes an adhesive to temporarily secure the device to the surface of the biological barrier. The adhesive can be essentially anywhere on the device to facilitate contact with the biological barrier. For example, the adhesive can be on the surface of the collar (same side as microneedles), on the surface of the substrate between the microneedles (near the base of the microneedles), or a combination thereof. [0083]
  • The microneedle devices of the present invention may be used for single or multiple uses for rapid transport across a biological barrier or may be left in place for longer times (e.g., hours or days) for long-term transport of molecules. Depending on the dimensions of the device, the application site, and the route in which the device is introduced into (or onto) the biological barrier, the device may be used to introduce or remove molecules at specific locations. [0084]
  • In particular embodiments, the device should be “user-friendly.” For example, in some transdermal applications, affixing the device to the skin should be relatively simple, and not require special skills. The embodiment of a microneedle may include an array of microneedles attached to a housing containing drug in an internal reservoir, wherein the housing has a bioadhesive coating around the microneedles and the microneedles are plugged with bioerodible elements. The patient can remove a peel-away backing to expose an adhesive coating, and then press the device onto a clean part of the skin, leaving it to administer drug over the course of, for example, several days. [0085]
  • Essentially any drug or other bioactive agents can be delivered using these devices. Drugs can be proteins, enzymes, polysaccharides, polynucleotide molecules, and synthetic organic and inorganic compounds. A preferred drug is insulin. Representative agents include anti-infectives, hormones, growth regulators, drugs regulating cardiac action or blood flow, vaccines, chemotherapy agents, pain relief agents, dialysis-related agents, blood thinning agents, and drugs for pain control. The drug can be for local treatment or for regional or systemic therapy. The following are representative examples, and disorders the drug is used to treat, or the drug's mode of action: calcitonin (osteoporosis), enoxaprin (anticoagulant), etanercept (rheumatoid arthritis), erythropoietin (anemia), fentanyl (postoperative and chronic pain), filgrastin (low white blood cells from chemotherapy), heparin (anticoagulant), insulin (human, diabetes), interferon beta 1 a (multiple sclerosis), lidocaine (local anesthesia), somatropin (growth hormone), sumatriptan (migraine headaches), vaccines towards tumors, and vaccines towards infectious diseases. [0086]
  • It will be understood that the microneedle device of the present invention can be used in many applications, including as a painless and convenient transdermal drug-delivery system for continuous and controlled outpatient therapies. Another use of the microneedle device of the present invention is to form a portable drug delivery system for outpatient delivery of the following drugs and therapeutic agents, for example: central nervous system therapy agents, psychic energizing drugs, tranquilizers, anticonvulsants, muscle relaxants and anti-parkinson agents, smoking cessation agents, analgesics, antipyretics and anti-inflammatory agents, antispasmodics and antiulcer agents, antimicrobials, antimalarias, sympathomimetric patches, antiparasitic agents, neoplastic agents, nutritional agents, and vitamins. [0087]
  • The devices may contain a predetermined dosage of therapeutic which may be dependent on the disease or disorder being treated, the size of the individual to be treated, the effective dose of the therapeutic, etc. [0088]
  • In this way, many drugs can be delivered at a variety of therapeutic rates. The rate can be controlled by varying a number of design factors, including the outer diameter of the microneedle, the number and size of channels in each microneedle, the number of microneedles in an array, the magnitude and frequency of application of the force driving the drug through the microneedle and/or the holes created by the microneedles. For example, devices designed to deliver drug at different rates might have more microneedles for more rapid delivery and fewer microneedles for less rapid delivery. As another example, a device designed to deliver drug at a variable rate could vary the driving force (e.g., pressure gradient controlled by a pump) for transport according to a schedule which was pre-programmed or controlled by, for example, the user or his doctor. The devices can be affixed to the skin or other tissue to deliver drugs continuously or intermittently, for durations ranging from a few seconds to several hours or days. [0089]
  • One of skill in the art can measure the rate of drug delivery for particular microneedle devices using in vitro and in vivo methods known in the art. For example, to measure the rate of transdermal drug delivery, human cadaver skin mounted on standard diffusion chambers can be used to predict actual rates. See Hadgraft & Guy, eds., Transdermal Drug Delivery: Developmental Issues and Research Initiatives (Marcel Dekker, New York 1989); Bronaugh & Maibach, Percutaneous Absorption, Mechanisms—Methodology—Drug Delivery (Marcel Dekker, New York 1989). After filling the compartment on the dermis side of the diffusion chamber with saline, a microneedle array is inserted into the stratum corneum; a drug solution is placed in the reservoir of the microneedle device; and samples of the saline solution are taken over time and assayed to determine the rates of drug transport. [0090]
  • One embodiment of the devices described herein may be used to remove material from the body across a biological barrier, i.e. for minimally invasive diagnostic sensing. For example, fluids can be transported from interstitial fluid in a tissue into a reservoir in the upper portion of the device. The fluid can then be assayed while in the reservoir or the fluid can be removed from the reservoir to be assayed, for diagnostic or other purposes. For example, interstitial fluids can be removed from the epidermis across the stratum corneum to assay for glucose concentration, which should be useful in aiding diabetics in determining their required insulin dose. Other substances or properties that would be desirable to detect include lactate (important for athletes), oxygen, pH, alcohol, tobacco metabolites, and illegal drugs (important for both medical diagnosis and law enforcement). [0091]
  • The sensing device can be in or attached to one or more microneedles, or in a housing adapted to the substrate. Sensing information or signals can be transferred optically (e.g., refractive index) or electrically (e.g., measuring changes in electrical impedance, resistance, current, voltage, or combination thereof). For example, it may be useful to measure a change as a function of change in resistance of tissue to an electrical current or voltage, or a change in response to channel binding or other criteria (such as an optical change) wherein different resistances are calibrated to signal that more or less flow of drug is needed, or that delivery has been completed. [0092]
  • In one embodiment, one or more microneedle devices can be used for (1) withdrawal of interstitial fluid, (2) assay of the fluid, and/or (3) delivery of the appropriate amount of a therapeutic agent based on the results of the assay, either automatically or with human intervention. For example, a sensor delivery system may be combined to form, for example, a system which withdraws bodily fluid, measures its glucose content, and delivers an appropriate amount of insulin. The sensing or delivery step also can be performed using conventional techniques, which would be integrated into use of the microneedle device. For example, the microneedle device could be used to withdraw and assay glucose, and a conventional syringe and needle used to administer the insulin, or vice versa. [0093]
  • Other than transport of drugs and biological molecules, the microneedles may be used to transmit or transfer other materials and energy forms, such as light, electricity, heat, or pressure. The microneedles, for example, could be used to direct light to specific locations within the body, in order that the light can directly act on a tissue or on an intermediary, such as light-sensitive molecules in photodynamic therapy. The microneedles can also be used for aerosolization or delivery for example directly to a mucosal surface in the nasal or buccal regions or to the pulmonary system. [0094]
  • The microneedle devices disclosed herein also should be useful for controlling transport across tissues other than skin. For example, microneedles could be inserted into the eye across, for example, conjunctiva, sclera, and/or cornea, to facilitate delivery of drugs into the eye. Similarly, microneedles inserted into the eye could facilitate transport of fluid out of the eye, which may be of benefit for treatment of glaucoma. Microneedles may also be inserted into the buccal (oral), nasal, vaginal, or other accessible mucosa to facilitate transport into, out of, or across those tissues. For example, a drug may be delivered across the buccal mucosa for local treatment in the mouth or for systemic uptake and delivery. As another example, microneedle devices may be used internally within the body on, for example, the lining of the gastrointestinal tract to facilitate uptake of orally-ingested drugs or the lining of blood vessels to facilitate penetration of drugs into the vessel wall. For example, cardiovascular applications include using microneedle devices to facilitate vessel distension or immobilization, similarly to a stent, wherein the microneedles/substrate can function as a “staple-like” device to penetrate into different tissue segments and hold their relative positions for a period of time to permit tissue regeneration. This application would be particularly useful with biodegradable devices. These uses may involve invasive procedures to introduce the microneedle devices into the body or could involve swallowing, inhaling, injecting or otherwise introducing the devices in a non-invasive or minimally-invasive manner. [0095]
  • It will also be understood that the length of the individual microneedles is by far the most important dimension with regard to providing a painless and bloodless drug-dispensing system, or a painless and bloodless body-fluids sampling system using the opposite direction of fluid flow. While the dimensions discussed hereinabove are preferred, and the ranges discussed are normal for human skin, it will further be understood that the microneedle arrays of the present invention can be used on skin of any other form of living (or even dead) creatures or organisms, and the preferred dimensions may be quite different as compared to those same dimensions for use with human skin, all without departing from the principles of the present invention. [0096]
  • While the invention has been disclosed in connection with the preferred embodiments shown and described in detail, various modifications and improvements thereon will become readily apparent to those skilled in the art. It should be understood that all matter contained in the above description or shown in the accompanying drawings shall be interpreted as illustrative, and not in a limiting sense, and that the following claims should be interpreted in the broadest sense allowable by law. [0097]

Claims (20)

1. A delivery device for introducing a substance into or below the stratum corneum of a patient, comprising
a microneedle having a distal end and an interior channel that extends to the distal end,
a pin dimensioned for slidably extending into the interior channel and out the distal end, and an adhesive patch of the type capable of adhering to biological tissue.
2. A delivery device according to claim 1, wherein
the pin has an arcuate distal end for piercing biological tissue.
3. A delivery device according to claim 1, comprising
means for sliding the pin into and out of the interior channel.
4. A delivery device according to claim 1, further comprising
a reservoir for storing a fluid substance to be introduce into the biological tissue.
5. A delivery device according to claim 1, further comprising
a reservoir having a plurality of chambers.
6. A delivery device according to claim 1, further comprising
a pump for pumping a fluid through the interior channel.
7. A delivery device according to claim 6, further comprising a flow controller for controlling the rate at which fluid flows through the interior channel.
8. A delivery device according to claim 1, further comprising a plug for insertion into a distal end of the channel to prevent tissue from entering the channel.
9. A delivery device according to claim 8, wherein the plug comprises a bioerodible material.
10. A delivery device according to claim 8, wherein the plug comprises a barb for gripping to biological tissue.
11. A delivery device according to claim 1, wherein the microneedle comprises an array of microneedles formed on a substrate.
12. A delivery device according to claim 1, wherein the pin comprises an array of pins fixed to a substrate and arranged to be co-axial with the interior channels of the array of microneedles.
13. A delivery device according to claim 12, further comprising a spring assembly for moving the springs axially within the interior channels.
14. A delivery device according to claim 1, further comprising a flange for coupling to the microneedle to an external device.
15. A delivery device according to claim 1, further comprising a pump for drawing a sample through the interior channel.
16. A transdermal patch, comprising at least one microneedle having an interior channel,
a removable plug disposed at a distal end of the interior channel, as
an adhesive patch for adhering at least one microneedle to biological tissue.
17. A method for introducing a substance into or below the stratum corneum of a patient, comprising
inserting into tissue of a patient a microneedle having a distal end and an interior channel that extends to the distal end, and
sliding a pin dimensioned into the interior channel and out the distal end.
18. A method according to claim 17, further comprising inserting a plurality of microneedles into the tissue of a patient.
19. A method according to claim 17, further comprising pumping a fluid through the microneedle.
20. A method according to claim 18, further comprising operating a syringe for pumping the fluid.
US10/681,777 2002-10-07 2003-10-07 Microneedle array patch Abandoned US20040106904A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US10/681,777 US20040106904A1 (en) 2002-10-07 2003-10-07 Microneedle array patch
US11/975,717 US8162901B2 (en) 2002-10-07 2007-10-19 Microneedle array patch

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41674002P 2002-10-07 2002-10-07
US10/681,777 US20040106904A1 (en) 2002-10-07 2003-10-07 Microneedle array patch

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/975,717 Continuation US8162901B2 (en) 2002-10-07 2007-10-19 Microneedle array patch

Publications (1)

Publication Number Publication Date
US20040106904A1 true US20040106904A1 (en) 2004-06-03

Family

ID=32093895

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/681,777 Abandoned US20040106904A1 (en) 2002-10-07 2003-10-07 Microneedle array patch
US11/975,717 Expired - Fee Related US8162901B2 (en) 2002-10-07 2007-10-19 Microneedle array patch

Family Applications After (1)

Application Number Title Priority Date Filing Date
US11/975,717 Expired - Fee Related US8162901B2 (en) 2002-10-07 2007-10-19 Microneedle array patch

Country Status (4)

Country Link
US (2) US20040106904A1 (en)
EP (1) EP1590034B1 (en)
AU (1) AU2003277306A1 (en)
WO (1) WO2004033021A1 (en)

Cited By (234)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050187521A1 (en) * 2002-01-15 2005-08-25 3M Innovative Properties Company Microneedle devices and methods of manufacture
WO2006015299A2 (en) * 2004-07-30 2006-02-09 Microchips, Inc. Multi-reservoir device for transdermal drug delivery and sensing
US20060034902A1 (en) * 2004-08-10 2006-02-16 Cormier Michel J Microprojection apparatus and system with low infection potential
US20060079836A1 (en) * 2004-10-12 2006-04-13 Holman Thomas J Reinforced and drug-eluting balloon catheters and methods for making same
WO2006089285A1 (en) * 2005-02-16 2006-08-24 Alza Corporation Microprojection arrays with improved biocompatibility
US20070078414A1 (en) * 2005-08-05 2007-04-05 Mcallister Devin V Methods and devices for delivering agents across biological barriers
US20070081977A1 (en) * 2003-11-17 2007-04-12 Lts Lohmann Therapie-Systeme Ag Device for transdermal administration of active substances
US20070161964A1 (en) * 2006-01-10 2007-07-12 Yuzhakov Vadim V Microneedle array, patch, and applicator for transdermal drug delivery
US20070179428A1 (en) * 2006-01-31 2007-08-02 Kralick D O Francis A Implantable micro-system for treatment of hydrocephalus
US20070191761A1 (en) * 2004-02-23 2007-08-16 3M Innovative Properties Company Method of molding for microneedle arrays
US20070219573A1 (en) * 2002-04-19 2007-09-20 Dominique Freeman Method and apparatus for penetrating tissue
US20070255205A1 (en) * 2004-08-30 2007-11-01 Patrick Griss Molded Micro-Needles
WO2007149514A2 (en) * 2006-06-19 2007-12-27 Corium International, Inc. Methods, devices, and kits for microjet drug delivery
US20080009800A1 (en) * 2004-12-02 2008-01-10 Nickel Janice H Transdermal drug delivery device
US20080008745A1 (en) * 2006-06-21 2008-01-10 University Of Kentucky Research Foundation Transdermal delivery of naltrexone hydrochloride, naltrexol hydrochloride, and bis(hydroxy-methyl)propionyl-3-0 ester naltrexone using microneedles
US20080102192A1 (en) * 2004-11-18 2008-05-01 Johnson Peter R Masking Method for Coating a Microneedle Array
WO2008053481A1 (en) * 2006-11-01 2008-05-08 Svip 6 Llc Microneedle arrays
US20080125743A1 (en) * 2006-11-28 2008-05-29 Yuzhakov Vadim V Tissue Conforming Microneedle Array and Patch For Transdermal Drug Delivery or Biological Fluid Collection
US20080154107A1 (en) * 2006-12-20 2008-06-26 Jina Arvind N Device, systems, methods and tools for continuous glucose monitoring
US20080195035A1 (en) * 2005-06-24 2008-08-14 Frederickson Franklyn L Collapsible Patch and Method of Application
US20080208134A1 (en) * 2006-08-18 2008-08-28 Toppan Printing Co., Ltd. Micro-needle and micro-needle patch
US20080234562A1 (en) * 2007-03-19 2008-09-25 Jina Arvind N Continuous analyte monitor with multi-point self-calibration
US20080262444A1 (en) * 2005-01-31 2008-10-23 Bioserentach Co., Ltd. Percutaneously Absorbable Preparation, Percutaneously Absorbable Preparation Holding Sheet, and Percutaneously Absorbable Preparation Holding Equipment
US20080269685A1 (en) * 2007-04-16 2008-10-30 Parminder Singh Solvent-cast microneedle arrays containing active
US20080312518A1 (en) * 2007-06-14 2008-12-18 Arkal Medical, Inc On-demand analyte monitor and method of use
US20090053673A1 (en) * 2007-08-23 2009-02-26 Zimmer, Inc. Method for localized treatment of periodontal tissue
US20090093775A1 (en) * 2007-10-03 2009-04-09 Raju Remesh S O Govinda Microstructures
US20090099427A1 (en) * 2007-10-12 2009-04-16 Arkal Medical, Inc. Microneedle array with diverse needle configurations
US20090131778A1 (en) * 2006-03-28 2009-05-21 Jina Arvind N Devices, systems, methods and tools for continuous glucose monitoring
US20090234288A1 (en) * 2008-03-12 2009-09-17 Ultradent Products, Inc. Dental intraligamentary injection needles and related methods of manufacture
US20090240270A1 (en) * 2008-03-21 2009-09-24 Peter Schneider Device and method for opening blood vessels by pre-angioplasty serration and dilatation of atherosclerotic plaque
US20090247984A1 (en) * 2007-10-24 2009-10-01 Masimo Laboratories, Inc. Use of microneedles for small molecule metabolite reporter delivery
US7648468B2 (en) 2002-04-19 2010-01-19 Pelikon Technologies, Inc. Method and apparatus for penetrating tissue
US20100042121A1 (en) * 2008-03-21 2010-02-18 Peter Schneider Pre-angioplasty serration of atherosclerotic plaque enabling low-pressure balloon angioplasty and avoidance of stenting
US7666149B2 (en) 1997-12-04 2010-02-23 Peliken Technologies, Inc. Cassette of lancet cartridges for sampling blood
US20100049021A1 (en) * 2006-03-28 2010-02-25 Jina Arvind N Devices, systems, methods and tools for continuous analyte monitoring
US7674232B2 (en) 2002-04-19 2010-03-09 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7682318B2 (en) 2001-06-12 2010-03-23 Pelikan Technologies, Inc. Blood sampling apparatus and method
US7699791B2 (en) 2001-06-12 2010-04-20 Pelikan Technologies, Inc. Method and apparatus for improving success rate of blood yield from a fingerstick
US7708701B2 (en) 2002-04-19 2010-05-04 Pelikan Technologies, Inc. Method and apparatus for a multi-use body fluid sampling device
US20100112068A1 (en) * 2008-10-31 2010-05-06 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Compositions and methods for biological remodeling with frozen particle compositions
US20100119557A1 (en) * 2008-10-31 2010-05-13 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Frozen compositions and methods for piercing a substrate
US7717863B2 (en) 2002-04-19 2010-05-18 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7731729B2 (en) 2002-04-19 2010-06-08 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7749174B2 (en) 2001-06-12 2010-07-06 Pelikan Technologies, Inc. Method and apparatus for lancet launching device intergrated onto a blood-sampling cartridge
US20100185174A1 (en) * 2008-10-31 2010-07-22 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems, devices, and methods for making or administering frozen particles
US7780631B2 (en) 1998-03-30 2010-08-24 Pelikan Technologies, Inc. Apparatus and method for penetration with shaft having a sensor for sensing penetration depth
US20100249746A1 (en) * 2004-06-25 2010-09-30 Klein Jeffrey A Drug delivery system for accelerated subcutaneous absorption
US20100256549A1 (en) * 2006-01-31 2010-10-07 Kralick Francis A Implantable micro-system for treatment of hydrocephalus
US20100256597A1 (en) * 2006-05-02 2010-10-07 Emory University Methods and Devices for Drug Delivery to Ocular Tissue Using Microneedle
US7822454B1 (en) 2005-01-03 2010-10-26 Pelikan Technologies, Inc. Fluid sampling device with improved analyte detecting member configuration
US7833171B2 (en) 2002-04-19 2010-11-16 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US20100292551A1 (en) * 2005-03-29 2010-11-18 Jina Arvind N Devices, systems, methods and tools for continuous glucose monitoring
US7850622B2 (en) 2001-06-12 2010-12-14 Pelikan Technologies, Inc. Tissue penetration device
US7850621B2 (en) 2003-06-06 2010-12-14 Pelikan Technologies, Inc. Method and apparatus for body fluid sampling and analyte sensing
US7862520B2 (en) 2002-04-19 2011-01-04 Pelikan Technologies, Inc. Body fluid sampling module with a continuous compression tissue interface surface
US7874994B2 (en) 2002-04-19 2011-01-25 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7892185B2 (en) 2002-04-19 2011-02-22 Pelikan Technologies, Inc. Method and apparatus for body fluid sampling and analyte sensing
US7892183B2 (en) 2002-04-19 2011-02-22 Pelikan Technologies, Inc. Method and apparatus for body fluid sampling and analyte sensing
US7901365B2 (en) 2002-04-19 2011-03-08 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7901362B2 (en) 2002-04-19 2011-03-08 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7909777B2 (en) 2002-04-19 2011-03-22 Pelikan Technologies, Inc Method and apparatus for penetrating tissue
US7914465B2 (en) 2002-04-19 2011-03-29 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US20110105952A1 (en) * 2009-10-30 2011-05-05 Seventh Sense Biosystems, Inc. Relatively small devices applied to the skin, modular systems, and methods of use thereof
US20110105951A1 (en) * 2009-10-30 2011-05-05 Seventh Sense Biosystems, Inc. Systems and methods for treating, sanitizing, and/or shielding the skin or devices applied to the skin
US7976476B2 (en) 2002-04-19 2011-07-12 Pelikan Technologies, Inc. Device and method for variable speed lancet
US7988645B2 (en) 2001-06-12 2011-08-02 Pelikan Technologies, Inc. Self optimizing lancing device with adaptation means to temporal variations in cutaneous properties
US8007446B2 (en) 2002-04-19 2011-08-30 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US20110251562A1 (en) * 2010-01-13 2011-10-13 Seventh Sense Biosystems, Inc. Rapid delivery and/or withdrawal of fluids
US8057842B2 (en) 2004-11-18 2011-11-15 3M Innovative Properties Company Method of contact coating a microneedle array
WO2011151807A1 (en) 2010-06-04 2011-12-08 Pfizer Vaccines Llc Conjugates for the prevention or treatment of nicotine addiction
US8079960B2 (en) 2002-04-19 2011-12-20 Pelikan Technologies, Inc. Methods and apparatus for lancet actuation
WO2011135530A3 (en) * 2010-04-28 2012-03-15 Kimberly-Clark Worldwide, Inc. Device for delivery of rheumatoid arthritis medication
US8197421B2 (en) 2002-04-19 2012-06-12 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US8221334B2 (en) 2002-04-19 2012-07-17 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US8262614B2 (en) 2003-05-30 2012-09-11 Pelikan Technologies, Inc. Method and apparatus for fluid injection
US8267870B2 (en) 2002-04-19 2012-09-18 Sanofi-Aventis Deutschland Gmbh Method and apparatus for body fluid sampling with hybrid actuation
US8282576B2 (en) 2003-09-29 2012-10-09 Sanofi-Aventis Deutschland Gmbh Method and apparatus for an improved sample capture device
US8337421B2 (en) 2001-06-12 2012-12-25 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US8360992B2 (en) 2002-04-19 2013-01-29 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US8409376B2 (en) 2008-10-31 2013-04-02 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US8414959B2 (en) 2004-11-18 2013-04-09 3M Innovative Properties Company Method of contact coating a microneedle array
US8435190B2 (en) 2002-04-19 2013-05-07 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US20130131598A1 (en) * 2009-04-24 2013-05-23 Corium International, Inc. Methods for manufacturing microprojection arrays
WO2013076602A1 (en) * 2011-11-01 2013-05-30 Lumenis Ltd. Device for pressure enhanced fractional treatment and drug delivery
US20130149459A1 (en) * 2010-07-02 2013-06-13 Aptar France Sas Method for the surface treatment of a fluid product dispensing device
US20130165772A1 (en) * 2011-12-27 2013-06-27 The General Hospital Corporation Microneedle devices and uses thereof
US8545855B2 (en) 2008-10-31 2013-10-01 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US8545857B2 (en) 2008-10-31 2013-10-01 The Invention Science Fund I, Llc Compositions and methods for administering compartmentalized frozen particles
US8545856B2 (en) 2008-10-31 2013-10-01 The Invention Science Fund I, Llc Compositions and methods for delivery of frozen particle adhesives
US8551505B2 (en) 2008-10-31 2013-10-08 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US8551506B2 (en) 2008-10-31 2013-10-08 The Invention Science Fund I, Llc Compositions and methods for administering compartmentalized frozen particles
US8556829B2 (en) 2002-04-19 2013-10-15 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US8561795B2 (en) 2010-07-16 2013-10-22 Seventh Sense Biosystems, Inc. Low-pressure packaging for fluid devices
US8574895B2 (en) 2002-12-30 2013-11-05 Sanofi-Aventis Deutschland Gmbh Method and apparatus using optical techniques to measure analyte levels
US8603495B2 (en) 2008-10-31 2013-12-10 The Invention Science Fund I, Llc Compositions and methods for biological remodeling with frozen particle compositions
US20140005606A1 (en) * 2012-06-29 2014-01-02 Mei-Chin Chen Embeddable micro-needle patch for transdermal drug delivery and method of manufacturing the same
US8636696B2 (en) 2011-06-10 2014-01-28 Kimberly-Clark Worldwide, Inc. Transdermal device containing microneedles
US8641644B2 (en) 2000-11-21 2014-02-04 Sanofi-Aventis Deutschland Gmbh Blood testing apparatus having a rotatable cartridge with multiple lancing elements and testing means
US8652831B2 (en) 2004-12-30 2014-02-18 Sanofi-Aventis Deutschland Gmbh Method and apparatus for analyte measurement test time
US8668656B2 (en) 2003-12-31 2014-03-11 Sanofi-Aventis Deutschland Gmbh Method and apparatus for improving fluidic flow and sample capture
US8696637B2 (en) 2011-02-28 2014-04-15 Kimberly-Clark Worldwide Transdermal patch containing microneedles
US8702624B2 (en) 2006-09-29 2014-04-22 Sanofi-Aventis Deutschland Gmbh Analyte measurement device with a single shot actuator
US8722068B2 (en) 2008-10-31 2014-05-13 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US8725420B2 (en) 2008-10-31 2014-05-13 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US8721583B2 (en) 2008-10-31 2014-05-13 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US8721671B2 (en) 2001-06-12 2014-05-13 Sanofi-Aventis Deutschland Gmbh Electric lancet actuator
US8731840B2 (en) 2008-10-31 2014-05-20 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US8731841B2 (en) 2008-10-31 2014-05-20 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US8762067B2 (en) 2008-10-31 2014-06-24 The Invention Science Fund I, Llc Methods and systems for ablation or abrasion with frozen particles and comparing tissue surface ablation or abrasion data to clinical outcome data
US8788211B2 (en) 2008-10-31 2014-07-22 The Invention Science Fund I, Llc Method and system for comparing tissue ablation or abrasion data to data related to administration of a frozen particle composition
US8784335B2 (en) 2002-04-19 2014-07-22 Sanofi-Aventis Deutschland Gmbh Body fluid sampling device with a capacitive sensor
US8793075B2 (en) 2008-10-31 2014-07-29 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US8808202B2 (en) 2010-11-09 2014-08-19 Seventh Sense Biosystems, Inc. Systems and interfaces for blood sampling
US8821412B2 (en) 2009-03-02 2014-09-02 Seventh Sense Biosystems, Inc. Delivering and/or receiving fluids
US8828203B2 (en) 2004-05-20 2014-09-09 Sanofi-Aventis Deutschland Gmbh Printable hydrogels for biosensors
US8900194B2 (en) 2002-07-19 2014-12-02 3M Innovative Properties Company Microneedle devices and microneedle delivery apparatus
US20150025496A1 (en) * 2009-12-24 2015-01-22 Rani Therapeutics, Llc Swallowable drug delivery device and method of delivery
WO2015016235A1 (en) * 2013-07-30 2015-02-05 Asti株式会社 Microneedle array and microneedle array manufacturing method
US8965476B2 (en) 2010-04-16 2015-02-24 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US20150065997A1 (en) * 2009-10-08 2015-03-05 Palo Alto Research Center Incorporated Transmucosal drug delivery device and method including chemical permeation enhancers
US9033898B2 (en) 2010-06-23 2015-05-19 Seventh Sense Biosystems, Inc. Sampling devices and methods involving relatively little pain
US9041541B2 (en) 2010-01-28 2015-05-26 Seventh Sense Biosystems, Inc. Monitoring or feedback systems and methods
US9050070B2 (en) 2008-10-31 2015-06-09 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US9050317B2 (en) 2008-10-31 2015-06-09 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US9060934B2 (en) 2008-10-31 2015-06-23 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US9060926B2 (en) 2008-10-31 2015-06-23 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US9060931B2 (en) 2008-10-31 2015-06-23 The Invention Science Fund I, Llc Compositions and methods for delivery of frozen particle adhesives
US20150182725A1 (en) * 2013-12-31 2015-07-02 Ip Liberty Vision Corporation Versatile light-guided ophthalmic treatment system
US9072688B2 (en) 2008-10-31 2015-07-07 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US9072799B2 (en) 2008-10-31 2015-07-07 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US9113836B2 (en) 2009-03-02 2015-08-25 Seventh Sense Biosystems, Inc. Devices and techniques associated with diagnostics, therapies, and other applications, including skin-associated applications
US9119578B2 (en) 2011-04-29 2015-09-01 Seventh Sense Biosystems, Inc. Plasma or serum production and removal of fluids under reduced pressure
US9144401B2 (en) 2003-06-11 2015-09-29 Sanofi-Aventis Deutschland Gmbh Low pain penetrating member
US9180047B2 (en) 2013-05-03 2015-11-10 Clearside Biomedical, Inc. Apparatus and methods for ocular injection
US9226699B2 (en) 2002-04-19 2016-01-05 Sanofi-Aventis Deutschland Gmbh Body fluid sampling module with a continuous compression tissue interface surface
US9248267B2 (en) 2002-04-19 2016-02-02 Sanofi-Aventis Deustchland Gmbh Tissue penetration device
USD750223S1 (en) 2014-10-14 2016-02-23 Clearside Biomedical, Inc. Medical injector for ocular injection
US9295417B2 (en) 2011-04-29 2016-03-29 Seventh Sense Biosystems, Inc. Systems and methods for collecting fluid from a subject
CN105492064A (en) * 2013-06-17 2016-04-13 延世大学校产学协力团 Painless and patchless shooting microstructure
US9314194B2 (en) 2002-04-19 2016-04-19 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US20160106931A1 (en) * 2009-09-17 2016-04-21 Zipline Medical, Inc. Rapid closing surgical closure device
US9351680B2 (en) 2003-10-14 2016-05-31 Sanofi-Aventis Deutschland Gmbh Method and apparatus for a variable user interface
US9375169B2 (en) 2009-01-30 2016-06-28 Sanofi-Aventis Deutschland Gmbh Cam drive for managing disposable penetrating member actions with a single motor and motor and control system
US9386944B2 (en) 2008-04-11 2016-07-12 Sanofi-Aventis Deutschland Gmbh Method and apparatus for analyte detecting device
US9427532B2 (en) 2001-06-12 2016-08-30 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US9442065B2 (en) 2014-09-29 2016-09-13 Zyomed Corp. Systems and methods for synthesis of zyotons for use in collision computing for noninvasive blood glucose and other measurements
WO2016168847A1 (en) * 2015-04-17 2016-10-20 Georgia Tech Research Corporation Drug delivery devices having separable microneedles
US20160317330A1 (en) * 2008-01-17 2016-11-03 Boston Scientific Scimed, Inc. Stent with anti-migration feature
US9498524B2 (en) 2007-04-16 2016-11-22 Corium International, Inc. Method of vaccine delivery via microneedle arrays
US9522262B2 (en) 2010-04-28 2016-12-20 Kimberly-Clark Worldwide, Inc. Medical devices for delivery of siRNA
US9526883B2 (en) 2010-04-28 2016-12-27 Kimberly-Clark Worldwide, Inc. Composite microneedle array including nanostructures thereon
US9526911B1 (en) * 2010-04-27 2016-12-27 Lazure Scientific, Inc. Immune mediated cancer cell destruction, systems and methods
US9554738B1 (en) 2016-03-30 2017-01-31 Zyomed Corp. Spectroscopic tomography systems and methods for noninvasive detection and measurement of analytes using collision computing
US9572800B2 (en) 2012-11-08 2017-02-21 Clearside Biomedical, Inc. Methods and devices for the treatment of ocular diseases in human subjects
US20170056637A1 (en) * 2014-05-06 2017-03-02 Mupharma Pty Ltd Non-invasive agent applicator
US9586044B2 (en) 2010-04-28 2017-03-07 Kimberly-Clark Worldwide, Inc. Method for increasing the permeability of an epithelial barrier
US20170080196A1 (en) * 2015-09-21 2017-03-23 B&L Biotech, Inc. Flexible microneedle for dental material delivery and method of manufacturing the same
US9629799B2 (en) 2010-12-23 2017-04-25 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9687641B2 (en) 2010-05-04 2017-06-27 Corium International, Inc. Method and device for transdermal delivery of parathyroid hormone using a microprojection array
US20170189661A1 (en) * 2014-06-02 2017-07-06 Amolifescience Co., Ltd. Microneedle patch and production method therefor
US9757514B2 (en) 2010-12-23 2017-09-12 Rani Therapeutics, Llc Device, system and methods for the oral delivery of therapeutic compounds
US9775553B2 (en) 2004-06-03 2017-10-03 Sanofi-Aventis Deutschland Gmbh Method and apparatus for a fluid sampling device
US9795747B2 (en) 2010-06-02 2017-10-24 Sanofi-Aventis Deutschland Gmbh Methods and apparatus for lancet actuation
US9808510B2 (en) 2011-06-29 2017-11-07 Rani Therapeutics, Llc Method for delivering gonadotropin releasing hormone into a lumen of the intestinal tract
US9814763B2 (en) 2010-12-23 2017-11-14 Incube Labs, Llc Method for delivery of somatostatin into a lumen of the intestinal tract
US9820684B2 (en) 2004-06-03 2017-11-21 Sanofi-Aventis Deutschland Gmbh Method and apparatus for a fluid sampling device
US9844505B2 (en) 2010-12-23 2017-12-19 Rani Therapeutics, Llc Methods for delivering etanercept preparations into a lumen of the intestinal tract using a swallowable drug delivery device
US9844655B2 (en) 2010-12-23 2017-12-19 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9861683B2 (en) 2010-12-23 2018-01-09 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9861801B2 (en) 2013-02-28 2018-01-09 Kimberly-Clark Worldwide, Inc. Drug delivery device
US9907747B2 (en) 2010-12-23 2018-03-06 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9956178B2 (en) 2010-12-23 2018-05-01 Rani Therapeutics, Llc Methods for delivering insulin preparations into a lumen of the intestinal tract using a swallowable drug delivery device
US9956114B2 (en) 2014-06-20 2018-05-01 Clearside Biomedical, Inc. Variable diameter cannula and methods for controlling insertion depth for medicament delivery
US9962534B2 (en) 2013-03-15 2018-05-08 Corium International, Inc. Microarray for delivery of therapeutic agent, methods of use, and methods of making
CN108014413A (en) * 2017-12-18 2018-05-11 优微(珠海)生物科技有限公司 Soluble micropin introducing apparatus and its application method
US9987487B2 (en) 2009-08-03 2018-06-05 Incube Labs, Llc Swallowable capsule and method for stimulating incretin production within the intestinal tract
US10004783B2 (en) 2010-12-23 2018-06-26 Rani Therapeutics, Llc Method for delivering pramlintide into a lumen of the intestinal tract using a swallowable drug delivery device
US20180193595A1 (en) * 2012-12-18 2018-07-12 Alcyone Lifesciences, Inc. Systems and methods for reducing or preventing backflow in a delivery system
US10029080B2 (en) 2010-12-23 2018-07-24 Rani Therapeutics, Llc Method for delivering exenatide into a lumen of the intestinal tract using a swallowable drug delivery device
US10123801B2 (en) 2011-11-01 2018-11-13 Zipline Medical, Inc. Means to prevent wound dressings from adhering to closure device
US10123800B2 (en) 2011-11-01 2018-11-13 Zipline Medical, Inc. Surgical incision and closure apparatus with integrated force distribution
US10166374B2 (en) 2015-09-17 2019-01-01 Cagent Vascular, Llc Wedge dissectors for a medical balloon
US10183156B2 (en) 2013-02-28 2019-01-22 Sorrento Therapeutics, Inc. Transdermal drug delivery device
US10188550B2 (en) 2013-06-03 2019-01-29 Clearside Biomedical, Inc. Apparatus and methods for drug delivery using multiple reservoirs
US10195409B2 (en) 2013-03-15 2019-02-05 Corium International, Inc. Multiple impact microprojection applicators and methods of use
US20190047278A1 (en) * 2016-10-14 2019-02-14 Xerox Corporation Chemical delivery devices produced using halftone screening in an additive manufacturing process
US10245422B2 (en) 2013-03-12 2019-04-02 Corium International, Inc. Microprojection applicators and methods of use
US10384046B2 (en) 2013-03-15 2019-08-20 Corium, Inc. Microarray for delivery of therapeutic agent and methods of use
US10384045B2 (en) 2013-03-15 2019-08-20 Corium, Inc. Microarray with polymer-free microstructures, methods of making, and methods of use
US10390901B2 (en) 2016-02-10 2019-08-27 Clearside Biomedical, Inc. Ocular injection kit, packaging, and methods of use
US10434251B2 (en) 2011-08-01 2019-10-08 Alcyone Lifesciences, Inc. Multi-directional microfluidic drug delivery device
US10441770B2 (en) 2013-07-31 2019-10-15 Alcyone Lifesciences, Inc. Systems and methods for drug delivery, treatment, and monitoring
US10456533B2 (en) 2013-06-17 2019-10-29 Alcyone Lifesciences, Inc. Methods and devices for protecting catheter tips and stereotactic fixtures for microcatheters
US10456136B2 (en) 2011-11-01 2019-10-29 Zipline Medical, Inc. Surgical incision and closure apparatus
US10471238B2 (en) 2014-11-03 2019-11-12 Cagent Vascular, Llc Serration balloon
US10487145B2 (en) 2010-12-23 2019-11-26 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US10531882B2 (en) 2016-01-04 2020-01-14 Alcyone Lifesciences, Inc. Methods and devices for treating stroke
US10543310B2 (en) 2011-12-19 2020-01-28 Seventh Sense Biosystems, Inc. Delivering and/or receiving material with respect to a subject surface
US10624843B2 (en) 2014-09-04 2020-04-21 Corium, Inc. Microstructure array, methods of making, and methods of use
US10639272B2 (en) 2010-12-23 2020-05-05 Rani Therapeutics, Llc Methods for delivering etanercept preparations into a lumen of the intestinal tract using a swallowable drug delivery device
US10752681B2 (en) 2010-12-23 2020-08-25 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US10806396B2 (en) 2015-01-26 2020-10-20 Alcyone Lifesciences, Inc. Drug delivery methods with tracer
US20200345994A1 (en) * 2018-01-03 2020-11-05 The Trustees Of Columbia University In The City Of New York Microneedle for local delivery of therapeutic agent
US10857028B2 (en) 2016-09-30 2020-12-08 Sara Heikali Method and device for treating and managing diseased ocular tissue
US10857093B2 (en) 2015-06-29 2020-12-08 Corium, Inc. Microarray for delivery of therapeutic agent, methods of use, and methods of making
US10888269B2 (en) 2014-01-05 2021-01-12 Zipline Medical, Inc. Instrumented wound closure device
US10905863B2 (en) 2016-11-16 2021-02-02 Cagent Vascular, Llc Systems and methods of depositing drug into tissue through serrations
US10918332B2 (en) 2016-10-31 2021-02-16 Zipline Medical, Inc. Systems and methods for monitoring physical therapy of the knee and other joints
US10952894B2 (en) 2010-10-15 2021-03-23 Clearside Biomedical, Inc. Device for ocular access
US20210085945A1 (en) * 2018-05-30 2021-03-25 Tze Guan Ong Non-invasive Transportation Method
US10973681B2 (en) 2016-08-12 2021-04-13 Clearside Biomedical, Inc. Devices and methods for adjusting the insertion depth of a needle for medicament delivery
US11051988B2 (en) 2010-06-14 2021-07-06 Zipline Medical, Inc. Methods and apparatus for inhibiting scar formation
US11052231B2 (en) 2012-12-21 2021-07-06 Corium, Inc. Microarray for delivery of therapeutic agent and methods of use
US11110066B2 (en) 2011-10-27 2021-09-07 Sorrento Therapeutics, Inc. Implantable devices for delivery of bioactive agents
US11177029B2 (en) 2010-08-13 2021-11-16 Yourbio Health, Inc. Systems and techniques for monitoring subjects
US11202895B2 (en) 2010-07-26 2021-12-21 Yourbio Health, Inc. Rapid delivery and/or receiving of fluids
US11219750B2 (en) 2008-03-21 2022-01-11 Cagent Vascular, Inc. System and method for plaque serration
US11311496B2 (en) * 2016-11-21 2022-04-26 Eirion Therapeutics, Inc. Transdermal delivery of large agents
US11311489B2 (en) * 2017-05-17 2022-04-26 Massachusetts Institute Of Technology Components with high API loading
US11369779B2 (en) 2018-07-25 2022-06-28 Cagent Vascular, Inc. Medical balloon catheters with enhanced pushability
US11452474B1 (en) 2021-04-14 2022-09-27 Satio, Inc. Dual lever dermal patch system
WO2022246184A1 (en) * 2021-05-21 2022-11-24 Veradermics Incorporated Microneedle patch for immunostimulatory drug delivery
US11510602B1 (en) 2021-11-08 2022-11-29 Satio, Inc. Dermal patch for collecting a physiological sample
US11541016B2 (en) 2017-05-17 2023-01-03 Massachusetts Institute Of Technology Self-righting systems, methods, and related components
US11596545B2 (en) 2016-05-02 2023-03-07 Clearside Biomedical, Inc. Systems and methods for ocular drug delivery
US11602623B2 (en) * 2014-12-03 2023-03-14 Industry-Academic Cooperation Foundation Yonsei University Balloon catheter having micro needles and manufacturing method for the same
US11690739B1 (en) 2020-08-25 2023-07-04 Francis A. Kralick Implantable device for treatment of hydrocephalus
US11730937B2 (en) 2017-10-11 2023-08-22 Georgia Tech Research Corporation Separable microneedle arrays for sustained release of drug
US11738181B2 (en) 2014-06-04 2023-08-29 Cagent Vascular, Inc. Cage for medical balloon
US11752101B2 (en) 2006-02-22 2023-09-12 Clearside Biomedical, Inc. Ocular injector and methods for accessing suprachoroidal space of the eye
US11849415B2 (en) 2018-07-27 2023-12-19 Mclaren Applied Technologies Limited Time synchronisation
US11877848B2 (en) 2021-11-08 2024-01-23 Satio, Inc. Dermal patch for collecting a physiological sample
US11898874B2 (en) 2019-10-18 2024-02-13 Mclaren Applied Technologies Limited Gyroscope bias estimation

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8353861B2 (en) 2003-09-18 2013-01-15 Texmac, Inc. Applicator for applying functional substances into human skin
CA2547382A1 (en) * 2003-11-28 2005-06-09 Acrux Dds Pty Ltd. Method and system for rapid transdermal administration
ES2463818T3 (en) 2004-08-16 2014-05-29 Functional Microstructures Limited Device to be applied to a biological barrier
US20080307849A1 (en) * 2004-11-26 2008-12-18 Agency For Science, Technology And Research Method And Apparatus For Forming Microstructures
EP1843811A2 (en) * 2005-01-31 2007-10-17 Alza Corporation, Inc. Coated microprojections having reduced variability and method for producing same
WO2006101459A1 (en) * 2005-03-23 2006-09-28 Agency For Science, Technology And Research Microneedles
WO2006138719A2 (en) 2005-06-17 2006-12-28 Georgia Tech Research Corporation Coated microstructures and method of manufacture thereof
GB0719577D0 (en) * 2007-10-08 2007-11-14 Kirby Andrew J Microimplant devices and methods of making and use thereof
US8062568B2 (en) * 2009-08-27 2011-11-22 Korea University Research And Business Foundation Nano pattern writer
US8834423B2 (en) 2009-10-23 2014-09-16 University of Pittsburgh—of the Commonwealth System of Higher Education Dissolvable microneedle arrays for transdermal delivery to human skin
US20110144591A1 (en) * 2009-12-11 2011-06-16 Ross Russell F Transdermal Delivery Device
KR101207561B1 (en) * 2009-12-15 2012-12-04 주식회사 코리아나화장품 siRNA oligonucleotide which inhibits Tryrosinase expression and Cosmetic composition comprising the same
GB201001030D0 (en) * 2010-01-22 2010-03-10 Ocelus Ltd Needleless device for delivery of an agent through a biological barrier
US9993625B2 (en) * 2010-01-29 2018-06-12 Mirus Llc Biodegradable protrusions on inflatable device
US20130331792A1 (en) * 2011-01-18 2013-12-12 The Brigham And Women's Hospital, Inc. Device and uses thereof
EP2701508A4 (en) 2011-04-26 2015-01-07 Univ Leland Stanford Junior Production and delivery of a stable collagen
KR102265775B1 (en) 2011-10-27 2021-06-16 소렌토 쎄라퓨틱스, 인코포레이티드 Transdermal delivery of high viscosity bioactive agents
US20170246439A9 (en) 2011-10-27 2017-08-31 Kimberly-Clark Worldwide, Inc. Increased Bioavailability of Transdermally Delivered Agents
US9394547B2 (en) 2012-01-03 2016-07-19 City University Of Hong Kong Method and apparatus for delivery of molecules to cells
CA2867158A1 (en) * 2012-04-03 2013-10-10 Theraject, Inc. Soluble microneedle arrays for buccal delivery of vaccines
AU2013256348B2 (en) 2012-05-01 2017-06-15 Carnegie Mellon University Tip-loaded microneedle arrays for transdermal insertion
WO2014053081A1 (en) 2012-10-01 2014-04-10 The Hong Kong University Of Science And Technology Design and manufacture of nonelectronic, active-infusion patch and device for transdermal delivery across skin
US9526884B2 (en) 2012-11-16 2016-12-27 City University Of Hong Kong Mechanically robust fast-dissolving microneedles for transdermal drug and vaccine delivery
GB201304669D0 (en) * 2013-03-15 2013-05-01 Univ Singapore Micro-needles integrated with nanotubes
GB201307262D0 (en) 2013-04-23 2013-05-29 Chowdhury Dewan F H Device for containment and release of drug formulation
EP3068435A1 (en) 2013-11-13 2016-09-21 Novartis AG Mtor inhibitors for enhancing the immune response
EP3087101A4 (en) 2013-12-20 2017-12-06 Novartis AG Regulatable chimeric antigen receptor
JP2017528433A (en) 2014-07-21 2017-09-28 ノバルティス アーゲー Low immunoenhancing dose of mTOR inhibitor and CAR combination
US10441768B2 (en) 2015-03-18 2019-10-15 University of Pittsburgh—of the Commonwealth System of Higher Education Bioactive components conjugated to substrates of microneedle arrays
CN105126243B (en) * 2015-09-06 2018-08-07 台州薇凯生物科技有限公司 Microneedle injection bullet and preparation method thereof and microneedle injection equipment
WO2017066768A1 (en) 2015-10-16 2017-04-20 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Mullti-component biio-active drug delivery and controlled release to the skin by microneedle array devices
BR112018013074A2 (en) 2015-12-30 2018-12-11 Novartis Ag immune effector cell therapies with enhanced efficacy
WO2017120322A1 (en) 2016-01-05 2017-07-13 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Skin microenvironment targeted delivery for promoting immune and other responses
EP3595515A4 (en) 2017-03-14 2020-12-30 University of Connecticut Biodegradable pressure sensor
TWI653968B (en) 2017-11-20 2019-03-21 研能科技股份有限公司 Blood glucose detecting device
CN112074227A (en) 2018-03-05 2020-12-11 康涅狄格大学 Core-shell microneedle platforms for transdermal and pulsatile drug/vaccine delivery and methods of making same
GB201804880D0 (en) * 2018-03-27 2018-05-09 Univ Swansea Microneedle platform for sensing and delivery
US11697008B2 (en) 2018-10-29 2023-07-11 Rutgers, The State University Of New Jersey 3D printed microneedle assemblies
US11678989B2 (en) 2019-03-01 2023-06-20 University Of Connecticut Biodegradable piezoelectric nanofiber scaffold for bone or tissue regeneration
US11826495B2 (en) 2019-03-01 2023-11-28 University Of Connecticut Biodegradable piezoelectric ultrasonic transducer system
WO2020256197A1 (en) * 2019-06-21 2020-12-24 엘지전자 주식회사 Multi-needle device
US11745001B2 (en) 2020-03-10 2023-09-05 University Of Connecticut Therapeutic bandage
GB2608290B (en) 2020-07-29 2023-07-26 Biolinq Incorporated Continuous analyte monitoring system with microneedle array
WO2022219432A1 (en) * 2021-04-15 2022-10-20 Cochlear Limited Implantable therapeutic substance delivery
JP7341583B6 (en) 2021-05-08 2023-09-29 バイオリンク インコーポレイテッド Fault detection for microneedle array-based continuous analyte monitoring devices
EP4176855A1 (en) * 2021-11-09 2023-05-10 Valsigna GmbH Glaucoma implant device

Citations (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2522309A (en) * 1948-12-01 1950-09-12 Frank A Simon Allergy testing instrument
US3289675A (en) * 1961-12-08 1966-12-06 Dunmire Hannah Tubular hypodermic needle
US3964482A (en) * 1971-05-17 1976-06-22 Alza Corporation Drug delivery device
US4324236A (en) * 1979-12-03 1982-04-13 Whitman Medical Corp. Fitting for use in performing a vascular puncture
US4685903A (en) * 1984-01-06 1987-08-11 Pacesetter Infusion, Ltd. External infusion pump apparatus
US5279544A (en) * 1990-12-13 1994-01-18 Sil Medics Ltd. Transdermal or interdermal drug delivery devices
US5569272A (en) * 1991-01-31 1996-10-29 Carnegie Mellon University Tissue-connective devices with micromechanical barbs
US5697901A (en) * 1989-12-14 1997-12-16 Elof Eriksson Gene delivery by microneedle injection
US5820570A (en) * 1993-10-13 1998-10-13 Integ Incorporated Interstitial fluid collection and constituent measurement
US5931794A (en) * 1997-10-21 1999-08-03 Pitesky; Isadore Allergy testing apparatus
US6020208A (en) * 1994-05-27 2000-02-01 Baylor College Of Medicine Systems for surface-enhanced affinity capture for desorption and detection of analytes
US6083196A (en) * 1997-12-11 2000-07-04 Alza Corporation Device for enhancing transdermal agent flux
US6132755A (en) * 1995-07-14 2000-10-17 Boehringer Ingelheim Kg Transcorneal drug-release system
US6183434B1 (en) * 1996-07-03 2001-02-06 Spectrx, Inc. Multiple mechanical microporation of skin or mucosa
US6230051B1 (en) * 1996-06-18 2001-05-08 Alza Corporation Device for enhancing transdermal agent delivery or sampling
US6256533B1 (en) * 1999-06-09 2001-07-03 The Procter & Gamble Company Apparatus and method for using an intracutaneous microneedle array
US6271037B1 (en) * 1992-05-29 2001-08-07 The Rockefeller University Method and product for the sequence determination of peptides using a mass spectrometer
US6293925B1 (en) * 1997-12-31 2001-09-25 Minimed Inc. Insertion device for an insertion set and method of using the same
US6329146B1 (en) * 1998-03-02 2001-12-11 Isis Pharmaceuticals, Inc. Mass spectrometric methods for biomolecular screening
US20010053891A1 (en) * 1999-12-30 2001-12-20 Ackley Donald E. Stacked microneedle systems
US6334856B1 (en) * 1998-06-10 2002-01-01 Georgia Tech Research Corporation Microneedle devices and methods of manufacture and use thereof
US20020010410A1 (en) * 2000-06-26 2002-01-24 Steponovich Stephen A. Patella tracking knee brace and magnets system/method
US20020082543A1 (en) * 2000-12-14 2002-06-27 Jung-Hwan Park Microneedle devices and production thereof
US6440096B1 (en) * 2000-07-14 2002-08-27 Becton, Dickinson And Co. Microdevice and method of manufacturing a microdevice
US6537242B1 (en) * 2000-06-06 2003-03-25 Becton, Dickinson And Company Method and apparatus for enhancing penetration of a member for the intradermal sampling or administration of a substance
US6558361B1 (en) * 2000-03-09 2003-05-06 Nanopass Ltd. Systems and methods for the transport of fluids through a biological barrier and production techniques for such systems
US6591124B2 (en) * 2001-05-11 2003-07-08 The Procter & Gamble Company Portable interstitial fluid monitoring system
US20030135201A1 (en) * 2001-09-28 2003-07-17 Gonnelli Robert R. Microneedle with membrane
US6603998B1 (en) * 1999-01-28 2003-08-05 Cyto Pulse Sciences, Inc. Delivery of macromolecules into cells
US6611707B1 (en) * 1999-06-04 2003-08-26 Georgia Tech Research Corporation Microneedle drug delivery device
US6623457B1 (en) * 1999-09-22 2003-09-23 Becton, Dickinson And Company Method and apparatus for the transdermal administration of a substance
US6629949B1 (en) * 2000-05-08 2003-10-07 Sterling Medivations, Inc. Micro infusion drug delivery device
US6656147B1 (en) * 2000-07-17 2003-12-02 Becton, Dickinson And Company Method and delivery device for the transdermal administration of a substance
US6695859B1 (en) * 1999-04-05 2004-02-24 Coalescent Surgical, Inc. Apparatus and methods for anastomosis
US6713291B2 (en) * 1999-01-28 2004-03-30 Alan D. King Electrodes coated with treating agent and uses thereof
US6743211B1 (en) * 1999-11-23 2004-06-01 Georgia Tech Research Corporation Devices and methods for enhanced microneedle penetration of biological barriers
US6767341B2 (en) * 2001-06-13 2004-07-27 Abbott Laboratories Microneedles for minimally invasive drug delivery
US6780171B2 (en) * 2002-04-02 2004-08-24 Becton, Dickinson And Company Intradermal delivery device
US6837988B2 (en) * 2001-06-12 2005-01-04 Lifescan, Inc. Biological fluid sampling and analyte measurement devices and methods
US6899717B2 (en) * 2002-09-18 2005-05-31 Allergan, Inc. Methods and apparatus for delivery of ocular implants

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4936835A (en) * 1988-05-26 1990-06-26 Haaga John R Medical needle with bioabsorbable tip
US5931764A (en) * 1998-06-24 1999-08-03 Viztec, Inc. Wearable device with flexible display
US6312612B1 (en) 1999-06-09 2001-11-06 The Procter & Gamble Company Apparatus and method for manufacturing an intracutaneous microneedle array

Patent Citations (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2522309A (en) * 1948-12-01 1950-09-12 Frank A Simon Allergy testing instrument
US3289675A (en) * 1961-12-08 1966-12-06 Dunmire Hannah Tubular hypodermic needle
US3964482A (en) * 1971-05-17 1976-06-22 Alza Corporation Drug delivery device
US4324236A (en) * 1979-12-03 1982-04-13 Whitman Medical Corp. Fitting for use in performing a vascular puncture
US4685903A (en) * 1984-01-06 1987-08-11 Pacesetter Infusion, Ltd. External infusion pump apparatus
US5697901A (en) * 1989-12-14 1997-12-16 Elof Eriksson Gene delivery by microneedle injection
US5279544A (en) * 1990-12-13 1994-01-18 Sil Medics Ltd. Transdermal or interdermal drug delivery devices
US5569272A (en) * 1991-01-31 1996-10-29 Carnegie Mellon University Tissue-connective devices with micromechanical barbs
US6271037B1 (en) * 1992-05-29 2001-08-07 The Rockefeller University Method and product for the sequence determination of peptides using a mass spectrometer
US5820570A (en) * 1993-10-13 1998-10-13 Integ Incorporated Interstitial fluid collection and constituent measurement
US6020208A (en) * 1994-05-27 2000-02-01 Baylor College Of Medicine Systems for surface-enhanced affinity capture for desorption and detection of analytes
US6132755A (en) * 1995-07-14 2000-10-17 Boehringer Ingelheim Kg Transcorneal drug-release system
US6230051B1 (en) * 1996-06-18 2001-05-08 Alza Corporation Device for enhancing transdermal agent delivery or sampling
US6183434B1 (en) * 1996-07-03 2001-02-06 Spectrx, Inc. Multiple mechanical microporation of skin or mucosa
US5931794A (en) * 1997-10-21 1999-08-03 Pitesky; Isadore Allergy testing apparatus
US6083196A (en) * 1997-12-11 2000-07-04 Alza Corporation Device for enhancing transdermal agent flux
US6293925B1 (en) * 1997-12-31 2001-09-25 Minimed Inc. Insertion device for an insertion set and method of using the same
US6329146B1 (en) * 1998-03-02 2001-12-11 Isis Pharmaceuticals, Inc. Mass spectrometric methods for biomolecular screening
US6334856B1 (en) * 1998-06-10 2002-01-01 Georgia Tech Research Corporation Microneedle devices and methods of manufacture and use thereof
US6503231B1 (en) * 1998-06-10 2003-01-07 Georgia Tech Research Corporation Microneedle device for transport of molecules across tissue
US6603998B1 (en) * 1999-01-28 2003-08-05 Cyto Pulse Sciences, Inc. Delivery of macromolecules into cells
US6713291B2 (en) * 1999-01-28 2004-03-30 Alan D. King Electrodes coated with treating agent and uses thereof
US6695859B1 (en) * 1999-04-05 2004-02-24 Coalescent Surgical, Inc. Apparatus and methods for anastomosis
US6611707B1 (en) * 1999-06-04 2003-08-26 Georgia Tech Research Corporation Microneedle drug delivery device
US6256533B1 (en) * 1999-06-09 2001-07-03 The Procter & Gamble Company Apparatus and method for using an intracutaneous microneedle array
US6623457B1 (en) * 1999-09-22 2003-09-23 Becton, Dickinson And Company Method and apparatus for the transdermal administration of a substance
US6743211B1 (en) * 1999-11-23 2004-06-01 Georgia Tech Research Corporation Devices and methods for enhanced microneedle penetration of biological barriers
US20010053891A1 (en) * 1999-12-30 2001-12-20 Ackley Donald E. Stacked microneedle systems
US6558361B1 (en) * 2000-03-09 2003-05-06 Nanopass Ltd. Systems and methods for the transport of fluids through a biological barrier and production techniques for such systems
US6629949B1 (en) * 2000-05-08 2003-10-07 Sterling Medivations, Inc. Micro infusion drug delivery device
US6537242B1 (en) * 2000-06-06 2003-03-25 Becton, Dickinson And Company Method and apparatus for enhancing penetration of a member for the intradermal sampling or administration of a substance
US20020010410A1 (en) * 2000-06-26 2002-01-24 Steponovich Stephen A. Patella tracking knee brace and magnets system/method
US6440096B1 (en) * 2000-07-14 2002-08-27 Becton, Dickinson And Co. Microdevice and method of manufacturing a microdevice
US6656147B1 (en) * 2000-07-17 2003-12-02 Becton, Dickinson And Company Method and delivery device for the transdermal administration of a substance
US20020082543A1 (en) * 2000-12-14 2002-06-27 Jung-Hwan Park Microneedle devices and production thereof
US6591124B2 (en) * 2001-05-11 2003-07-08 The Procter & Gamble Company Portable interstitial fluid monitoring system
US6837988B2 (en) * 2001-06-12 2005-01-04 Lifescan, Inc. Biological fluid sampling and analyte measurement devices and methods
US6767341B2 (en) * 2001-06-13 2004-07-27 Abbott Laboratories Microneedles for minimally invasive drug delivery
US20030135201A1 (en) * 2001-09-28 2003-07-17 Gonnelli Robert R. Microneedle with membrane
US6780171B2 (en) * 2002-04-02 2004-08-24 Becton, Dickinson And Company Intradermal delivery device
US6899717B2 (en) * 2002-09-18 2005-05-31 Allergan, Inc. Methods and apparatus for delivery of ocular implants

Cited By (498)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7666149B2 (en) 1997-12-04 2010-02-23 Peliken Technologies, Inc. Cassette of lancet cartridges for sampling blood
US7780631B2 (en) 1998-03-30 2010-08-24 Pelikan Technologies, Inc. Apparatus and method for penetration with shaft having a sensor for sensing penetration depth
US8439872B2 (en) 1998-03-30 2013-05-14 Sanofi-Aventis Deutschland Gmbh Apparatus and method for penetration with shaft having a sensor for sensing penetration depth
US8641644B2 (en) 2000-11-21 2014-02-04 Sanofi-Aventis Deutschland Gmbh Blood testing apparatus having a rotatable cartridge with multiple lancing elements and testing means
US8216154B2 (en) 2001-06-12 2012-07-10 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US8211037B2 (en) 2001-06-12 2012-07-03 Pelikan Technologies, Inc. Tissue penetration device
US8622930B2 (en) 2001-06-12 2014-01-07 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US9937298B2 (en) 2001-06-12 2018-04-10 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US9427532B2 (en) 2001-06-12 2016-08-30 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US7682318B2 (en) 2001-06-12 2010-03-23 Pelikan Technologies, Inc. Blood sampling apparatus and method
US8679033B2 (en) 2001-06-12 2014-03-25 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US8382683B2 (en) 2001-06-12 2013-02-26 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US8360991B2 (en) 2001-06-12 2013-01-29 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US8337421B2 (en) 2001-06-12 2012-12-25 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US7699791B2 (en) 2001-06-12 2010-04-20 Pelikan Technologies, Inc. Method and apparatus for improving success rate of blood yield from a fingerstick
US8282577B2 (en) 2001-06-12 2012-10-09 Sanofi-Aventis Deutschland Gmbh Method and apparatus for lancet launching device integrated onto a blood-sampling cartridge
US8721671B2 (en) 2001-06-12 2014-05-13 Sanofi-Aventis Deutschland Gmbh Electric lancet actuator
US8641643B2 (en) 2001-06-12 2014-02-04 Sanofi-Aventis Deutschland Gmbh Sampling module device and method
US8206317B2 (en) 2001-06-12 2012-06-26 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US8206319B2 (en) 2001-06-12 2012-06-26 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US8123700B2 (en) 2001-06-12 2012-02-28 Pelikan Technologies, Inc. Method and apparatus for lancet launching device integrated onto a blood-sampling cartridge
US9694144B2 (en) 2001-06-12 2017-07-04 Sanofi-Aventis Deutschland Gmbh Sampling module device and method
US8016774B2 (en) 2001-06-12 2011-09-13 Pelikan Technologies, Inc. Tissue penetration device
US7988645B2 (en) 2001-06-12 2011-08-02 Pelikan Technologies, Inc. Self optimizing lancing device with adaptation means to temporal variations in cutaneous properties
US7981055B2 (en) 2001-06-12 2011-07-19 Pelikan Technologies, Inc. Tissue penetration device
US7909775B2 (en) 2001-06-12 2011-03-22 Pelikan Technologies, Inc. Method and apparatus for lancet launching device integrated onto a blood-sampling cartridge
US7850622B2 (en) 2001-06-12 2010-12-14 Pelikan Technologies, Inc. Tissue penetration device
US8845550B2 (en) 2001-06-12 2014-09-30 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US7749174B2 (en) 2001-06-12 2010-07-06 Pelikan Technologies, Inc. Method and apparatus for lancet launching device intergrated onto a blood-sampling cartridge
US9802007B2 (en) 2001-06-12 2017-10-31 Sanofi-Aventis Deutschland Gmbh Methods and apparatus for lancet actuation
US9560993B2 (en) 2001-11-21 2017-02-07 Sanofi-Aventis Deutschland Gmbh Blood testing apparatus having a rotatable cartridge with multiple lancing elements and testing means
US20050187521A1 (en) * 2002-01-15 2005-08-25 3M Innovative Properties Company Microneedle devices and methods of manufacture
US8007446B2 (en) 2002-04-19 2011-08-30 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7909778B2 (en) 2002-04-19 2011-03-22 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US8808201B2 (en) 2002-04-19 2014-08-19 Sanofi-Aventis Deutschland Gmbh Methods and apparatus for penetrating tissue
US8403864B2 (en) 2002-04-19 2013-03-26 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US8388551B2 (en) 2002-04-19 2013-03-05 Sanofi-Aventis Deutschland Gmbh Method and apparatus for multi-use body fluid sampling device with sterility barrier release
US8845549B2 (en) 2002-04-19 2014-09-30 Sanofi-Aventis Deutschland Gmbh Method for penetrating tissue
US8382682B2 (en) 2002-04-19 2013-02-26 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US9907502B2 (en) 2002-04-19 2018-03-06 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US8372016B2 (en) 2002-04-19 2013-02-12 Sanofi-Aventis Deutschland Gmbh Method and apparatus for body fluid sampling and analyte sensing
US8366637B2 (en) 2002-04-19 2013-02-05 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US7648468B2 (en) 2002-04-19 2010-01-19 Pelikon Technologies, Inc. Method and apparatus for penetrating tissue
US20070219573A1 (en) * 2002-04-19 2007-09-20 Dominique Freeman Method and apparatus for penetrating tissue
US8360992B2 (en) 2002-04-19 2013-01-29 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US8905945B2 (en) 2002-04-19 2014-12-09 Dominique M. Freeman Method and apparatus for penetrating tissue
US8430828B2 (en) 2002-04-19 2013-04-30 Sanofi-Aventis Deutschland Gmbh Method and apparatus for a multi-use body fluid sampling device with sterility barrier release
US7674232B2 (en) 2002-04-19 2010-03-09 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US8267870B2 (en) 2002-04-19 2012-09-18 Sanofi-Aventis Deutschland Gmbh Method and apparatus for body fluid sampling with hybrid actuation
US8690796B2 (en) 2002-04-19 2014-04-08 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US8235915B2 (en) 2002-04-19 2012-08-07 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US7708701B2 (en) 2002-04-19 2010-05-04 Pelikan Technologies, Inc. Method and apparatus for a multi-use body fluid sampling device
US9839386B2 (en) 2002-04-19 2017-12-12 Sanofi-Aventis Deustschland Gmbh Body fluid sampling device with capacitive sensor
US8221334B2 (en) 2002-04-19 2012-07-17 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US7713214B2 (en) 2002-04-19 2010-05-11 Pelikan Technologies, Inc. Method and apparatus for a multi-use body fluid sampling device with optical analyte sensing
US8435190B2 (en) 2002-04-19 2013-05-07 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US7717863B2 (en) 2002-04-19 2010-05-18 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US9498160B2 (en) 2002-04-19 2016-11-22 Sanofi-Aventis Deutschland Gmbh Method for penetrating tissue
US7731729B2 (en) 2002-04-19 2010-06-08 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US9795334B2 (en) 2002-04-19 2017-10-24 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US8491500B2 (en) 2002-04-19 2013-07-23 Sanofi-Aventis Deutschland Gmbh Methods and apparatus for lancet actuation
US8496601B2 (en) 2002-04-19 2013-07-30 Sanofi-Aventis Deutschland Gmbh Methods and apparatus for lancet actuation
US8202231B2 (en) 2002-04-19 2012-06-19 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US8636673B2 (en) 2002-04-19 2014-01-28 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US9072842B2 (en) 2002-04-19 2015-07-07 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US8197423B2 (en) 2002-04-19 2012-06-12 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US9089294B2 (en) 2002-04-19 2015-07-28 Sanofi-Aventis Deutschland Gmbh Analyte measurement device with a single shot actuator
US9089678B2 (en) 2002-04-19 2015-07-28 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US8197421B2 (en) 2002-04-19 2012-06-12 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7833171B2 (en) 2002-04-19 2010-11-16 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US8157748B2 (en) 2002-04-19 2012-04-17 Pelikan Technologies, Inc. Methods and apparatus for lancet actuation
US8579831B2 (en) 2002-04-19 2013-11-12 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US8079960B2 (en) 2002-04-19 2011-12-20 Pelikan Technologies, Inc. Methods and apparatus for lancet actuation
US9339612B2 (en) 2002-04-19 2016-05-17 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US8062231B2 (en) 2002-04-19 2011-11-22 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7862520B2 (en) 2002-04-19 2011-01-04 Pelikan Technologies, Inc. Body fluid sampling module with a continuous compression tissue interface surface
US7875047B2 (en) 2002-04-19 2011-01-25 Pelikan Technologies, Inc. Method and apparatus for a multi-use body fluid sampling device with sterility barrier release
US7874994B2 (en) 2002-04-19 2011-01-25 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7892185B2 (en) 2002-04-19 2011-02-22 Pelikan Technologies, Inc. Method and apparatus for body fluid sampling and analyte sensing
US7892183B2 (en) 2002-04-19 2011-02-22 Pelikan Technologies, Inc. Method and apparatus for body fluid sampling and analyte sensing
US9186468B2 (en) 2002-04-19 2015-11-17 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US7901365B2 (en) 2002-04-19 2011-03-08 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7901362B2 (en) 2002-04-19 2011-03-08 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US9226699B2 (en) 2002-04-19 2016-01-05 Sanofi-Aventis Deutschland Gmbh Body fluid sampling module with a continuous compression tissue interface surface
US7909777B2 (en) 2002-04-19 2011-03-22 Pelikan Technologies, Inc Method and apparatus for penetrating tissue
US8414503B2 (en) 2002-04-19 2013-04-09 Sanofi-Aventis Deutschland Gmbh Methods and apparatus for lancet actuation
US7914465B2 (en) 2002-04-19 2011-03-29 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US9724021B2 (en) 2002-04-19 2017-08-08 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US9248267B2 (en) 2002-04-19 2016-02-02 Sanofi-Aventis Deustchland Gmbh Tissue penetration device
US7938787B2 (en) 2002-04-19 2011-05-10 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US8562545B2 (en) 2002-04-19 2013-10-22 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US7976476B2 (en) 2002-04-19 2011-07-12 Pelikan Technologies, Inc. Device and method for variable speed lancet
US9314194B2 (en) 2002-04-19 2016-04-19 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US8556829B2 (en) 2002-04-19 2013-10-15 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US7981056B2 (en) 2002-04-19 2011-07-19 Pelikan Technologies, Inc. Methods and apparatus for lancet actuation
US7988644B2 (en) 2002-04-19 2011-08-02 Pelikan Technologies, Inc. Method and apparatus for a multi-use body fluid sampling device with sterility barrier release
US8784335B2 (en) 2002-04-19 2014-07-22 Sanofi-Aventis Deutschland Gmbh Body fluid sampling device with a capacitive sensor
US8900194B2 (en) 2002-07-19 2014-12-02 3M Innovative Properties Company Microneedle devices and microneedle delivery apparatus
US9034639B2 (en) 2002-12-30 2015-05-19 Sanofi-Aventis Deutschland Gmbh Method and apparatus using optical techniques to measure analyte levels
US8574895B2 (en) 2002-12-30 2013-11-05 Sanofi-Aventis Deutschland Gmbh Method and apparatus using optical techniques to measure analyte levels
US8262614B2 (en) 2003-05-30 2012-09-11 Pelikan Technologies, Inc. Method and apparatus for fluid injection
US8251921B2 (en) 2003-06-06 2012-08-28 Sanofi-Aventis Deutschland Gmbh Method and apparatus for body fluid sampling and analyte sensing
US7850621B2 (en) 2003-06-06 2010-12-14 Pelikan Technologies, Inc. Method and apparatus for body fluid sampling and analyte sensing
US9144401B2 (en) 2003-06-11 2015-09-29 Sanofi-Aventis Deutschland Gmbh Low pain penetrating member
US10034628B2 (en) 2003-06-11 2018-07-31 Sanofi-Aventis Deutschland Gmbh Low pain penetrating member
US8282576B2 (en) 2003-09-29 2012-10-09 Sanofi-Aventis Deutschland Gmbh Method and apparatus for an improved sample capture device
US8945910B2 (en) 2003-09-29 2015-02-03 Sanofi-Aventis Deutschland Gmbh Method and apparatus for an improved sample capture device
US9351680B2 (en) 2003-10-14 2016-05-31 Sanofi-Aventis Deutschland Gmbh Method and apparatus for a variable user interface
US20070081977A1 (en) * 2003-11-17 2007-04-12 Lts Lohmann Therapie-Systeme Ag Device for transdermal administration of active substances
US8296918B2 (en) 2003-12-31 2012-10-30 Sanofi-Aventis Deutschland Gmbh Method of manufacturing a fluid sampling device with improved analyte detecting member configuration
US9561000B2 (en) 2003-12-31 2017-02-07 Sanofi-Aventis Deutschland Gmbh Method and apparatus for improving fluidic flow and sample capture
US8668656B2 (en) 2003-12-31 2014-03-11 Sanofi-Aventis Deutschland Gmbh Method and apparatus for improving fluidic flow and sample capture
US20070191761A1 (en) * 2004-02-23 2007-08-16 3M Innovative Properties Company Method of molding for microneedle arrays
US9261476B2 (en) 2004-05-20 2016-02-16 Sanofi Sa Printable hydrogel for biosensors
US8828203B2 (en) 2004-05-20 2014-09-09 Sanofi-Aventis Deutschland Gmbh Printable hydrogels for biosensors
US9820684B2 (en) 2004-06-03 2017-11-21 Sanofi-Aventis Deutschland Gmbh Method and apparatus for a fluid sampling device
US9775553B2 (en) 2004-06-03 2017-10-03 Sanofi-Aventis Deutschland Gmbh Method and apparatus for a fluid sampling device
US8167866B2 (en) * 2004-06-25 2012-05-01 Klein Jeffrey A Drug delivery system for accelerated subcutaneous absorption
US20100249746A1 (en) * 2004-06-25 2010-09-30 Klein Jeffrey A Drug delivery system for accelerated subcutaneous absorption
US20090234214A1 (en) * 2004-07-30 2009-09-17 Microchips, Inc. Multi-reservoir device and method for transdermal sensing
WO2006015299A3 (en) * 2004-07-30 2006-05-04 Microchips Inc Multi-reservoir device for transdermal drug delivery and sensing
WO2006015299A2 (en) * 2004-07-30 2006-02-09 Microchips, Inc. Multi-reservoir device for transdermal drug delivery and sensing
US20060034902A1 (en) * 2004-08-10 2006-02-16 Cormier Michel J Microprojection apparatus and system with low infection potential
WO2006020842A1 (en) * 2004-08-10 2006-02-23 Alza Corporation Microprojection apparatus and system with low infection potential
JP2008509747A (en) * 2004-08-10 2008-04-03 アルザ コーポレイション Microprojection device and system with low probability of infection
US7981346B2 (en) * 2004-08-30 2011-07-19 Bonsens Ab Molded micro-needles
US20070255205A1 (en) * 2004-08-30 2007-11-01 Patrick Griss Molded Micro-Needles
US20060079836A1 (en) * 2004-10-12 2006-04-13 Holman Thomas J Reinforced and drug-eluting balloon catheters and methods for making same
US7491188B2 (en) * 2004-10-12 2009-02-17 Boston Scientific Scimed, Inc. Reinforced and drug-eluting balloon catheters and methods for making same
US20080102192A1 (en) * 2004-11-18 2008-05-01 Johnson Peter R Masking Method for Coating a Microneedle Array
US8414959B2 (en) 2004-11-18 2013-04-09 3M Innovative Properties Company Method of contact coating a microneedle array
US7846488B2 (en) 2004-11-18 2010-12-07 3M Innovative Properties Company Masking method for coating a microneedle array
US8741377B2 (en) 2004-11-18 2014-06-03 3M Innovative Properties Company Method of contact coating a microneedle array
US8057842B2 (en) 2004-11-18 2011-11-15 3M Innovative Properties Company Method of contact coating a microneedle array
US20080009800A1 (en) * 2004-12-02 2008-01-10 Nickel Janice H Transdermal drug delivery device
US8652831B2 (en) 2004-12-30 2014-02-18 Sanofi-Aventis Deutschland Gmbh Method and apparatus for analyte measurement test time
US7822454B1 (en) 2005-01-03 2010-10-26 Pelikan Technologies, Inc. Fluid sampling device with improved analyte detecting member configuration
US8506980B2 (en) 2005-01-31 2013-08-13 Bioserentach Co., Ltd. Percutaneously absorbable preparation, percutaneously absorbable preparation holding sheet, and percutaneously absorbable preparation holding equipment
US20080262444A1 (en) * 2005-01-31 2008-10-23 Bioserentach Co., Ltd. Percutaneously Absorbable Preparation, Percutaneously Absorbable Preparation Holding Sheet, and Percutaneously Absorbable Preparation Holding Equipment
US20110046575A1 (en) * 2005-01-31 2011-02-24 Kanji Takada Percutaneously absorbable preparation, percutaneously absorbable preparation holding sheet, and percutaneously absorbable preparation holding equipment
WO2006089285A1 (en) * 2005-02-16 2006-08-24 Alza Corporation Microprojection arrays with improved biocompatibility
US20100292551A1 (en) * 2005-03-29 2010-11-18 Jina Arvind N Devices, systems, methods and tools for continuous glucose monitoring
US7949382B2 (en) 2005-03-29 2011-05-24 Arkal Medical, Inc. Devices, systems, methods and tools for continuous glucose monitoring
US20080195035A1 (en) * 2005-06-24 2008-08-14 Frederickson Franklyn L Collapsible Patch and Method of Application
US10315021B2 (en) 2005-06-24 2019-06-11 3M Innovative Properties Company Collapsible patch and method of application
US20090187160A1 (en) * 2005-08-05 2009-07-23 Mcallister Devin V Methods and devices for delivering agents across biological barriers
US20070078414A1 (en) * 2005-08-05 2007-04-05 Mcallister Devin V Methods and devices for delivering agents across biological barriers
US20100152701A1 (en) * 2005-08-05 2010-06-17 Mcallister Devin V Methods and devices for delivering agents across biological barriers
US9561042B2 (en) 2005-08-05 2017-02-07 Valeritas, Inc. Methods and devices for delivering agents across biological barriers
US9011392B2 (en) 2005-08-05 2015-04-21 Valeritas, Inc. Methods and devices for delivering agents across biological barriers
US20070161964A1 (en) * 2006-01-10 2007-07-12 Yuzhakov Vadim V Microneedle array, patch, and applicator for transdermal drug delivery
US8414548B2 (en) 2006-01-10 2013-04-09 Vadim V. Yuzhakov Method of making microneedle array and device for applying microneedle array to skin
US7658728B2 (en) 2006-01-10 2010-02-09 Yuzhakov Vadim V Microneedle array, patch, and applicator for transdermal drug delivery
US20100130940A1 (en) * 2006-01-10 2010-05-27 Yuzhakov Vadim V Method of making microneedle array and device for applying microneedle array to skin
US20070179428A1 (en) * 2006-01-31 2007-08-02 Kralick D O Francis A Implantable micro-system for treatment of hydrocephalus
US7691077B2 (en) 2006-01-31 2010-04-06 Kralick Francis A Implantable micro-system for treatment of hydrocephalus
US20100256549A1 (en) * 2006-01-31 2010-10-07 Kralick Francis A Implantable micro-system for treatment of hydrocephalus
US8206334B2 (en) 2006-01-31 2012-06-26 Kralick Francis A Implantable micro-system for treatment of hydrocephalus
WO2007130718A3 (en) * 2006-01-31 2008-01-24 Francis A Kralick Implantable micro-system for treatment of hydrocephalus
JP2009525156A (en) * 2006-01-31 2009-07-09 エイ. クラリック、フランシス Implantable microsystem for the treatment of hydrocephalus
US11752101B2 (en) 2006-02-22 2023-09-12 Clearside Biomedical, Inc. Ocular injector and methods for accessing suprachoroidal space of the eye
US20100049021A1 (en) * 2006-03-28 2010-02-25 Jina Arvind N Devices, systems, methods and tools for continuous analyte monitoring
US20090131778A1 (en) * 2006-03-28 2009-05-21 Jina Arvind N Devices, systems, methods and tools for continuous glucose monitoring
US10632013B2 (en) * 2006-05-02 2020-04-28 Georgia Tech Research Corporation Methods and devices for drug delivery to ocular tissue using microneedle
US8636713B2 (en) 2006-05-02 2014-01-28 Emory University Methods and devices for drug delivery to ocular tissue using microneedle
US9788995B2 (en) 2006-05-02 2017-10-17 Georgia Tech Research Corporation Methods and devices for drug delivery to ocular tissue using microneedle
US8197435B2 (en) 2006-05-02 2012-06-12 Emory University Methods and devices for drug delivery to ocular tissue using microneedle
US10905586B2 (en) 2006-05-02 2021-02-02 Georgia Tech Research Corporation Methods and devices for drug delivery to ocular tissue using microneedle
US20100256597A1 (en) * 2006-05-02 2010-10-07 Emory University Methods and Devices for Drug Delivery to Ocular Tissue Using Microneedle
US8808225B2 (en) 2006-05-02 2014-08-19 Emory University Methods and devices for drug delivery to ocular tissue using microneedle
WO2007149514A3 (en) * 2006-06-19 2008-03-20 Corium Int Inc Methods, devices, and kits for microjet drug delivery
WO2007149514A2 (en) * 2006-06-19 2007-12-27 Corium International, Inc. Methods, devices, and kits for microjet drug delivery
US20080008745A1 (en) * 2006-06-21 2008-01-10 University Of Kentucky Research Foundation Transdermal delivery of naltrexone hydrochloride, naltrexol hydrochloride, and bis(hydroxy-methyl)propionyl-3-0 ester naltrexone using microneedles
US20080208134A1 (en) * 2006-08-18 2008-08-28 Toppan Printing Co., Ltd. Micro-needle and micro-needle patch
US20090292254A1 (en) * 2006-08-18 2009-11-26 Toppan Printing Co., Ltd. Micro-needle and micro-needle patch
US8702624B2 (en) 2006-09-29 2014-04-22 Sanofi-Aventis Deutschland Gmbh Analyte measurement device with a single shot actuator
WO2008053481A1 (en) * 2006-11-01 2008-05-08 Svip 6 Llc Microneedle arrays
US20100305473A1 (en) * 2006-11-28 2010-12-02 Yuzhakov Vadim V Tissue conforming microneedle device for drug delivery or biological fluid collection
US7785301B2 (en) 2006-11-28 2010-08-31 Vadim V Yuzhakov Tissue conforming microneedle array and patch for transdermal drug delivery or biological fluid collection
US20080125743A1 (en) * 2006-11-28 2008-05-29 Yuzhakov Vadim V Tissue Conforming Microneedle Array and Patch For Transdermal Drug Delivery or Biological Fluid Collection
US20080154107A1 (en) * 2006-12-20 2008-06-26 Jina Arvind N Device, systems, methods and tools for continuous glucose monitoring
US20080234562A1 (en) * 2007-03-19 2008-09-25 Jina Arvind N Continuous analyte monitor with multi-point self-calibration
US9114238B2 (en) * 2007-04-16 2015-08-25 Corium International, Inc. Solvent-cast microprotrusion arrays containing active ingredient
US9452280B2 (en) 2007-04-16 2016-09-27 Corium International, Inc. Solvent-cast microprotrusion arrays containing active ingredient
US20080269685A1 (en) * 2007-04-16 2008-10-30 Parminder Singh Solvent-cast microneedle arrays containing active
US10238848B2 (en) 2007-04-16 2019-03-26 Corium International, Inc. Solvent-cast microprotrusion arrays containing active ingredient
US9498524B2 (en) 2007-04-16 2016-11-22 Corium International, Inc. Method of vaccine delivery via microneedle arrays
US20080312518A1 (en) * 2007-06-14 2008-12-18 Arkal Medical, Inc On-demand analyte monitor and method of use
US20090053673A1 (en) * 2007-08-23 2009-02-26 Zimmer, Inc. Method for localized treatment of periodontal tissue
US20090093775A1 (en) * 2007-10-03 2009-04-09 Raju Remesh S O Govinda Microstructures
US20090099427A1 (en) * 2007-10-12 2009-04-16 Arkal Medical, Inc. Microneedle array with diverse needle configurations
US20090247984A1 (en) * 2007-10-24 2009-10-01 Masimo Laboratories, Inc. Use of microneedles for small molecule metabolite reporter delivery
US20160317330A1 (en) * 2008-01-17 2016-11-03 Boston Scientific Scimed, Inc. Stent with anti-migration feature
US10426641B2 (en) * 2008-01-17 2019-10-01 Boston Scientific Scimed, Inc. Stent with anti-migration feature
US20090234288A1 (en) * 2008-03-12 2009-09-17 Ultradent Products, Inc. Dental intraligamentary injection needles and related methods of manufacture
US8398397B2 (en) 2008-03-12 2013-03-19 Ultradent Products, Inc. Dental intraligamentary injection needles and related methods of manufacture
US11229777B2 (en) 2008-03-21 2022-01-25 Cagent Vascular, Inc. System and method for plaque serration
US11529501B2 (en) 2008-03-21 2022-12-20 Gagent Vascular, Inc. System and method for plaque serration
US20090240270A1 (en) * 2008-03-21 2009-09-24 Peter Schneider Device and method for opening blood vessels by pre-angioplasty serration and dilatation of atherosclerotic plaque
US20100042121A1 (en) * 2008-03-21 2010-02-18 Peter Schneider Pre-angioplasty serration of atherosclerotic plaque enabling low-pressure balloon angioplasty and avoidance of stenting
US8323243B2 (en) 2008-03-21 2012-12-04 Innovasc Llc Device and method for opening blood vessels by pre-angioplasty serration and dilatation of atherosclerotic plaque
US9480826B2 (en) * 2008-03-21 2016-11-01 Cagent Vascular, Llc Intravascular device
US11141573B2 (en) 2008-03-21 2021-10-12 Cagent Vascular, Inc. Method for plaque serration
US11166742B2 (en) 2008-03-21 2021-11-09 Cagent Vascular, Inc. Method of enhancing drug uptake from a drug-eluting balloon
US9393386B2 (en) 2008-03-21 2016-07-19 Cagent Vascular, Llc Intravascular device
US11219750B2 (en) 2008-03-21 2022-01-11 Cagent Vascular, Inc. System and method for plaque serration
US9386944B2 (en) 2008-04-11 2016-07-12 Sanofi-Aventis Deutschland Gmbh Method and apparatus for analyte detecting device
US9060934B2 (en) 2008-10-31 2015-06-23 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US8568363B2 (en) 2008-10-31 2013-10-29 The Invention Science Fund I, Llc Frozen compositions and methods for piercing a substrate
US8731841B2 (en) 2008-10-31 2014-05-20 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US8858912B2 (en) 2008-10-31 2014-10-14 The Invention Science Fund I, Llc Frozen compositions and methods for piercing a substrate
US8731840B2 (en) 2008-10-31 2014-05-20 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US8721583B2 (en) 2008-10-31 2014-05-13 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US8788212B2 (en) 2008-10-31 2014-07-22 The Invention Science Fund I, Llc Compositions and methods for biological remodeling with frozen particle compositions
US8725420B2 (en) 2008-10-31 2014-05-13 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US8793075B2 (en) 2008-10-31 2014-07-29 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US20100112068A1 (en) * 2008-10-31 2010-05-06 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Compositions and methods for biological remodeling with frozen particle compositions
US20100112067A1 (en) * 2008-10-31 2010-05-06 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Compositions and methods for biological remodeling with frozen particle compositions
US8722068B2 (en) 2008-10-31 2014-05-13 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US20100119557A1 (en) * 2008-10-31 2010-05-13 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Frozen compositions and methods for piercing a substrate
US20100143243A1 (en) * 2008-10-31 2010-06-10 Searete Llc, A Limited Liability Corporation Of The State Of Delware Frozen compositions and methods for piercing a substrate
US20100185174A1 (en) * 2008-10-31 2010-07-22 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems, devices, and methods for making or administering frozen particles
US9040087B2 (en) 2008-10-31 2015-05-26 The Invention Science Fund I, Llc Frozen compositions and methods for piercing a substrate
US9050070B2 (en) 2008-10-31 2015-06-09 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US9050317B2 (en) 2008-10-31 2015-06-09 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US9050251B2 (en) 2008-10-31 2015-06-09 The Invention Science Fund I, Llc Compositions and methods for delivery of frozen particle adhesives
US9056047B2 (en) 2008-10-31 2015-06-16 The Invention Science Fund I, Llc Compositions and methods for delivery of frozen particle adhesives
US8784385B2 (en) 2008-10-31 2014-07-22 The Invention Science Fund I, Llc Frozen piercing implements and methods for piercing a substrate
US9060926B2 (en) 2008-10-31 2015-06-23 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US9060931B2 (en) 2008-10-31 2015-06-23 The Invention Science Fund I, Llc Compositions and methods for delivery of frozen particle adhesives
US8798932B2 (en) 2008-10-31 2014-08-05 The Invention Science Fund I, Llc Frozen compositions and methods for piercing a substrate
US8409376B2 (en) 2008-10-31 2013-04-02 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US9072799B2 (en) 2008-10-31 2015-07-07 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US8414356B2 (en) 2008-10-31 2013-04-09 The Invention Science Fund I, Llc Systems, devices, and methods for making or administering frozen particles
US8485861B2 (en) 2008-10-31 2013-07-16 The Invention Science Fund I, Llc Systems, devices, and methods for making or administering frozen particles
US8798933B2 (en) 2008-10-31 2014-08-05 The Invention Science Fund I, Llc Frozen compositions and methods for piercing a substrate
US8613937B2 (en) 2008-10-31 2013-12-24 The Invention Science Fund I, Llc Compositions and methods for biological remodeling with frozen particle compositions
US8603496B2 (en) 2008-10-31 2013-12-10 The Invention Science Fund I, Llc Compositions and methods for biological remodeling with frozen particle compositions
US8518031B2 (en) 2008-10-31 2013-08-27 The Invention Science Fund I, Llc Systems, devices and methods for making or administering frozen particles
US8603495B2 (en) 2008-10-31 2013-12-10 The Invention Science Fund I, Llc Compositions and methods for biological remodeling with frozen particle compositions
US8603494B2 (en) 2008-10-31 2013-12-10 The Invention Science Fund I, Llc Compositions and methods for administering compartmentalized frozen particles
US8762067B2 (en) 2008-10-31 2014-06-24 The Invention Science Fund I, Llc Methods and systems for ablation or abrasion with frozen particles and comparing tissue surface ablation or abrasion data to clinical outcome data
US8731842B2 (en) 2008-10-31 2014-05-20 The Invention Science Fund I, Llc Compositions and methods for biological remodeling with frozen particle compositions
US8563012B2 (en) 2008-10-31 2013-10-22 The Invention Science Fund I, Llc Compositions and methods for administering compartmentalized frozen particles
US9072688B2 (en) 2008-10-31 2015-07-07 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US8551506B2 (en) 2008-10-31 2013-10-08 The Invention Science Fund I, Llc Compositions and methods for administering compartmentalized frozen particles
US8545855B2 (en) 2008-10-31 2013-10-01 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US8784384B2 (en) * 2008-10-31 2014-07-22 The Invention Science Fund I, Llc Frozen compositions and array devices thereof
US8545857B2 (en) 2008-10-31 2013-10-01 The Invention Science Fund I, Llc Compositions and methods for administering compartmentalized frozen particles
US8551505B2 (en) 2008-10-31 2013-10-08 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US8788211B2 (en) 2008-10-31 2014-07-22 The Invention Science Fund I, Llc Method and system for comparing tissue ablation or abrasion data to data related to administration of a frozen particle composition
US8545856B2 (en) 2008-10-31 2013-10-01 The Invention Science Fund I, Llc Compositions and methods for delivery of frozen particle adhesives
US8545806B2 (en) 2008-10-31 2013-10-01 The Invention Science Fund I, Llc Compositions and methods for biological remodeling with frozen particle compositions
US9375169B2 (en) 2009-01-30 2016-06-28 Sanofi-Aventis Deutschland Gmbh Cam drive for managing disposable penetrating member actions with a single motor and motor and control system
US10939860B2 (en) 2009-03-02 2021-03-09 Seventh Sense Biosystems, Inc. Techniques and devices associated with blood sampling
US8821412B2 (en) 2009-03-02 2014-09-02 Seventh Sense Biosystems, Inc. Delivering and/or receiving fluids
US9775551B2 (en) 2009-03-02 2017-10-03 Seventh Sense Biosystems, Inc. Devices and techniques associated with diagnostics, therapies, and other applications, including skin-associated applications
US10799166B2 (en) 2009-03-02 2020-10-13 Seventh Sense Biosystems, Inc. Delivering and/or receiving fluids
US9730624B2 (en) 2009-03-02 2017-08-15 Seventh Sense Biosystems, Inc. Delivering and/or receiving fluids
US9113836B2 (en) 2009-03-02 2015-08-25 Seventh Sense Biosystems, Inc. Devices and techniques associated with diagnostics, therapies, and other applications, including skin-associated applications
US20130131598A1 (en) * 2009-04-24 2013-05-23 Corium International, Inc. Methods for manufacturing microprojection arrays
US9987487B2 (en) 2009-08-03 2018-06-05 Incube Labs, Llc Swallowable capsule and method for stimulating incretin production within the intestinal tract
US11439817B2 (en) 2009-08-03 2022-09-13 Incube Labs, Llc Swallowable capsule and method for stimulating incretin production within the intestinal tract
US11872396B2 (en) 2009-08-03 2024-01-16 Incube Labs, Llc Swallowable capsule and method for stimulating incretin production within the intestinal tract
US10010710B2 (en) 2009-09-17 2018-07-03 Zipline Medical, Inc. Rapid closing surgical closure device
US10159825B2 (en) 2009-09-17 2018-12-25 Zipline Medical, Inc. Rapid closing surgical closure device
US20160106931A1 (en) * 2009-09-17 2016-04-21 Zipline Medical, Inc. Rapid closing surgical closure device
CN102781508A (en) * 2009-09-18 2012-11-14 因诺瓦斯克有限责任公司 Pre-angioplasty serration of atherosclerotic plaque enabling low-pressure balloon angioplasty & avoidance of stenting
US10632294B2 (en) * 2009-10-08 2020-04-28 Palo Alto Research Center Incorporated Transmucosal drug delivery device and method including chemical permeation enhancers
US20150065997A1 (en) * 2009-10-08 2015-03-05 Palo Alto Research Center Incorporated Transmucosal drug delivery device and method including chemical permeation enhancers
US20110105951A1 (en) * 2009-10-30 2011-05-05 Seventh Sense Biosystems, Inc. Systems and methods for treating, sanitizing, and/or shielding the skin or devices applied to the skin
US20110105952A1 (en) * 2009-10-30 2011-05-05 Seventh Sense Biosystems, Inc. Relatively small devices applied to the skin, modular systems, and methods of use thereof
US11253686B2 (en) 2009-12-24 2022-02-22 Rani Therapeutics, Llc Swallowable drug delivery device and methods of drug delivery
US10039908B2 (en) * 2009-12-24 2018-08-07 Rani Therapeutics, Llc Swallowable drug delivery device and method of delivery
US10179228B2 (en) 2009-12-24 2019-01-15 Rani Therapeutics, Llc Swallowable drug delivery device and methods of drug delivery
US11338118B2 (en) 2009-12-24 2022-05-24 Rani Therapeutics, Llc Swallowable drug delivery device and methods of drug delivery
US10493253B2 (en) 2009-12-24 2019-12-03 Rani Therapeutics, Llc Therapeutic agent preparations into a lumen of the intestinal tract using a swallowable drug delivery device
US20150025496A1 (en) * 2009-12-24 2015-01-22 Rani Therapeutics, Llc Swallowable drug delivery device and method of delivery
US10596359B2 (en) 2009-12-24 2020-03-24 Rani Therapeutics, Llc Therapeutic agent preparations into a lumen of the intestinal tract using a swallowable drug delivery device
US10987499B2 (en) 2009-12-24 2021-04-27 Rani Therapeutics, Llc Swallowable drug delivery device and method of delivery
US9757548B2 (en) 2009-12-24 2017-09-12 Rani Therapeutics, Llc Method for delivering a therapeutic agent into the wall of the small intestine
US10603475B2 (en) 2009-12-24 2020-03-31 Rani Therapeutics, Llc Swallowable drug delivery device and methods of drug delivery
US10252039B2 (en) 2009-12-24 2019-04-09 Rani Therapeutics, Llc Therapeutic agent preparations into a lumen of the intestinal tract using a swallowable drug delivery device
US11376405B2 (en) 2009-12-24 2022-07-05 Rani Therapeutics, Llc Therapeutic agent preparations into a lumen of the intestinal tract using a swallowable drug delivery device
US20110251562A1 (en) * 2010-01-13 2011-10-13 Seventh Sense Biosystems, Inc. Rapid delivery and/or withdrawal of fluids
US9041541B2 (en) 2010-01-28 2015-05-26 Seventh Sense Biosystems, Inc. Monitoring or feedback systems and methods
US8965476B2 (en) 2010-04-16 2015-02-24 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US9526911B1 (en) * 2010-04-27 2016-12-27 Lazure Scientific, Inc. Immune mediated cancer cell destruction, systems and methods
US11565098B2 (en) 2010-04-28 2023-01-31 Sorrento Therapeutics, Inc. Device for delivery of rheumatoid arthritis medication
US20130144257A1 (en) * 2010-04-28 2013-06-06 Russell Frederick Ross Device for delivery of rheumatoid arthritis medication
US20190209818A1 (en) * 2010-04-28 2019-07-11 Sorrento Therapeutics, Inc. Device for Delivery of Rheumatoid Arthritis Medication
US10342965B2 (en) 2010-04-28 2019-07-09 Sorrento Therapeutics, Inc. Method for increasing the permeability of an epithelial barrier
US9526883B2 (en) 2010-04-28 2016-12-27 Kimberly-Clark Worldwide, Inc. Composite microneedle array including nanostructures thereon
US20170157380A1 (en) * 2010-04-28 2017-06-08 Kimberly-Clark Worldwide, Inc. Device for Delivery of Rheumatoid Arthritis Medication
US11179555B2 (en) 2010-04-28 2021-11-23 Sorrento Therapeutics, Inc. Nanopatterned medical device with enhanced cellular interaction
US11135414B2 (en) 2010-04-28 2021-10-05 Sorrento Therapeutics, Inc. Medical devices for delivery of siRNA
US9586044B2 (en) 2010-04-28 2017-03-07 Kimberly-Clark Worldwide, Inc. Method for increasing the permeability of an epithelial barrier
US10245421B2 (en) 2010-04-28 2019-04-02 Sorrento Therapeutics, Inc. Nanopatterned medical device with enhanced cellular interaction
WO2011135530A3 (en) * 2010-04-28 2012-03-15 Kimberly-Clark Worldwide, Inc. Device for delivery of rheumatoid arthritis medication
US10029083B2 (en) 2010-04-28 2018-07-24 Kimberly-Clark Worldwide, Inc. Medical devices for delivery of siRNA
US9545507B2 (en) 2010-04-28 2017-01-17 Kimberly-Clark Worldwide, Inc. Injection molded microneedle array and method for forming the microneedle array
US9522262B2 (en) 2010-04-28 2016-12-20 Kimberly-Clark Worldwide, Inc. Medical devices for delivery of siRNA
US9522263B2 (en) * 2010-04-28 2016-12-20 Kimberly-Clark Worldwide, Inc. Device for delivery of rheumatoid arthritis medication
US10709884B2 (en) * 2010-04-28 2020-07-14 Sorrento Therapeutics, Inc. Device for delivery of rheumatoid arthritis medication
US11083881B2 (en) 2010-04-28 2021-08-10 Sorrento Therapeutics, Inc. Method for increasing permeability of a cellular layer of epithelial cells
US10029082B2 (en) * 2010-04-28 2018-07-24 Kimberly-Clark Worldwide, Inc. Device for delivery of rheumatoid arthritis medication
US10806914B2 (en) 2010-04-28 2020-10-20 Sorrento Therapeutics, Inc. Composite microneedle array including nanostructures thereon
US10029084B2 (en) 2010-04-28 2018-07-24 Kimberly-Clark Worldwide, Inc. Composite microneedle array including nanostructures thereon
US11419816B2 (en) 2010-05-04 2022-08-23 Corium, Inc. Method and device for transdermal delivery of parathyroid hormone using a microprojection array
US9687641B2 (en) 2010-05-04 2017-06-27 Corium International, Inc. Method and device for transdermal delivery of parathyroid hormone using a microprojection array
US9795747B2 (en) 2010-06-02 2017-10-24 Sanofi-Aventis Deutschland Gmbh Methods and apparatus for lancet actuation
WO2011151807A1 (en) 2010-06-04 2011-12-08 Pfizer Vaccines Llc Conjugates for the prevention or treatment of nicotine addiction
US11051988B2 (en) 2010-06-14 2021-07-06 Zipline Medical, Inc. Methods and apparatus for inhibiting scar formation
US9033898B2 (en) 2010-06-23 2015-05-19 Seventh Sense Biosystems, Inc. Sampling devices and methods involving relatively little pain
US20130149459A1 (en) * 2010-07-02 2013-06-13 Aptar France Sas Method for the surface treatment of a fluid product dispensing device
US8561795B2 (en) 2010-07-16 2013-10-22 Seventh Sense Biosystems, Inc. Low-pressure packaging for fluid devices
US11202895B2 (en) 2010-07-26 2021-12-21 Yourbio Health, Inc. Rapid delivery and/or receiving of fluids
US11177029B2 (en) 2010-08-13 2021-11-16 Yourbio Health, Inc. Systems and techniques for monitoring subjects
US10952894B2 (en) 2010-10-15 2021-03-23 Clearside Biomedical, Inc. Device for ocular access
US8808202B2 (en) 2010-11-09 2014-08-19 Seventh Sense Biosystems, Inc. Systems and interfaces for blood sampling
US10487145B2 (en) 2010-12-23 2019-11-26 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9757514B2 (en) 2010-12-23 2017-09-12 Rani Therapeutics, Llc Device, system and methods for the oral delivery of therapeutic compounds
US9956178B2 (en) 2010-12-23 2018-05-01 Rani Therapeutics, Llc Methods for delivering insulin preparations into a lumen of the intestinal tract using a swallowable drug delivery device
US10478396B2 (en) 2010-12-23 2019-11-19 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US10967050B2 (en) 2010-12-23 2021-04-06 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US10953077B2 (en) 2010-12-23 2021-03-23 Rani Therapeutics, Llc Method of delivering a somatostatin compound into a lumen of the intestinal tract using a swallowable drug delivery device
US11638690B2 (en) 2010-12-23 2023-05-02 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US10004783B2 (en) 2010-12-23 2018-06-26 Rani Therapeutics, Llc Method for delivering pramlintide into a lumen of the intestinal tract using a swallowable drug delivery device
US9907747B2 (en) 2010-12-23 2018-03-06 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US10926073B2 (en) 2010-12-23 2021-02-23 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US11229684B2 (en) 2010-12-23 2022-01-25 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US10029080B2 (en) 2010-12-23 2018-07-24 Rani Therapeutics, Llc Method for delivering exenatide into a lumen of the intestinal tract using a swallowable drug delivery device
US9861683B2 (en) 2010-12-23 2018-01-09 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9844655B2 (en) 2010-12-23 2017-12-19 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9844505B2 (en) 2010-12-23 2017-12-19 Rani Therapeutics, Llc Methods for delivering etanercept preparations into a lumen of the intestinal tract using a swallowable drug delivery device
US9814763B2 (en) 2010-12-23 2017-11-14 Incube Labs, Llc Method for delivery of somatostatin into a lumen of the intestinal tract
US10888517B2 (en) 2010-12-23 2021-01-12 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US10980749B2 (en) 2010-12-23 2021-04-20 Rani Therapeutics, Llc Therapeutic preparation comprising insulin for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US11555068B2 (en) 2010-12-23 2023-01-17 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US11844867B2 (en) 2010-12-23 2023-12-19 Rani Therapeutics, Llc Method of delivering insulin into a lumen of the intestinal tract using a swallowable drug delivery device
US11813314B2 (en) 2010-12-23 2023-11-14 Rani Therapeutics, Llc Method of delivering a somatostatin compound into a lumen of the intestinal tract using a swallowable drug delivery device
US10874840B2 (en) 2010-12-23 2020-12-29 Rani Therapeutics, Llc Preparation comprising exanatide for delivery into a lumen of the intestinal tract
US10864254B2 (en) 2010-12-23 2020-12-15 Rani Therapeutics, Llc Method of delivering gonadotropin releasing hormone or an analogue thereof into a lumen of the intestinal tract using a swallowable drug delivery device
US11654182B2 (en) 2010-12-23 2023-05-23 Rani Therapeutics, Llc Method of delivering gonadotropin releasing hormone or an analogue thereof into a lumen of the intestinal tract using a swallowable drug delivery device
US11684761B2 (en) 2010-12-23 2023-06-27 Rani Therapeutics, Llc Preparation comprising exanatide for delivery into a lumen of the intestinal tract
US10632251B2 (en) 2010-12-23 2020-04-28 Rani Therapeutics, Llc Device, system and methods for the oral delivery of therapeutic compounds
US11814427B2 (en) 2010-12-23 2023-11-14 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US10548850B2 (en) 2010-12-23 2020-02-04 Rani Therapeutics, Llc Therapeutic composition comprising insulin prepared for delivery into an intestinal tract
US11304895B2 (en) 2010-12-23 2022-04-19 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US11806504B2 (en) 2010-12-23 2023-11-07 Rani Therapeutics, Llc Device, system and methods for the oral delivery of therapeutic compounds
US11419812B2 (en) 2010-12-23 2022-08-23 Rani Therapeutics, Llc Methods for delivering etanercept preparations into a lumen of the intestinal tract using a swallowable drug delivery device
US10300010B2 (en) 2010-12-23 2019-05-28 Rani Therapeutics, Llc Methods for delivering entanercept preparations into a lumen of the intestinal tract using a swallowable drug delivery device
US10307579B2 (en) 2010-12-23 2019-06-04 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US10314891B2 (en) 2010-12-23 2019-06-11 Rani Therapeutics, Llc Method for delivering pramlintide into a lumen of the intestinal tract using a swallowable drug delivery device
US10752681B2 (en) 2010-12-23 2020-08-25 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US10314892B2 (en) 2010-12-23 2019-06-11 Rani Therapeutics, Llc Method of delivering a somatostatin compound into a lumen of the intestinal tract using a swallowable drug delivery device
US10322167B2 (en) 2010-12-23 2019-06-18 Rani Therapeutics, Llc Method of delivering gonadotropin releasing hormone or an analogue thereof into a lumen of the intestinal tract using a swallowable drug delivery device
US10335463B2 (en) 2010-12-23 2019-07-02 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US10639272B2 (en) 2010-12-23 2020-05-05 Rani Therapeutics, Llc Methods for delivering etanercept preparations into a lumen of the intestinal tract using a swallowable drug delivery device
US9629799B2 (en) 2010-12-23 2017-04-25 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US10350163B2 (en) 2010-12-23 2019-07-16 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US11771879B2 (en) 2010-12-23 2023-10-03 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8696637B2 (en) 2011-02-28 2014-04-15 Kimberly-Clark Worldwide Transdermal patch containing microneedles
US8827971B2 (en) 2011-04-29 2014-09-09 Seventh Sense Biosystems, Inc. Delivering and/or receiving fluids
US10835163B2 (en) 2011-04-29 2020-11-17 Seventh Sense Biosystems, Inc. Systems and methods for collecting fluid from a subject
US10188335B2 (en) 2011-04-29 2019-01-29 Seventh Sense Biosystems, Inc. Plasma or serum production and removal of fluids under reduced pressure
US11253179B2 (en) 2011-04-29 2022-02-22 Yourbio Health, Inc. Systems and methods for collection and/or manipulation of blood spots or other bodily fluids
US9119578B2 (en) 2011-04-29 2015-09-01 Seventh Sense Biosystems, Inc. Plasma or serum production and removal of fluids under reduced pressure
US9295417B2 (en) 2011-04-29 2016-03-29 Seventh Sense Biosystems, Inc. Systems and methods for collecting fluid from a subject
US8636696B2 (en) 2011-06-10 2014-01-28 Kimberly-Clark Worldwide, Inc. Transdermal device containing microneedles
US9808510B2 (en) 2011-06-29 2017-11-07 Rani Therapeutics, Llc Method for delivering gonadotropin releasing hormone into a lumen of the intestinal tract
US10434251B2 (en) 2011-08-01 2019-10-08 Alcyone Lifesciences, Inc. Multi-directional microfluidic drug delivery device
US11110066B2 (en) 2011-10-27 2021-09-07 Sorrento Therapeutics, Inc. Implantable devices for delivery of bioactive agents
US10456136B2 (en) 2011-11-01 2019-10-29 Zipline Medical, Inc. Surgical incision and closure apparatus
US9463308B2 (en) 2011-11-01 2016-10-11 Lumenis Ltd. Device for pressure enhanced fractional treatment and drug delivery
US10123801B2 (en) 2011-11-01 2018-11-13 Zipline Medical, Inc. Means to prevent wound dressings from adhering to closure device
EP2773415B1 (en) * 2011-11-01 2016-12-14 Lumenis Ltd. Device for ultrasound enhanced fractional treatment and drug delivery
US10123800B2 (en) 2011-11-01 2018-11-13 Zipline Medical, Inc. Surgical incision and closure apparatus with integrated force distribution
WO2013076602A1 (en) * 2011-11-01 2013-05-30 Lumenis Ltd. Device for pressure enhanced fractional treatment and drug delivery
US11439395B2 (en) 2011-11-01 2022-09-13 Zipline Medical, Inc. Surgical incision and closure apparatus
US10543310B2 (en) 2011-12-19 2020-01-28 Seventh Sense Biosystems, Inc. Delivering and/or receiving material with respect to a subject surface
US10814115B2 (en) * 2011-12-27 2020-10-27 Massachusetts Institute Of Technology Microneedle devices and uses thereof
US20130165772A1 (en) * 2011-12-27 2013-06-27 The General Hospital Corporation Microneedle devices and uses thereof
US20140005606A1 (en) * 2012-06-29 2014-01-02 Mei-Chin Chen Embeddable micro-needle patch for transdermal drug delivery and method of manufacturing the same
US9675789B2 (en) * 2012-06-29 2017-06-13 National Cheng Kung University Embeddable micro-needle patch for transdermal drug delivery and method of manufacturing the same
US9572800B2 (en) 2012-11-08 2017-02-21 Clearside Biomedical, Inc. Methods and devices for the treatment of ocular diseases in human subjects
US9931330B2 (en) 2012-11-08 2018-04-03 Clearside Biomedical, Inc. Methods and devices for the treatment of ocular diseases in human subjects
US9636332B2 (en) 2012-11-08 2017-05-02 Clearside Biomedical, Inc. Methods and devices for the treatment of ocular diseases in human subjects
US10363394B2 (en) * 2012-12-18 2019-07-30 Alcyone Lifesciences, Inc. Systems and methods for reducing or preventing backflow in a delivery system
US20180193595A1 (en) * 2012-12-18 2018-07-12 Alcyone Lifesciences, Inc. Systems and methods for reducing or preventing backflow in a delivery system
US11213653B2 (en) 2012-12-18 2022-01-04 Alcyone Lifesciences, Inc. Systems and methods for reducing or preventing backflow in a delivery system
US11260201B2 (en) 2012-12-18 2022-03-01 Alcyone Lifesciences, Inc. Systems and methods for reducing or preventing backflow in a delivery system
US11052231B2 (en) 2012-12-21 2021-07-06 Corium, Inc. Microarray for delivery of therapeutic agent and methods of use
US11883622B2 (en) 2013-02-28 2024-01-30 Sorrento Therapeutics, Inc. Transdermal drug delivery device
US10953211B2 (en) 2013-02-28 2021-03-23 Sorrento Therapeutics, Inc. Transdermal drug delivery device
US10183156B2 (en) 2013-02-28 2019-01-22 Sorrento Therapeutics, Inc. Transdermal drug delivery device
US9861801B2 (en) 2013-02-28 2018-01-09 Kimberly-Clark Worldwide, Inc. Drug delivery device
US11110259B2 (en) 2013-03-12 2021-09-07 Corium, Inc. Microprojection applicators and methods of use
US10245422B2 (en) 2013-03-12 2019-04-02 Corium International, Inc. Microprojection applicators and methods of use
US10195409B2 (en) 2013-03-15 2019-02-05 Corium International, Inc. Multiple impact microprojection applicators and methods of use
US11565097B2 (en) 2013-03-15 2023-01-31 Corium Pharma Solutions, Inc. Microarray for delivery of therapeutic agent and methods of use
US9962534B2 (en) 2013-03-15 2018-05-08 Corium International, Inc. Microarray for delivery of therapeutic agent, methods of use, and methods of making
US10384045B2 (en) 2013-03-15 2019-08-20 Corium, Inc. Microarray with polymer-free microstructures, methods of making, and methods of use
US10384046B2 (en) 2013-03-15 2019-08-20 Corium, Inc. Microarray for delivery of therapeutic agent and methods of use
US9937075B2 (en) 2013-05-03 2018-04-10 Clearside Biomedical, Inc. Apparatus and methods for ocular injection
US10555833B2 (en) 2013-05-03 2020-02-11 Clearside Biomedical, Inc. Apparatus and methods for ocular injection
US9180047B2 (en) 2013-05-03 2015-11-10 Clearside Biomedical, Inc. Apparatus and methods for ocular injection
US9770361B2 (en) 2013-05-03 2017-09-26 Clearside Biomedical, Inc. Apparatus and methods for ocular injection
US10722396B2 (en) 2013-05-03 2020-07-28 Clearside Biomedical., Inc. Apparatus and methods for ocular injection
US10517756B2 (en) 2013-05-03 2019-12-31 Clearside Biomedical, Inc Apparatus and methods for ocular injection
US9636253B1 (en) 2013-05-03 2017-05-02 Clearside Biomedical, Inc. Apparatus and methods for ocular injection
US11559428B2 (en) 2013-05-03 2023-01-24 Clearside Biomedical, Inc. Apparatus and methods for ocular injection
US9539139B2 (en) 2013-05-03 2017-01-10 Clearside Biomedical, Inc. Apparatus and methods for ocular injection
US10188550B2 (en) 2013-06-03 2019-01-29 Clearside Biomedical, Inc. Apparatus and methods for drug delivery using multiple reservoirs
US10737081B2 (en) * 2013-06-17 2020-08-11 Juvic Inc. Painless and patchless shooting microstructure
US10456533B2 (en) 2013-06-17 2019-10-29 Alcyone Lifesciences, Inc. Methods and devices for protecting catheter tips and stereotactic fixtures for microcatheters
US11602375B2 (en) 2013-06-17 2023-03-14 Alcyone Therapeutics, Inc. Methods and devices for protecting catheter tips and stereotactic fixtures for microcatheters
CN105492064A (en) * 2013-06-17 2016-04-13 延世大学校产学协力团 Painless and patchless shooting microstructure
US20160361527A1 (en) * 2013-06-17 2016-12-15 Industry-Academic Cooperation Foundation, Yonsei University Painless and patchless shooting microstructure
WO2015016235A1 (en) * 2013-07-30 2015-02-05 Asti株式会社 Microneedle array and microneedle array manufacturing method
US10500386B2 (en) 2013-07-30 2019-12-10 Asti Corporation Microneedle array manufacturing method
US10441770B2 (en) 2013-07-31 2019-10-15 Alcyone Lifesciences, Inc. Systems and methods for drug delivery, treatment, and monitoring
US11534592B2 (en) 2013-07-31 2022-12-27 Alcyone Therapeutics, Inc. Systems and methods for drug delivery, treatment, and monitoring
US10166143B2 (en) * 2013-12-31 2019-01-01 Ip Liberty Vision Corporation Versatile light-guided ophthalmic treatment system
CN106061443A (en) * 2013-12-31 2016-10-26 Ip自由视觉公司 Versatile light-guided ophthalmic treatment system
US11045351B2 (en) * 2013-12-31 2021-06-29 Ip Liberty Vision Corporation Versatile light-guided ophthalmic treatment system
US20190240068A1 (en) * 2013-12-31 2019-08-08 Ip Liberty Vision Corporation Versatile light-guided ophthalmic treatment system
WO2015102801A1 (en) * 2013-12-31 2015-07-09 Ip Liberty Vision Corporation Versatile light-guided ophthalmic treatment system
US20150182725A1 (en) * 2013-12-31 2015-07-02 Ip Liberty Vision Corporation Versatile light-guided ophthalmic treatment system
JP2017500973A (en) * 2013-12-31 2017-01-12 アイピー リバティー ヴィジョン コーポレイション Versatile ophthalmic treatment system with light guide
US10888269B2 (en) 2014-01-05 2021-01-12 Zipline Medical, Inc. Instrumented wound closure device
US11844625B2 (en) 2014-01-05 2023-12-19 Zipline Medical, Inc. Instrumented wound closure device
US20170056637A1 (en) * 2014-05-06 2017-03-02 Mupharma Pty Ltd Non-invasive agent applicator
US20210100995A1 (en) * 2014-05-06 2021-04-08 Mupharma Pty Ltd Non-Invasive Agent Applicator
US20170189661A1 (en) * 2014-06-02 2017-07-06 Amolifescience Co., Ltd. Microneedle patch and production method therefor
US11738181B2 (en) 2014-06-04 2023-08-29 Cagent Vascular, Inc. Cage for medical balloon
US9956114B2 (en) 2014-06-20 2018-05-01 Clearside Biomedical, Inc. Variable diameter cannula and methods for controlling insertion depth for medicament delivery
US10624843B2 (en) 2014-09-04 2020-04-21 Corium, Inc. Microstructure array, methods of making, and methods of use
US9459201B2 (en) 2014-09-29 2016-10-04 Zyomed Corp. Systems and methods for noninvasive blood glucose and other analyte detection and measurement using collision computing
US9610018B2 (en) 2014-09-29 2017-04-04 Zyomed Corp. Systems and methods for measurement of heart rate and other heart-related characteristics from photoplethysmographic (PPG) signals using collision computing
US9459203B2 (en) 2014-09-29 2016-10-04 Zyomed, Corp. Systems and methods for generating and using projector curve sets for universal calibration for noninvasive blood glucose and other measurements
US9442065B2 (en) 2014-09-29 2016-09-13 Zyomed Corp. Systems and methods for synthesis of zyotons for use in collision computing for noninvasive blood glucose and other measurements
US9448165B2 (en) 2014-09-29 2016-09-20 Zyomed Corp. Systems and methods for control of illumination or radiation collection for blood glucose and other analyte detection and measurement using collision computing
US9448164B2 (en) 2014-09-29 2016-09-20 Zyomed Corp. Systems and methods for noninvasive blood glucose and other analyte detection and measurement using collision computing
US9453794B2 (en) 2014-09-29 2016-09-27 Zyomed Corp. Systems and methods for blood glucose and other analyte detection and measurement using collision computing
US9459202B2 (en) 2014-09-29 2016-10-04 Zyomed Corp. Systems and methods for collision computing for detection and noninvasive measurement of blood glucose and other substances and events
USD750223S1 (en) 2014-10-14 2016-02-23 Clearside Biomedical, Inc. Medical injector for ocular injection
US11298513B2 (en) 2014-11-03 2022-04-12 Cagent Vascular, Inc. Serration balloon
US10471238B2 (en) 2014-11-03 2019-11-12 Cagent Vascular, Llc Serration balloon
US11701502B2 (en) 2014-11-03 2023-07-18 Cagent Vascular, Inc. Serration balloon
US11040178B2 (en) 2014-11-03 2021-06-22 Cagent Vascular, Llc Serration balloon
US11602623B2 (en) * 2014-12-03 2023-03-14 Industry-Academic Cooperation Foundation Yonsei University Balloon catheter having micro needles and manufacturing method for the same
US10806396B2 (en) 2015-01-26 2020-10-20 Alcyone Lifesciences, Inc. Drug delivery methods with tracer
WO2016168847A1 (en) * 2015-04-17 2016-10-20 Georgia Tech Research Corporation Drug delivery devices having separable microneedles
US20210196937A1 (en) * 2015-04-17 2021-07-01 Georgia Tech Research Corporation Drug delivery devices having separable microneedles and methods
EP4205793A1 (en) * 2015-04-17 2023-07-05 Georgia Tech Research Corporation Drug delivery devices having separable microneedles
RU2721298C2 (en) * 2015-04-17 2020-05-18 Джорджия Тек Рисёч Корпорейшн Drug delivery devices having detachable microneedles
US10940301B2 (en) 2015-04-17 2021-03-09 Georgia Tech Research Corporation Drug delivery devices having separable microneedles
US10857093B2 (en) 2015-06-29 2020-12-08 Corium, Inc. Microarray for delivery of therapeutic agent, methods of use, and methods of making
US11033270B2 (en) 2015-08-07 2021-06-15 Zipline Medical, Inc. Means to prevent wound dressings from adhering to closure device
US11491314B2 (en) 2015-09-17 2022-11-08 Cagent Vascular Lac. Wedge dissectors for a medical balloon
US11266818B2 (en) 2015-09-17 2022-03-08 Cagent Vascular, Inc. Wedge dissectors for a medical balloon
US10166374B2 (en) 2015-09-17 2019-01-01 Cagent Vascular, Llc Wedge dissectors for a medical balloon
US11266819B2 (en) 2015-09-17 2022-03-08 Cagent Vascular, Inc. Wedge dissectors for a medical balloon
US10689154B2 (en) 2015-09-17 2020-06-23 Cagent Vascular, Llc Wedge dissectors for a medical balloon
US11717654B2 (en) 2015-09-17 2023-08-08 Cagent Vascular, Inc. Wedge dissectors for a medical balloon
US20170080196A1 (en) * 2015-09-21 2017-03-23 B&L Biotech, Inc. Flexible microneedle for dental material delivery and method of manufacturing the same
US10980991B2 (en) * 2015-09-21 2021-04-20 B&L Biotech, Inc. Flexible microneedle for dental material delivery and method of manufacturing the same
US10531882B2 (en) 2016-01-04 2020-01-14 Alcyone Lifesciences, Inc. Methods and devices for treating stroke
US10390901B2 (en) 2016-02-10 2019-08-27 Clearside Biomedical, Inc. Ocular injection kit, packaging, and methods of use
US9554738B1 (en) 2016-03-30 2017-01-31 Zyomed Corp. Spectroscopic tomography systems and methods for noninvasive detection and measurement of analytes using collision computing
US11596545B2 (en) 2016-05-02 2023-03-07 Clearside Biomedical, Inc. Systems and methods for ocular drug delivery
US10973681B2 (en) 2016-08-12 2021-04-13 Clearside Biomedical, Inc. Devices and methods for adjusting the insertion depth of a needle for medicament delivery
US10857028B2 (en) 2016-09-30 2020-12-08 Sara Heikali Method and device for treating and managing diseased ocular tissue
US11419760B2 (en) 2016-09-30 2022-08-23 Sara Heikali Method and device for treating and managing diseased ocular tissue
US11571859B2 (en) * 2016-10-14 2023-02-07 Xerox Corporation Chemical delivery devices produced using halftone screening in an additive manufacturing process
US20190047278A1 (en) * 2016-10-14 2019-02-14 Xerox Corporation Chemical delivery devices produced using halftone screening in an additive manufacturing process
US11337649B2 (en) 2016-10-31 2022-05-24 Zipline Medical, Inc. Systems and methods for monitoring physical therapy of the knee and other joints
US10918332B2 (en) 2016-10-31 2021-02-16 Zipline Medical, Inc. Systems and methods for monitoring physical therapy of the knee and other joints
US10905863B2 (en) 2016-11-16 2021-02-02 Cagent Vascular, Llc Systems and methods of depositing drug into tissue through serrations
US11311496B2 (en) * 2016-11-21 2022-04-26 Eirion Therapeutics, Inc. Transdermal delivery of large agents
US11541016B2 (en) 2017-05-17 2023-01-03 Massachusetts Institute Of Technology Self-righting systems, methods, and related components
US11541015B2 (en) 2017-05-17 2023-01-03 Massachusetts Institute Of Technology Self-righting systems, methods, and related components
US11712421B2 (en) 2017-05-17 2023-08-01 Massachusetts Institute Of Technology Self-actuating articles
US11311489B2 (en) * 2017-05-17 2022-04-26 Massachusetts Institute Of Technology Components with high API loading
US11730937B2 (en) 2017-10-11 2023-08-22 Georgia Tech Research Corporation Separable microneedle arrays for sustained release of drug
CN108014413A (en) * 2017-12-18 2018-05-11 优微(珠海)生物科技有限公司 Soluble micropin introducing apparatus and its application method
US20200345994A1 (en) * 2018-01-03 2020-11-05 The Trustees Of Columbia University In The City Of New York Microneedle for local delivery of therapeutic agent
US11844919B2 (en) * 2018-01-03 2023-12-19 The Trustees Of Columbia University In The City Of New York Microneedle for local delivery of therapeutic agent
US20210085945A1 (en) * 2018-05-30 2021-03-25 Tze Guan Ong Non-invasive Transportation Method
US11369779B2 (en) 2018-07-25 2022-06-28 Cagent Vascular, Inc. Medical balloon catheters with enhanced pushability
US11849415B2 (en) 2018-07-27 2023-12-19 Mclaren Applied Technologies Limited Time synchronisation
US11898874B2 (en) 2019-10-18 2024-02-13 Mclaren Applied Technologies Limited Gyroscope bias estimation
US11690739B1 (en) 2020-08-25 2023-07-04 Francis A. Kralick Implantable device for treatment of hydrocephalus
US11452474B1 (en) 2021-04-14 2022-09-27 Satio, Inc. Dual lever dermal patch system
WO2022246184A1 (en) * 2021-05-21 2022-11-24 Veradermics Incorporated Microneedle patch for immunostimulatory drug delivery
US11510602B1 (en) 2021-11-08 2022-11-29 Satio, Inc. Dermal patch for collecting a physiological sample
US11877848B2 (en) 2021-11-08 2024-01-23 Satio, Inc. Dermal patch for collecting a physiological sample

Also Published As

Publication number Publication date
EP1590034B1 (en) 2014-05-14
WO2004033021A1 (en) 2004-04-22
US8162901B2 (en) 2012-04-24
AU2003277306A1 (en) 2004-05-04
US20090118672A1 (en) 2009-05-07
EP1590034A1 (en) 2005-11-02

Similar Documents

Publication Publication Date Title
US8162901B2 (en) Microneedle array patch
US8920375B2 (en) Gas pressure actuated microneedle arrays, and systems and methods relating to same
US8361037B2 (en) Microneedles, microneedle arrays, and systems and methods relating to same
EP1187653B1 (en) Devices for enhanced microneedle penetration of biological barriers
US9302903B2 (en) Microneedle devices and production thereof
US8708966B2 (en) Microneedle devices and methods of manufacture and use thereof
US6743211B1 (en) Devices and methods for enhanced microneedle penetration of biological barriers
US20090043250A1 (en) Microneedle with membrane
US20090062752A1 (en) Switchcable microneedle arrays and systems and methods relating to same
US20020138049A1 (en) Microneedle devices and methods of manufacture and use thereof
Prausnitz et al. Microneedles for drug delivery
Prausnitz Assessment of microneedles for transdermal drug delivery
AU2002253812A1 (en) Microneedle devices and production thereof

Legal Events

Date Code Title Description
AS Assignment

Owner name: BIOVALVE TECHNOLOGIES, INC., MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GONNELLI, ROBERT R.;MCALLISTER, DEVIN V.;REEL/FRAME:017200/0341;SIGNING DATES FROM 20051027 TO 20051031

AS Assignment

Owner name: VALERITAS LLC,NEW JERSEY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BIOVALVE TECHNOLOGIES, INC.;REEL/FRAME:018171/0828

Effective date: 20060822

Owner name: VALERITAS LLC, NEW JERSEY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BIOVALVE TECHNOLOGIES, INC.;REEL/FRAME:018171/0828

Effective date: 20060822

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: VALERITAS, INC., NEW JERSEY

Free format text: CHANGE OF NAME;ASSIGNOR:VALERITAS LLC;REEL/FRAME:021354/0554

Effective date: 20071227

Owner name: VALERITAS, INC.,NEW JERSEY

Free format text: CHANGE OF NAME;ASSIGNOR:VALERITAS LLC;REEL/FRAME:021354/0554

Effective date: 20071227

AS Assignment

Owner name: PARALLEL INVESTMENT OPPORTUNITIES PARTNERS II L.P.

Free format text: SHORT-FORM PATENT SECURITY AGREEMENT;ASSIGNOR:VALERITAS, INC.;REEL/FRAME:030497/0800

Effective date: 20130524

Owner name: CAPITAL ROYALTY PARTNERS II L.P., TEXAS

Free format text: SHORT-FORM PATENT SECURITY AGREEMENT;ASSIGNOR:VALERITAS, INC.;REEL/FRAME:030497/0800

Effective date: 20130524

Owner name: CAPITAL ROYALTY PARTNERS II - PARALLEL FUND "A" L.

Free format text: SHORT-FORM PATENT SECURITY AGREEMENT;ASSIGNOR:VALERITAS, INC.;REEL/FRAME:030497/0800

Effective date: 20130524